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Abstract
Cancer prevalence is an important epidemiological measure of the disease burden. It is 
defined as the number of people in a given population who are alive at a specified point
in time (the index date) and who have previously been diagnosed with cancer. It may 
be expressed as either a count or as a proportion of the population. Members of the 
prevalent population are known as ‘cancer survivors’ and the time spent as such is 
known as ‘cancer survivorship’. Complete prevalence includes all survivors regardless of 
when they were diagnosed, whereas N-year limited duration prevalence includes only 
those who have received at least one cancer diagnosis in the N years prior to the index 
date.
In the United Kingdom (UK), addressing the needs of cancer survivors is a high 
priority for the Department of Health, as well as for voluntary sector organisations, and
the need for further research into cancer survivorship has been highlighted. Despite 
this, in recent years little study has focused on cancer prevalence in the UK. The aims 
in preparing this thesis were to provide up-to-date estimates of cancer prevalence in the
UK, to describe levels of acute health service utilisation among cancer survivors in 
diﬀerent temporal phases of survivorship and to provide projections of future cancer 
prevalence.
National cancer registry data for the UK were analysed, together with National Health 
Service hospital activity data for England. It was found that there are currently around
two million cancer survivors in the UK, a figure far higher than previously thought. 
Levels of acute in-patient health service utilisation were, however, generally low among 
cancer survivors who had survived at least five years and who were not in the final year
of their life. A discrete time model for projecting cancer prevalence was derived and 
used to project cancer prevalence in the UK from 2009 to 2040 under various diﬀerent 
scenarios of future cancer incidence and survival. It was shown that in the coming 
decades cancer prevalence is likely to increase substantially.
This thesis contains a detailed description of cancer prevalence and aspects of cancer 
survivorship in the UK which highlights the need for adequate planning to meet the 
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In this introductory chapter, the basic epidemiological concepts that are used in the 
rest of this thesis are explained, the motivation for studying cancer prevalence is set out
and some background context concerning the United Kingdom (UK) is given. Finally, 
an overview of the aims of this thesis and its structure is provided.
1.1 Cancer and epidemiology
Cancer is defined by the presence in the body of “an abnormal and unregulated growth 
of cells [a tumour] which ultimately evolves into a population of cells capable of 
invading nearby tissues as well as metastasising to distant sites causing significant 
morbidity and, if untreated, death of the host” (Ruddon, 2007: p.4). In fact, the term 
‘cancer’ includes a rich variety of disease sub-types. Each type is usually distinguished 
by the location in the body of the primary tumour and by the morphology of the 
tumour cells. The World Health Organisation’s International Classification of Diseases 
for Oncology (ICD-O) is commonly used to classify the diﬀerent types (Fritz et al., 
2000). Throughout this thesis, cancer types are identified topographically using ICD-10 
codes which condense the detail of ICD-O (World Health Organisation, 2010).
Cancer epidemiology is the study of the “distribution and determinants of [cancer]-
related states or events in specified populations” (Last, 2001: p.62). Basic 
epidemiological statistics include incidence, mortality and survival. Cancer incidence is 
the number of new cancers diagnosed and is generally expressed as a rate – for 
example, the number of cancers diagnosed per 100,000 population in a given year. 
Cancer mortality is the number of people who, according to death certification, died 
from cancer and, similarly, is often expressed as a rate. Cancer survival measures the 
probability of living a specified amount of time after being diagnosed and can be 
expressed in a number of ways – for example, as the proportion of cancer patients alive 
1, 5 or 10 years after diagnosis. This is known as crude survival. It is also possible to 
calculate relative survival – an estimate of the probability of surviving in the absence of
other non-cancer causes of death (Rutherford et al., in press). Survival is often 
described as a ‘rate’ but this is technically inaccurate since a rate should, strictly 
speaking, be expressed per unit time. Survival is a dimensionless quantity and should 
correctly be referred to as a probability or, equivalently, a proportion. Therefore, 
throughout this thesis, the term ‘survival rate’ is avoided.
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Cancer is one of the most significant diseases suﬀered by humans, is found in almost all
other animal species and has been recorded in pictures and writings throughout history
(and in recent years, bone cancers have been diagnosed in the remains of ancient 
Egyptian mummies (Zink et al., 1999)). It is estimated that 12.7 million people 
worldwide were diagnosed with cancer in 2008 (Ferlay et al., 2010). In the UK, cancer 
incidence rates have been steadily increasing since records began and, overall, are 
currently around 500 per 100,000 population, with approximately 300,000 new cases 
being diagnosed each year (Cancer Research UK, 2011b). It is estimated that, in the 
UK, one third of people will be diagnosed with cancer during their lifetime and one 
quarter of all deaths are due to cancer (Cancer Research UK, 2011a).
Unlike many other diseases, systematic recording of the number and types of diagnosed 
cancers is well established in numerous countries, and the importance of population-
based cancer registries to perform this task is widely accepted. In England, there are 
currently eight regional cancer registries with statutory mandates which, together, cover
the whole population of the country. Each is responsible for a separate geographical 
area, although a national system – as seen in some other European countries, including 
Wales, Scotland and Northern Ireland – is currently being introduced. The Thames 
Cancer Registry, for example, covers a population of around 12 million people in South 
East England and recently celebrated the collation of its 50th year of data (Thames 
Cancer Registry, 2011). UK cancer registries collect a wide variety of patient and 
tumour data including demographic, histological, treatment and follow-up information. 
Generally, tumour registrations are created using a combination of electronic data feeds
from hospital and laboratory systems and manual data collection by hospital-based 
registration oﬃcers.
1.2 Prevalence
Cancer prevalence, in addition to cancer incidence, mortality and survival, is another 
important epidemiological measure. It can be defined in a number of ways, but for the 
purposes of this thesis ‘cancer prevalence’ pertains to people who are alive at a given 
point in time and who have been previously diagnosed with cancer – this is the ‘lifetime
prevalence’ definition (Last, 2001: p.140). It can be expressed as a simple count or as a 
proportion of the population. Unlike incidence and mortality, it cannot be expressed as 
a rate since it relates to a static point in time only (the ‘index’ or ‘census’ date).
It is possible to calculate tumour prevalence – the number of tumours of diﬀerent types 
that have been diagnosed in those alive at a given point in time – but it is generally 
Chapter 1. Introduction
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considered more useful to calculate person prevalence, as described above. In this 
thesis, all analyses pertain to person prevalence, denoted either ‘prevalence count’ (the 
number of people) or ‘prevalence proportion’ (the number of people per 100,000 
population, or as a percentage).
In recent times, it has become customary to refer to those people who are included in 
the cancer prevalence count as ‘cancer survivors’. The lifetime definition of cancer 
prevalence is such that every person is considered to be a cancer survivor from the 
moment of diagnosis until the moment of death. Clearly this is a broad definition and 
the population of cancer survivors is therefore highly heterogeneous – from those who 
are recently diagnosed and in active cancer treatment, to those who have survived long 
enough to be considered cured. Despite being broad, this definition has many 
advantages since a diagnosis of cancer has wide-ranging and long-lasting physical, 
mental and psychosocial consequences for the individual, and disease remission and 
recurrence may occur many years after the initial diagnosis.
For other diseases, diﬀerent definitions of prevalence may be more appropriate. For 
example, when considering AIDS, the prevalence of infection with its causative virus 
HIV is an important measure since it determines the number of people at risk of 
developing the disease and the likelihood of a future epidemic (World Health 
Organisation, 2005). Prevalence of a disease such as seasonal flu, which is caused by 
diﬀerent variants of the influenza virus each year, and which, in most cases, has a short
duration before recovery, may be defined as the number of people with active disease at
a given point in time or as the number of people diagnosed during the previous year. 
Such definitions lead to the possibility of people moving in and out of the prevalent 
population over time – something which is not entertained in this thesis when 
considering cancer prevalence. However, previous work has modelled the progression of 
cancer patients through diﬀerent states of disease, from diagnosis and initial treatment 
through remission, relapse and death (Jackson and Aspden, 1979), with applications to 
the evaluation of new therapies and clinical trials or options for screening programmes 
(Jackson et al., 1981, 1982; Jenkins et al., 1994; Gallivan et al., 2007).
The lifetime or ‘ever diagnosed’ definition of cancer prevalence raises practical 
considerations and, in this thesis, a distinction is made between ‘limited duration 
prevalence’ and ‘complete prevalence’. The former includes only those survivors who 
have been diagnosed with cancer in a given time period prior to the index date – e.g. 5-
year prevalence at a particular point in time includes everyone who is alive and has 
received a diagnosis of cancer in the previous five years. In contrast, complete 
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prevalence includes every person diagnosed with cancer regardless of how long ago that 
diagnosis occurred. The best source of data from which to directly estimate cancer 
prevalence is a population-based cancer registry, but data with an extremely long time 
series are required to capture complete prevalence, and this is therefore not possible in 
most cases. The oldest cancer registry in the world is the Connecticut Tumour Registry
in the United States which holds 75 years of data (US Department of Public Health, 
2011) and from which direct estimates of complete prevalence can be practically made 
(although, since this is not a national registry, inter-state migration should be 
considered). In England, quality assured cancer registry data are available for diagnoses
made from 1971 onwards, but other registries (for example, the national registries of 
Northern Ireland and Wales) are younger. Statistical methods must therefore be used to
estimate complete prevalence based on limited duration prevalence, and the extent of 
the available data determines how substantial this adjustment is.
1.3 Motivation
As cancer treatments become more eﬀective and survival increases, the long-term care 
needs of cancer survivors become more prominent. Increasingly, the prospect of long-
term survival or cure is a realistic one for many cancer survivors, leading to a greater 
focus on long-term management of the disease and its sequelae. In light of this, ‘cancer 
survivorship’, defined in broad terms as the experience of living with and beyond 
cancer, is currently a key focus for the Department of Health in England (as well as for 
the other organisations responsible for health care in the UK). The National Cancer 
Survivorship Initiative (NCSI) was established in England in 2008 as a partnership 
between the Department of Health and the charitable organisation Macmillan Cancer 
Support. Its primary aim is to “ensure that survivors get the care and support they 
need to lead as healthy and active a life as possible, for as long as possible” 
(Department of Health, 2010).
Recent publications in the UK and elsewhere have highlighted the need for a greater 
focus on cancer survivorship in medical research (Rebbeck et al., 2011; Richards et al., 
2011). Such research is key to achieving the vision of the NCSI. Indeed, Richards et al. 
(2011) suggested that there are 10 specific research questions that need to be answered 
“if health outcomes for survivors are to be improved”. Of particular relevance to this 
thesis are the following:
• “How many people are currently living with a cancer diagnosis, and how is this likely 
to change over time?”
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• “What care are cancer survivors currently receiving from the NHS in hospitals and in 
the community?”
Understanding the factors that characterise diﬀerent phases of cancer survivorship is 
also a key theme, with questions such as:
• “What specific problems, concerns or needs do cancer survivors report at diﬀerent 
times after diagnosis and at diﬀerent phases in the pathway of care?”
• “What are the risks of survivors experiencing adverse consequences from cancer 
treatment at diﬀerent time intervals after diagnosis?”
Evidently, gaining a greater understanding of cancer survivorship and the 
characteristics of the population of cancer survivors through the study of cancer 
prevalence is a fundamental starting point for answering these questions. Cancer 
prevalence pertains to newly diagnosed patients as well as to those at risk of recurrence
and/or late eﬀects of treatment and cured patients. Study of cancer prevalence and 
survivorship therefore has the potential to provide valuable intelligence regarding the 
characteristics, experiences and needs of all people living with cancer. Furthermore, by 
identifying areas of unmet need, such studies can help to inform the development of 
appropriate models of care.
From a resource planning perspective, it is important to understand the current and 
likely future burden of cancer on the health service. This is not only related to the 
volume of cases and types of initial treatment required, but also to the amount of 
surveillance, rehabilitation, palliative care and treatment for tumour recurrence and 
secondary and late eﬀects of cancer treatment that is required. Cancer prevalence is one
measure of the cancer burden and is complementary to other statistics such as cancer 
incidence and mortality (Lagiou and Adami, 2002). However cancer prevalence, by 
considering cancer survivors at all stages of survivorship, provides the most 
comprehensive description of the cancer burden, especially when augmented with, for 
example, analyses of health service activity data.
Therefore, the comprehensive account of cancer prevalence and cancer survivorship 
contained in this thesis forms the basis of much of the intelligence that will be vital in 
achieving the aims of the NCSI in the coming years, and thus will help, albeit 
indirectly, to ensure that the best possible health outcomes are achieved for cancer 
survivors in the UK.
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1.4 Aims and outline of thesis
The most recent previous publication to present national estimates of cancer prevalence
in the UK came in 2003 from the EUROPREVAL project (Forman et al., 2003), but 
used a data series ending in 1992. Beyond this, little published research has focused on 
cancer prevalence in the UK. The aims of this thesis are to provide up-to-date basic 
estimates of cancer prevalence, to enrich these estimates with information that allows a 
greater understanding of the diﬀerent phases of cancer survivorship and the burden of 
cancer to the individual and to society in general and to provide projections of future 
cancer prevalence in the UK.
This thesis is broadly arranged into three sections, each addressing one of these aims. 
In Chapter 2, cancer registry data from all the regional registries in England, as well as 
the national registries in Northern Ireland, Scotland and Wales, are used to estimate 
complete cancer prevalence in the UK at the end of 2008. Next, in Chapter 3, a person-
time analysis of linked cancer registry and hospital activity data is used to describe the 
levels of acute health service utilisation among cancer survivors in diﬀerent temporal 
phases of survivorship. Finally, the focus of Chapters 4–6 is on projections of cancer 
prevalence: in Chapter 4 a mathematical model is derived that allows projections of 
cancer prevalence to be made based on cancer registry data; the required input data for
this model is considered in detail and model evaluation exercises are described in 
Chapter 5; and in Chapter 6 projections of cancer prevalence in the UK up to the year 
2040, under various diﬀerent scenarios of future cancer incidence and survival, are 
presented.
The scope of the results contained in these chapters is limited to four major groups of 
cancer types: colon, rectum and anus (ICD-10 C18–C21); lung, bronchus and trachea 
(ICD-10 C33–C34); prostate (ICD-10 C61); and female breast cancer (ICD-10 C50). 
These are four of the most commonly diagnosed types of cancer in the UK – together 
they account for over half of all cancer diagnoses – and exhibit large variations in 
survival characteristics, from lung cancer with its extremely poor prognosis to breast 
and prostate cancers with relatively good prognoses. In addition, since it is desirable to 
provide an overview of the prevalence of all cancers combined, as well as of specific 
types, analysis is, where appropriate, conducted for a fifth group – ‘all other’ cancer 
types – defined as ICD-10 C00–C97 excluding C44 (non-melanoma skin cancer) and the
four major types previously mentioned. This group contains a large number of very 
diﬀerent types of cancer, from the very rare (such as cancer of the thymus) to relatively
common (such as bladder cancer), and is included only to provide a complement to the 
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other groups from which prevalence of all cancer types combined (excluding non-
melanoma skin cancer) can be estimated. Non-melanoma skin cancer is excluded since, 
historically, it has not been systematically recorded by all cancer registries in the UK.
Attained age (i.e. the age of survivors on the index date) and time since diagnosis are 
key variables of interest when considering cancer prevalence. In this thesis, attained age
is generally grouped into three broad ranges: 0–44, 45–64 and ≥65 years. Where 
necessary, time since diagnosis is also grouped into three broad ranges: <1, 1–5 and ≥5 
years.
Finally, a general summary and discussion of the work is contained in Chapter 7.
1.5 Literature
Searches of relevant literature on the topics of cancer prevalence and survivorship were 
conducted using standard web-based databases (PubMed, Web of Science, Embase and 
Scopus). A variety of search terms were used, including “cancer prevalence”, 
“completeness index”, “health care” or “quality of life” with “cancer survivors”, “cancer 
survivorship” and “cancer prevalence projections”, as well as more specific searches 
relating to relevant prominent authors. There are three main areas of study in this 
thesis (estimates of current cancer prevalence, health service utilisation/phases of 
survivorship and projections of cancer prevalence) and each has a separate body of 
published research. Therefore the narrative flow of this thesis is maintained by 
background and literature sections being positioned where they most usefully inform 
the materials and methods. In section 3.2, the need to go beyond a basic enumeration 
of cancer survivors when studying cancer survivorship and examples of this in the 
literature are discussed, including studies of temporal phases of survivorship, cure 
modelling and health service utilisation. In section 4.2, examples in the literature of 
approaches to the task of projecting cancer prevalence are presented. This usually 
involves the description of a mathematical model to relate cancer incidence, survival 
and prevalence, as well as methods for providing input data to the model, but 
approaches have often varied depending on the local availability of comprehensive 
cancer registry data. In section 6.1, previous eﬀorts to assess the independent influences
of cancer incidence and survival and population demographics on projections of cancer 
prevalence are discussed. Relevant literature is also noted in the discussion sections of 
this thesis (see sections 2.4, 3.5 and 6.5) and elsewhere, in order to place the findings of




Chapter 2. Cancer prevalence in 2008
In this chapter, cancer prevalence in the UK at the end of the year 2008 is estimated 
using national cancer registry data for England, Northern Ireland, Scotland and Wales. 
Methods are developed to account for cancer survivors who were diagnosed before the 
earliest available year of cancer registry data, and recent trends in cancer prevalence 
are described.
This work was first published as an article in the British Journal of Cancer in 2009 
(Maddams et al., 2009). The substance and structure of this chapter are therefore the 
same as that article, but minor edits and amendments to the writing style and figures 
have been made. A reprint of the original article is contained in Appendix C.
2.1 Introduction
Identifying and addressing the requirements of cancer survivors in England was a high 
priority in the Cancer Reform Strategy (Department of Health, 2007) and, as a result, 
the National Cancer Survivorship Initiative was set up in 2008. Similar initiatives are 
being established in Northern Ireland, Scotland and Wales. However, little is known 
about the size and demography of the population of cancer survivors in the UK; the 
most recent estimates of cancer prevalence in the UK, provided by the EUROPREVAL 
project (Forman et al., 2003), were for 1992.
Cancer survivors may be recently diagnosed and in active treatment, or they may have 
survived long enough to be considered cured. However, in this analysis, such 
distinctions are not made; once an individual is diagnosed with cancer, he or she is 
considered to be a survivor until death. This approach is adopted because a diagnosis of
cancer may aﬀect a person’s life in diﬀerent ways (mental health problems, fear of 
recurrence, financial hardship, relationship issues, etc.), and its eﬀects may be felt for 
many years after diagnosis. Also, this approach is practical as the currently available 
cancer registration data do not readily allow survivors to be classified as having active 
disease, in remission or cured of their cancer.
2.2 Materials and methods
The eight cancer registries in England, together with the national registries in Northern
Ireland, Scotland and Wales, provided anonymised records of all registered malignant 
neoplasms (ICD-10 C00–C97) diagnosed in the residents of those countries, excluding 
non-melanoma skin cancer (ICD-10 C44) as it is not covered systematically by all 
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registries. Each record included demographic, tumour, diagnosis, follow-up and death 
details. Data were available for the periods 1971–2004 for England, 1971–2005 for 
Scotland, 1990–2006 for Wales and 1993–2006 for Northern Ireland. All tumours 
apparently diagnosed in patients over the age of 99 years were excluded (approximately
0.04% of the total), leaving 7.7 million registration records for analysis.
The UK cancer registries receive death notifications from the Oﬃce for National 
Statistics (ONS) (England and Wales) and the General Register Oﬃces (Scotland and 
Northern Ireland), which are then matched to the cancer registration records, although 
a small percentage are never so matched. The patients associated with these ‘lost to 
follow-up’ registrations are, at face value, eﬀectively immortal and result in apparent 
cancer survivors of a much higher age than is known to be likely. The proportion of 
registrations lost to follow-up in many European registries is believed to be less than  
1% (Micheli et al., 2002), but is not precisely known in UK registries. Therefore, in 
computing prevalence, cancer survivors were censored at the attained age of 105 years.
Cancer prevalence can be expressed as the number of prevalent tumours or the number 
of prevalent patients. As each patient may, in their lifetime, be diagnosed with more 
than one tumour, patient prevalence will always be lower than tumour prevalence. The 
analysis presented here focused on patient prevalence, and only the first diagnosed 
malignant neoplasm (excluding non-melanoma skin cancer) in each patient was 
considered.
Although cancer registry data for Northern Ireland, Scotland and Wales were available 
for diagnoses made in the years 2005 and 2006, data for England were available only up
to 2004 at the time of analysis. For this reason, the most recent index date common to 
all data was used – i.e. 31 December 2004. The number of people diagnosed with cancer
and alive on this date was counted and disaggregated by country of residence, sex, age 
group on the index date (0–44, 45–64 and ≥65 years), number of years since diagnosis 
and the following broad groups of cancer diagnoses:
1. Colon, rectum and anus (ICD-10 C18–C21);
2. Lung, bronchus and trachea (ICD-10 C33–C34);
3. Prostate (ICD-10 C61);
4. Female breast (ICD-10 C50);
5. All other malignant neoplasms excluding non-melanoma skin cancer (ICD-10 C00–
C97 excluding C44 and (1) to (4)).
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Death Certificate Only (DCO) registrations are those for which the only source of 
patient or tumour information is a death certificate stating cancer as a cause of death. 
These registrations lack much information, particularly the actual date of diagnosis. An
unknown proportion of the DCO registrations since the index date will pertain to 
patients diagnosed before, and alive on, the index date. However, no attempt has been 
made to estimate this proportion, and therefore such registrations are not included in 
the prevalence estimates presented here.
2.2.1 Complete prevalence
N -year limited duration prevalence includes only those survivors diagnosed in the last 
N years before the index date. Complete prevalence includes all cancer survivors, 
regardless of when they were diagnosed. It is not currently possible to directly count 
complete prevalence on the basis of cancer registry data alone, given that no UK 
registry has been collecting data for a suﬃciently long period of time. Instead, complete
prevalence was estimated by extrapolating from limited duration prevalence as follows.
With an index date of 31 December 2004, the available cancer registry data provided 
34-year prevalence estimates for England and Scotland, 15-year estimates for Wales and
12-year estimates for Northern Ireland. To extend these limited duration estimates to 
complete estimates, a negative binomial regression model with a log-link function was 
constructed for each type of cancer, sex and age group (0–44, 45–64 and ≥65 years). 
The prevalence count on the index date was the response variable, and the explanatory 
variables were country of residence and number of years since diagnosis. Given that the 
primary objective was to obtain a reasonable estimate for the number of people who 
had survived at least 12 years (Northern Ireland) and 15 years (Wales) beyond 
diagnosis, data pertaining to the most recent five years of diagnoses were not used in 
the regression models. Prostate cancer was treated as a special case and modelled in 
two stages; first, for diagnoses made in the period 1992–1999 and second, for all 
diagnoses made before 1992. An oﬀset term was also included in all models, defined as 
the logarithm of the number of people in each country who could contribute to the 
prevalence count (i.e. the population at risk), taking into account the age group being 
considered and the fact that years since diagnosis cannot exceed attained age on the 
index date. The models were run using the proc genmod procedure in the SAS 
statistical programming package (SAS Institute Inc., Cary, NC, USA).
The performance of the regression models was tested by initially excluding from them 
data for Scotland covering diagnoses made between 1971 and 1992, and by comparing 
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the modelled estimates with the empirical data for those years. Furthermore, the 
calculated ratios of 15-year prevalence to complete prevalence (known as the 
‘completeness index’) in England and Scotland were compared with previously 
published estimates (Forman et al., 2003) – see Table 2.1.
Table 2.1. Comparison of 15-year completeness index, by sex and type of cancer.
Data source
Maddams et al.† EUROPREVAL‡
Males
Colon, rectum and anus 0.81 0.87**
Lung, bronchus and trachea 0.58 0.73***
Prostate 0.95 0.97
All malignant neoplasms* 0.78 0.82
Females
Colon, rectum and anus 0.74 0.80
Lung, bronchus and trachea 0.77 0.79
Breast 0.74 0.80
All malignant neoplasms* 0.70 0.72
The 15-year completeness index is defined as 15-year prevalence divided by complete prevalence. 
*Excluding non-melanoma skin cancer (ICD-10 C44). †Based on the work described in this chapter: 15-
year prevalence divided by estimated complete prevalence in the UK; Index date 31 December 2004. ‡From
Forman et al. (2003): Average 15-year completeness index using data from South Thames, West Midlands, 
Yorkshire and Scotland cancer registries with index date 31 December 1992. **Unweighted average of 
indices for cancer of the colon and rectum. ***Cancer of the lung only.
2.2.2 Projections from 2004 to 2008
Through an analysis of recent empirical trends in limited duration cancer prevalence, 
estimates of complete cancer prevalence in the UK were projected from 31 December 
2004 forward to 2008. Combined data for England and Scotland (covering cancer 
diagnoses made in the period 1971–2004) were used to estimate limited duration 
prevalence between 2000 and 2004, for each sex and cancer type. Log-linear functions, 
considered appropriate for short-term projections, were fitted to provide estimates of 
the annual growth in the number of cancer survivors that could be expected from 2004 
to 2008. The following assumptions were made:
1. The yearly rates of change of cancer prevalence in England and Scotland combined 
can reasonably be applied to each constituent country of the UK;
2. The rate of change of cancer prevalence in each age group (0–44, 45–64 and ≥65 
years) can be approximated by the rate of change in all age groups combined;
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3. For each sex and cancer type, the rate of change of complete prevalence is the same 
as that of 30-year limited duration prevalence.
Estimated prevalence counts were converted to proportions of the population by using 
the mid-year ONS population estimates for 2007; these were the most recent estimates 
available at the time of analysis and likely to be only slightly lower than the actual 
population at the end of 2008 (Oﬃce for National Statistics, 2011a).
2.3 Results
Tables 2.2–2.4 present complete prevalence – the sum of observed prevalence from the 
years of diagnosis that were available in the data and modelled prevalence from those 
that were not. Estimates for which more than 20% of the total is derived from 
modelling are underlined.
It was estimated that at the end of 2008 there were just over two million cancer 
survivors in the UK – 40.9% were male and 59.1% were female. Approximately 2.7% of 
the male population, and 3.8% of the female population, were cancer survivors. Table 
2.2 shows the variation in cancer prevalence by country, sex and cancer type. Wales had
the highest prevalence proportions (3.1% of males and 4.2% of females were cancer 
survivors), and Northern Ireland had the lowest (2.4% of males and 3.4% of females).
Prostate and female breast cancers were the most prevalent, and accounted for 30.9% of
male, and 46.4% of female, cancer prevalence in the UK. Of the cancer types studied 
here, lung cancer was the least prevalent. Figure 2.1 shows, for each sex, the 
proportions of total incident cases, cancer deaths and cancer prevalence that were 
accounted for by colorectal, lung, prostate and female breast cancers (incidence and 
mortality data taken from the UK Cancer Information Service (National Cancer 
Intelligence Network, 2011b)). For both males and females, colorectal cancer accounted 
for approximately 10–15% of all the three measures. In contrast, for males, lung cancer 
accounted for 15% of all newly diagnosed cancers, 25% of cancer deaths and for only 
5% of cancer prevalence. A similar pattern was seen for female lung cancer, which 
accounted only for 2% of female cancer prevalence. Prostate and female breast cancers 
provided further contrasts, the latter accounting for 31% of newly diagnosed cancers, 
17% of cancer deaths and 46% of cancer prevalence among females.
Table 2.3 presents cancer prevalence in the UK, according to time since diagnosis. The 
proportion of survivors in each time since diagnosis band varied according to sex and 
cancer type, as illustrated in Figure 2.2. Overall, female cancer survivors tended to be 
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further beyond their diagnosis than males – 67% of female survivors had been 
diagnosed more than 5 years earlier, compared with 55% of male survivors.
Table 2.4 shows the variation of cancer prevalence with attained age. Less than 1% of 
the UK population aged under 45 years at the end of 2008 were cancer survivors, 
compared with around 13% of those aged at least 65 years. There were twice as many 
female survivors aged between 45 and 64 years as there were males, largely because of 
the dominance of female breast cancer that accounted for 54% of female survivors in 
this age range. The most prevalent types of cancer in those aged at least 65 years were 
prostate and female breast cancers; 5.2% of males and 5.7% of females in this age group
were survivors of these cancers.
Figure 2.3 shows the trends in 1, 5, 10 and 30-year limited duration prevalence in the 
period 2000–2004, and projected to 2008. Only male lung cancer did not show an 
increasing trend, the total number of survivors decreasing by 1.4% per year. Prostate 
cancer prevalence was, by a considerable margin, the most rapidly increasing type – the
total number of prostate cancer survivors increased by 9.8% per year in the period 
2000–2004. Overall, the number of male cancer survivors increased by 3.8% per year 
and the number of female cancer survivors increased by 2.7% per year.
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Figure 2.1. Proportion of total cancer incidence*, cancer deaths† and cancer 




































*England, 2006 (data from UKCIS). †England, 2005 (data from UKCIS). **UK, 2008. ‡ICD-10 codes as 
follows: Colorectal=C18–C21; Lung=C33–C34; Prostate=C61; Breast=C50.
Figure 2.2. Time since diagnosis distribution of cancer survivors in the UK at the end 
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Figure 2.3. Empirical and projected trends in limited duration cancer prevalence in 



















































































































*ICD-10 codes as follows: Colorectal=C18–C21; Lung=C33–C34; Prostate=C61; Breast=C50. All=C00–
C97 excluding non-melanoma skin cancer C44.   
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
Table 2.2. Prevalence of cancer at the end of 2008 in the UK, by country of residence, cancer type and sex. Number of survivors 
(proportion per 100,000 population).
Country of residence
England Scotland Wales Northern Ireland UK
Males
Colon, rectum and anus 100,608 (401) 11,522 (464) 6,921 (476) 3,480 (404) 122,531 (410)
Lung, bronchus and trachea 32,034 (128) 3,760 (151) 1,889 (130) 1,058 (123) 38,741 (130)
Prostate 215,654 (859) 19,163 (771) 13,312 (916) 5,307 (616) 253,436 (847)
All other malignant neoplasms* 334,147 (1,330) 36,853 (1,483) 22,998 (1,582) 10,482 (1,216) 404,480 (1,352)
All malignant neoplasms* 682,443 (2,717) 71,298 (2,868) 45,120 (3,103) 20,327 (2,358) 819,188 (2,738)
Females
Colon, rectum and anus 92,439 (356) 11,419 (430) 5,885 (386) 3,542 (395) 113,285 (365)
Lung, bronchus and trachea 19,634 (76) 3,215 (121) 1,239 (81) 693 (77) 24,781 (80)
Breast 460,041 (1,771) 46,211 (1,738) 29,838 (1,955) 12,908 (1,439) 548,998 (1,768)
All other malignant neoplasms* 409,284 (1,576) 46,607 (1,753) 26,683 (1,749) 13,690 (1,526) 496,264 (1,598)
All malignant neoplasms* 981,398 (3,778) 107,452 (4,042) 63,645 (4,171) 30,833 (3,437) 1,183,328 (3,810)
The sum of observed prevalence where available from cancer registry data, and modelled prevalence where not. Underlined numbers are those which are based on 
estimates of prevalence in 2004 that were at least 20% modelled. *Excluding non-melanoma skin cancer (ICD-10 C44).
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Table 2.3. Prevalence of cancer at the end of 2008 in the UK, by time since diagnosis, cancer type and sex. Number of survivors 
(proportion per 100,000 population).
Time since diagnosis
<1 year 1–5 years 5–10 years 10–20 years ≥20 years All
Males
Colon, rectum and anus 14,619 (49) 38,075 (127) 31,162 (104) 24,534 (82) 14,141 (47) 122,531 (410)
Lung, bronchus and trachea 8,263 (28) 7,850 (26) 3,810 (13) 4,769 (16) 14,049† (47)† 38,741 (130)
Prostate 37,967 (127) 125,470 (419) 61,376 (205) 22,601 (76) 6,022 (20) 253,436 (847)
All other malignant neoplasms* 40,891 (137) 97,529 (326) 87,008 (291) 98,726 (330) 80,326 (269) 404,480 (1,352)
All malignant neoplasms* 101,740 (340) 268,924 (899) 183,356 (613) 150,630 (504) 114,538 (383) 819,188 (2,738)
Females
Colon, rectum and anus 11,309 (36) 30,341 (98) 27,128 (87) 25,532 (82) 18,975 (61) 113,285 (365)
Lung, bronchus and trachea 6,905 (22) 7,255 (23) 3,671 (12) 2,682 (9) 4,268 (14) 24,781 (80)
Breast 42,432 (137) 140,111 (451) 128,672 (414) 145,035 (467) 92,748 (299) 548,998 (1,768)
All other malignant neoplasms* 40,655 (131) 109,179 (352) 96,400 (310) 119,366 (384) 130,664 (421) 496,264 (1,598)
All malignant neoplasms* 101,301 (326) 286,886 (924) 255,871 (824) 292,615 (942) 246,655 (794) 1,183,328 (3,810)
The sum of observed prevalence where available from cancer registry data, and modelled prevalence where not. Underlined numbers are those which are based on 
estimates of prevalence in 2004 that were at least 20% modelled. *Excluding non-melanoma skin cancer (ICD-10 C44). †Possibly unreliable, see discussion section 2.4.
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Table 2.4. Prevalence of cancer at the end of 2008 in the UK, by age, cancer type and sex. Number of survivors (proportion per 100,000 
population).
Age (at the end of 2008)
0–44 years 45–64 years ≥65 years All
Males
Colon, rectum and anus 2,091 (11) 25,690 (343) 94,750 (2,238) 122,531 (410)
Lung, bronchus and trachea 441 (2) 6,643 (89) 31,657 (748) 38,741 (130)
Prostate 181 (1) 34,511 (461) 218,744 (5,168) 253,436 (847)
All other malignant neoplasms* 68,539 (377) 125,077 (1,671) 210,864 (4,982) 404,480 (1,352)
All malignant neoplasms* 71,252 (392) 191,921 (2,563) 556,015 (13,136) 819,188 (2,738)
Females
Colon, rectum and anus 2,134 (12) 19,723 (255) 91,428 (1,648) 113,285 (365)
Lung, bronchus and trachea 530 (3) 5,904 (76) 18,347 (331) 24,781 (80)
Breast 25,428 (143) 208,076 (2,694) 315,494 (5,688) 548,998 (1,768)
All other malignant neoplasms* 67,530 (380) 151,756 (1,965) 276,978 (4,994) 496,264 (1,598)
All malignant neoplasms* 95,622 (538) 385,459 (4,990) 702,247 (12,661) 1,183,328 (3,810)
The sum of observed prevalence where available from cancer registry data, and modelled prevalence where not. Underlined numbers are those which are based on 
estimates of prevalence in 2004 that were at least 20% modelled. *Excluding non-melanoma skin cancer (ICD-10 C44).
  
2.4 Discussion
The prevalence estimates presented in this chapter were produced using incidence and 
follow-up data collected by cancer registries in the UK, where available. These 
estimates were not adjusted to account for DCO registrations that occurred after the 
index date. DCOs account for less than 5% of all registrations in the UK and most 
often relate to patients who have died soon after diagnosis. The assumption that their 
eﬀect on cancer prevalence is small was, therefore, reasonable. No attempt was made to
estimate the proportion lost to follow-up, including emigrations. Nor was it possible to 
include UK immigrants with a diagnosis of cancer pre-dating their move. To a certain 
extent, the eﬀects of including emigrants and excluding immigrants cancel each other 
out.
Log-linear regression models of the prevalence count as a function of time since 
diagnosis were developed and used to estimate the number of survivors from the period 
before cancer registration in their country. Treating prevalence in this manner as an 
isolated statistic does not explicitly model the joint eﬀect of incidence and survival, and
is based on the observation that the relationship between the number of years since 
diagnosis and the number of survivors was approximately log-linear in most instances, 
as in Phillips et al. (2002). However, this relationship was clearly not log-linear for 
prostate cancer, and so the regression model was, for this cancer, applied in two stages. 
This was designed to account for the introduction of Prostate Specific Antigen (PSA) 
testing as a screening tool for prostate cancer in the early 1990s, which eﬀectively 
changed the definition of the disease with many more localised tumours diagnosed 
(Evans and Møller, 2003). The number of prostate cancer survivors increased at the 
fastest rate of the cancers studied here, by almost 10% each year between 2000 and 
2004. Since the changes in incidence and survival caused by the introduction of PSA 
testing are relatively recent, the number of prostate cancer survivors could realistically 
be expected to increase at a similar rate for some years to come, until a situation is 
reached in which very few were diagnosed in the era before PSA testing.
Table 2.1 shows that this analysis resulted in 15-year completeness indices for 2004 that
were consistently lower than those previously published for 1992 (Forman et al., 2003). 
A lower completeness index corresponds to a higher proportion of long-term survivors 
in the prevalent population. The diﬀerences in the completeness index are, therefore, 
consistent with the increases in survival observed between 1992 and 2004 for many 
cancers (Cancer Research UK, 2009a; Rachet et al., 2008b). Although most diﬀerences 
in these indices were small, for male lung cancer the diﬀerence was large (0.58 
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compared with the published estimate of 0.73). Such a large discrepancy was 
unexpected, despite the two estimates relating to diﬀerent index dates and the changes 
in lung cancer incidence between the two dates. For lung cancer, as with prostate 
cancer, modelling the number of survivors as a simple log-linear function of time since 
diagnosis was not appropriate. Owing to its poor prognosis, lung cancer prevalence is 
dominated by short-term survivors (Figure 2.2) and therefore the regression model has 
most likely overestimated the number of long-term male lung cancer survivors. If a 
completeness index of 0.73 was used (as calculated by Forman et al. (2003)), then an 
estimate of 6,000 (rather than 14,000) would be produced for the number of male lung 
cancer survivors who, at the end of 2008, had survived more than 20 years. This lower 
estimate seems more plausible, especially when compared with evidence from other 
Northern European countries which indicates that in 1992 only 31% of male lung 
cancer survivors had survived more than 10 years (Möller et al., 2003).
A pragmatic approach to the modelling of cancer prevalence has been adopted in this 
study. Owing to the long time series of cancer registry data available in the UK, the 
majority of the estimates presented contain only a small contribution of modelled data. 
This contribution is most significant in the estimates for Northern Ireland and, to a 
lesser extent, for Wales. With 34 years of data available for England and Scotland, the 
modelled proportions of the complete prevalence estimates were typically around 5% for
males and 8% for females. Therefore, these estimates are considered to be robust and fit
for purpose.
2.4.1 Substantial results of the analysis
There were approximately 2 million cancer survivors in the UK at the end of 2008. 
Around 13% of all people aged at least 65 years were cancer survivors. Approximately 
one in three of the UK population will be diagnosed with cancer during their lifetime 
and one in four will die from it (Cancer Research UK, 2011a); it can also now be stated
that around one in eight of those aged at least 65 years are currently cancer survivors.
The overall estimate of 2.0 million cancer survivors at the end of 2008 is far higher than
that of 1.2 million at the end of 1992 that was published by Forman et al. (2003). 
However, this analysis has shown that in recent years the absolute number of cancer 
survivors in the UK has increased by approximately 3% per annum, and if a similar 
rate of increase is assumed to apply over the entire period between 1992 and 2008, then
the two figures are consistent. Not only is cancer prevalence increasing overall, but the 
relative prevalence of diﬀerent types of cancer is also changing. For example, prostate 
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and female breast cancers have shown some of the largest increases in incidence rates 
and survival of all cancers in the UK since 1992 (Cancer Research UK, 2009a), 
resulting in the proportion of total sex-specific prevalence accounted for by each 
increasing from 14% and 37% in 1992 (Forman et al., 2003) to 31% and 46% in 2008, 
respectively.
Cancer prevalence varied between the constituent countries of the UK, with Northern 
Ireland having the lowest prevalence proportion per 100,000 population and Wales the 
highest. Age-specific proportions for each country are not presented here, but these 
observed diﬀerences are, at least in part, attributable to the diﬀerent age structures in 
each country; Northern Ireland has the youngest population (63% aged under 45 years; 
UK average of 59%) and Wales has the oldest population (18% aged at least 65 years; 
UK average of 16%). Diﬀerent patterns of adoption of the PSA test in the early 1990s 
resulted in higher detection rates of prostate cancer in mainland Britain compared with
those in Northern Ireland. Consequently, recorded prostate cancer incidence rates 
between 1993 and 2003 remained lower in Northern Ireland than in the rest of the UK 
(Fitzpatrick et al., 2006) and this may also help to explain the lower prevalence of 
prostate cancer in Northern Ireland.
In areas where cancer registration is less comprehensive than in the UK, models of 
historical incidence and survival have been developed to estimate current cancer 
prevalence (Capocaccia and De Angelis, 1997). However, in the work presented here, 
little modelling was required due to the large amount of available cancer registry data 
and for simplicity prevalence was treated as an isolated statistic. Nevertheless, it is 
important to appreciate that prevalence is not a completely isolated measure, and that 
historical incidence and survival combine to produce the prevalence figures of today. 
Figure 2.1 provides an illustration of this: a cancer with a poor prognosis, such as lung 
cancer, accounts for a very small proportion of prevalence, despite being one of the 
most commonly diagnosed cancers. Conversely, prostate and female breast cancers, with
relatively good prognoses, account for larger proportions of prevalence than they do for 
new incident cases. Changes in incidence and survival (brought about by changes in 
lifestyle, population demographics, cancer diagnosis and treatment, health service 
policy, etc.) will therefore have significant consequences for the prevalence of cancer. 
For example, since the 1970s, the proportion of the UK male population who are 
smokers has decreased from over 50% to under 30% (Davy, 2006), resulting in a 
decrease in male lung cancer incidence and, in turn, a decrease in prevalence. The 
Chapter 2. Cancer prevalence in 2008
36
eﬀects of changing incidence rates, survival and population demographics on cancer 
prevalence are explored in greater depth in Chapter 6.
The previous most recent estimates of UK cancer prevalence related to 1992 (Forman et
al., 2003). Since then, cancer prevalence has changed markedly. Therefore, the up-to-
date estimates contained here are highly relevant for both statutory and voluntary 
sector organisations that are responsible for planning and providing treatment and 
support to cancer survivors in the UK. In the coming years, cancer prevalence is likely 
to continue increasing as a result of the growing and ageing population of the UK, 
increased detection of cancer and longer survival. It was estimated that, overall, the 
annual rate of increase in the number of cancer survivors is currently around 3%, and it
is anticipated that this rate of increase will continue in the near future. Issues 
surrounding care and support for cancer survivors ought to, therefore, remain high on 
the public health agenda, and analysis and projections of cancer incidence, prevalence 
and mortality should become increasingly central to resource planning decisions. Cancer
detection and treatment resources tend to focus on the most commonly diagnosed types
of cancer, or those that cause the most deaths, but when considering cancer prevalence 
the most significant cancers are those with both a high incidence rate and a relatively 
good prognosis in terms of survival (such as prostate cancer and female breast cancer).
Knowledge of the natural progression of a particular type of cancer, together with 
analysis of prevalence according to time since diagnosis, gives some indication of 
diﬀerent phases of survivorship, but does not fully show the extent to which survivors 
require, or are receiving, care and support. Many survivors will be newly diagnosed and
in active treatment, others may be in a state of remission or recurrence with or without
late eﬀects of treatment, others may be receiving palliative care, whereas some may 
consider themselves to be completely free of cancer. Awareness of these diﬀerences is 
important when assessing the health care burden of cancer, the financial costs of which 
have been shown to be highest during initial treatment and end of life care (Brown et 
al., 1999). The work presented in this chapter is extended to provide additional details 
about the diﬀerent phases of survivorship (see Chapter 3), as well as to analyse the 
factors that influence cancer prevalence over time (see Chapter 6).      
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Chapter 3. Health service utilisation and phases of 
survivorship
In Chapter 2, estimates of cancer prevalence in the UK at the end of 2008 were 
presented for a variety of diﬀerent cancer types, according to attained age and time 
since diagnosis. These are significant as the most up-to-date national estimates of 
cancer prevalence in the UK. 
In this chapter, the basic description of cancer prevalence in the UK is enhanced with 
information about the level of health service utilisation among cancer survivors in 
diﬀerent temporal ‘phases’ of survivorship. Much of the work presented in this chapter 
was published in 2011 as two journal articles (Maddams et al., 2011a, b) – reprints of 
these articles can be found in Appendix C.
3.1 Introduction
There are approximately two million cancer survivors in the UK and in recent years 
this number has increased by approximately 3% per annum (Chapter 2). The increasing
prevalence of cancer in the UK is largely due to the ageing population, earlier detection
of cancers and improved treatment regimes leading to increased recorded survival. The 
Cancer Reform Strategy, (Department of Health, 2007) highlighted the need for a 
National Cancer Survivorship Initiative (eventually established in 2008) to focus on the 
needs of the growing population of survivors. Cancer survivorship has been defined as 
the experience of ‘living with or beyond cancer’ – the time spent as a survivor – and is 
often described in such terms (McCabe, 2007; Cooley, 2010a, b; Nyatanga, 2010; 
National Cancer Survivorship Initiative, 2011). Yet, until recently, there has been little 
co-ordinated study of cancer survivors’ experiences and interaction with health services.
It is important that a study of cancer survivorship adds to our understanding of the 
cancer burden in terms of a) the personal psychosocial and physical burden to the 
individual survivor; and b) the resource burden to the health service and society at 
large. Whilst valuable, a simple enumeration of cancer survivors tells us only a limited 
amount about the burden presented by the disease in these terms, and there is 
therefore a need for more detailed analyses of cancer prevalence and cancer survivors in
the UK.
In this chapter, person-time analyses of a linked cancer registry and health service 
activity dataset are presented. Firstly, acute health service utilisation among cancer 
survivors in the UK is described according to attained age and time since diagnosis. 
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Secondly, four diﬀerent ‘phases of survivorship’ are defined in terms of time since 
diagnosis and time until death. These phases are then combined with three categories 
of health service utilisation intensity, as well as three broad age groups, to define a set 
of survivorship states. The number of cancer survivors in the UK at the end of 2008 in 
each of these states is then estimated.
3.2 Background and literature
Recorded cancer survival in the UK has increased substantially over the last 25 years 
(Rachet et al., 2008b, 2009). Large increases have been observed particularly for 
colorectal, female breast and prostate cancers, which have seen deprivation adjusted 
increases in 10-year relative survival of around 5%, 10% and 16%, respectively (Mitry 
et al., 2008a, b; Quinn et al., 2008; Rowan et al., 2008). Lung cancer, although one of 
the most commonly diagnosed cancers in the UK, continues to have extremely low 
survival which has remained largely constant since the 1970s (Rachet et al., 2008a). 
Earlier detection of cancer through, for example, the PSA test for prostate cancer, 
mammography screening programmes for female breast cancer and better public 
awareness of early cancer symptoms, as well as improved treatment regimes, have all 
contributed to the observed increases in survival in the UK (partly due to the 
introduction of lead time or length bias (Duﬀy et al., 2008)). Consequently, for many 
people diagnosed with cancer it is no longer considered the death sentence it once was 
(Maliski et al., 2002; Hubbard, 2010). Indeed, it has been argued that in many cases 
cancer may be better described as a chronic illness, i.e. one characterised by a 
prolonged duration and a recurring nature (Markman, 2006). For some, this description
is unhelpful (Vera-Garcia, 2005), but for others the proposed shift towards thinking of 
cancer as a chronic illness is positive and provides the opportunity for long-term 
planning of eﬀective disease surveillance and intervention (Phillips and Currow, 2010).
As survival increases, so does the number of long-term survivors and survivorship 
experiences become more diverse. The study of survivorship must therefore go beyond a
simple enumeration of survivors. Describing cancer prevalence according to pre-defined 
phases of survivorship can provide a greater understanding of the population of 
survivors, their needs and experiences. Prevalence is often estimated directly from 
cancer registry data, and using these data it is convenient to simply disaggregate the 
prevalence estimates according to year of diagnosis or equivalently time since diagnosis 
(Capocaccia et al., 1997; Benhamiche-Bouvier et al., 2000; Parkin et al., 2001; 
McCarthy, 2002; Pisani et al., 2002; Gatta et al., 2004; Louchini et al., 2006; Yabroﬀ et 
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al., 2008a). Intuitively this appears a good way to broadly categorise cancer survivors –
certainly the first year following diagnosis is likely to be one of the most traumatic 
physically (as initial treatment is received) and emotionally (as survivors adjust to life 
post-diagnosis). However, in the medium and long term after diagnosis, survivorship 
experiences are likely to vary greatly across individuals, and it may not be suﬃcient to 
classify survivors by time since diagnosis alone. 
Dates of death are also available in data from most cancer registries and can be used to
identify, retrospectively, those survivors who are nearing the end of their life – for 
example, those who are less than one year from death. When combined, time since 
diagnosis and time until death can be used to define more detailed temporal phases of 
survivorship, such as ‘initial treatment’, ‘follow-up and monitoring’ and ‘end of life’ 
(Brown et al., 1999; Mariotto et al., 2006). 
Survival analysis has also been used to classify survivors. Cure modelling suggests that,
for certain types of cancer, it is possible to estimate the proportion of patients falling 
into each of two separate groups: those bound to die of their cancer, and those who will
eventually be ‘cured’ in the sense that, after a period of time, they have no excess 
mortality risk when compared with the general population (Coldman et al., 1992). 
Cured proportions can therefore be defined for cancers with relative survival functions 
that are approximately constant a certain amount of time after diagnosis. Survivors of 
colorectal cancer have been shown to suﬀer little excess mortality compared with the 
general population after about 6–8 years of survival, and therefore could be considered 
‘cured’ (Verdecchia et al., 1998; Lambert et al., 2007; Smastuen et al., 2008), but this is
not possible for all cancers – for example, survivors of female breast cancer are unlikely 
ever to reach a point of cure in this sense (Brenner and Hakulinen, 2004; Francisci et 
al., 2009). Nonetheless, statistical cure defined in this fashion has been used to estimate
the number of ‘cured survivors’ who could be considered as no longer contributing to 
the cancer burden (Capocaccia et al., 1997; Verdecchia et al., 1998; Phillips et al., 2002;
Gatta et al., 2004; Lambert et al., 2007; Francisci et al., 2009). This is a rather heavy-
handed approach to survivorship though, since the concept of statistical cure is quite 
theoretical, and distinct from clinical cure. Indeed, even a genuinely, clinically ‘cured’ 
survivor may continue to suﬀer the consequences of their diagnosis through late eﬀects 
or disability from treatment, financial hardship, anxiety and depression, fear of 
recurrence, etc. (Simonelli et al., 2008). 
Another dimension that can augment the basic prevalence statistics is the use of health
care services by cancer survivors. This not only helps to describe one aspect of the 
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survivorship experience, but also provides an estimate of a proportion of the financial 
and resource burden of the disease to health care services and society. Detailed 
information regarding health service utilisation is not generally available in cancer 
registry data, and so an external data source is required as a supplement. In the UK, 
hospital activity data are routinely collected and have been used in Scotland to analyse 
hospital admission rates in terms of the number of episodes of care (not specific to 
cancer or cancer survivors) per 100,000 population (Information Services Division 
Scotland, 2011), as well as the average lengths of stay and number of bed days utilised. 
In the USA, the SEER-Medicare linked dataset has been used to estimate the burden 
of colorectal cancer by analysing the quantity of health care given to survivors in four 
phases of survivorship – initial diagnosis and treatment, post-diagnostic monitoring, 
treatment for recurrent/metastatic disease and terminal care (Mariotto et al., 2003). 
The patterns of recurrence or later metastatic disease in cancer survivors have also been
the subject of direct cohort follow-up studies in Europe (Benhamiche-Bouvier et al., 
2000; Colonna et al., 2001; Gatta et al., 2004), and these have led to estimates of the 
proportion of survivors who are in complete remission – a complement to the estimates 
of statistically cured survivors. In France, Colonna et al. (2012) demonstrated how a 
joint analysis of cancer registry data and hospital medico-administrative data could be 
used to estimate ‘hospital prevalence’ – i.e. the number (and proportion) of cancer 
survivors admitted to hospital for cancer-related care within a given time period. They 
found that, of the women who had been diagnosed with breast cancer in the previous 
33 years, 17% were hospitalised during 2007. This was considered to be a good measure
of the amount of care required by cancer survivors, although explicit consideration was 
not given to any unmet needs.
In certain countries it has been possible to use hospital activity and administrative data
to directly estimate the financial costs associated with cancer at diﬀerent stages of the 
survivorship pathway. Yabroﬀ et al. (2008b) developed the work of Mariotto et al. 
(2003) by estimating the financial costs incurred by Medicare (the medical insurance 
company) relating to treatment and care of colorectal cancer survivors in the USA. By 
matching cancer patients to non-cancer controls in the dataset, cancer-specific costs 
were estimated for the ‘initial’, ‘continuing’ and ‘last year of life’ phases of survivorship,
and projected from the year 2000 to 2020. The estimated costs of colorectal cancer care
among those aged over 65 were projected to increase substantially – by 53% over the 20
year period if incidence, survival and financial costs remained constant, and by 89% if 
existing trends continued. A similar analysis of the SEER-Medicare database was 
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conducted by Ramsey et al. (2002) to estimate the lifetime cancer-attributable costs of 
care for long-term colorectal cancer survivors. The financial cost of medical care for 
these cancer survivors was found to be significantly higher than matched non-cancer 
controls, even up to 10 years after the date of diagnosis. In Sweden, Norlund et al. 
(2003) used cancer registry and regional administrative data to estimate the total costs 
of in-patient and out-patient healthcare for prostate cancer survivors up to three years 
after diagnosis. They found that costs were highest in the first year after diagnosis and 
decreased in subsequent years. 
It is clear that as the cancer care agenda in the UK shifts attention towards 
survivorship, there is a need for more in-depth prevalence statistics that identify 
distinct sub-groups of the cancer survivor population and describe the experience of 
survivorship in more detail. 
3.3 Materials and methods
3.3.1 Data
The analysis presented in this chapter was based on two datasets which were linked at 
the patient level: the English national merged cancer registry dataset and the English 
Cancer Registries’ National Hospital Episode Statistics (HES) extract. The former 
featured patient and diagnostic information relating to all cancers diagnosed between 
1990 and 2006 and recorded by the eight regional population-based cancer registries in 
England which, together, provide 100% geographical coverage of the country. HES is a 
record level data repository managed by the National Health Service Information 
Centre on behalf of the Secretary of State for Health. It contains patient, clinical and 
administrative details for admitted patients and out-patients treated in any hospital 
operated by the National Health Service (NHS) in England, and is mainly populated by
extracts from routine data flows exchanged between health care providers and 
commissioners (NHS Health and Social Care Information Centre, 2010). Each HES 
record defines a Finished Consultant Episode (FCE) of care under a given consultant in
a given NHS provider. A patient’s journey from admission to discharge may be made 
up of many FCEs. The English Cancer Registries’ National HES extract is a subset of 
the complete HES database and contains only episodes for admitted patients (i.e. in-
patients and day case patients) who have at least one recorded episode ‘for or with’ 
cancer. An episode is considered to be ‘for or with’ cancer if any of its 14 diagnostic 
fields contain an ICD-10 code between C00 and C97 (malignant neoplasms), between 
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D01 and D48 (in situ, benign or uncertain neoplasms) or equal to O01 (Hydatidiform 
mole).
The linkage between these two datasets was designed and developed jointly by the 
Thames Cancer Registry and the Northern and Yorkshire Cancer Registry and 
Information Service on behalf of the UK Association of Cancer Registries and the 
National Cancer Intelligence Network. The methodology was ‘rules-based’ and used 
NHS number (which is unique to each patient), date of birth, date of death where 
appropriate, sex and postcode of residence to match HES episodes of care to cancer 
patients in the national cancer registry dataset.
The national cancer registry dataset was used to define a cohort of cancer survivors 
who had been diagnosed with a malignant neoplasm (ICD-10 C00–C97 excluding C44) 
in the period 1990–2006, and alive for at least some portion of 2006. Sub-cohorts were 
defined according to type of cancer: colon, rectum and anus cancers (ICD-10 C18–C21);
lung, bronchus and trachea cancers (ICD-10 C33–C34); prostate cancer (ICD-10 C61); 
and female breast cancer (ICD-10 C50). Survivors with multiple diagnoses were 
permitted to be members of multiple sub-cohorts. The unique patient identifiers 
produced by the linkage algorithm were then used to extract all HES episodes of care 
that occurred in, or overlapped, the year 2006 for the cancer survivors in each cohort.
Not all of the extracted episodes mentioned cancer, since the English Cancer Registries’
HES extract contains all in-patient and day case episodes (from any time period) for 
those patients with at least one cancer related episode. Episodes not mentioning cancer 
may pertain to an entirely unrelated condition, or (less likely) may have been 
incorrectly coded. Equally, some cancer survivors had no matching HES episode of care
in 2006, due to either a failure to register episodes that did occur, a failure in the 
matching procedure between the two datasets or simply because they were not 
admitted to hospital in 2006. In this analysis, matched episodes of care were considered
to be ‘cancer related’ if one of the 14 diagnostic codes was between C00 and C97 
(excluding C44), otherwise they were considered to be ‘non-cancer related’.
3.3.2 Hospital activity among cancer survivors
Traditionally, prevalence estimates are calculated as a static enumeration of survivors 
at a given point in time, for example the end of the year. An alternative formulation is 
to count the amount of person-time that a population spends in cancer survivorship 
during a given period of time, for example a complete calendar year. When considering 
the interaction of survivors with the health service, the person-time formulation has a 
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distinct advantage since it allows us to estimate the proportion of survivor-time spent 
admitted to hospital as well as to count the number of admissions. For this reason, a 
person-time approach was used throughout this analysis.
The first goal of the person-time analysis was to describe the eﬀect of attained age and 
time since diagnosis on the amount of hospital activity in the population of cancer 
survivors. The most recent calendar year for which data were available, 2006, was 
chosen to be the period of analysis. Attained age was considered in 5-year groups up to 
and including 84 with a final group for those aged 85 and over. Time since diagnosis 
was considered in the broad ranges: <1, 1–5 and ≥5 years. Diagnoses were available for
the period 1990–2006 inclusive, so in the data there were some survivors prevalent 
during 2006 who had been diagnosed more than 16 (but less than 17) years previously. 
However, the 2006 cohort did not contain all such survivors (since no diagnoses from 
1989 were available) and therefore the maximum time since diagnosis considered was 16
years. Hence, the ‘≥5 years’ time since diagnosis band actually related to 5–16 years 
since diagnosis.
For each survivor in each cohort, the person-time for which they were prevalent in 2006
(i.e. that which was post-diagnosis and pre-death and overlapped the calendar year 
2006) was split into segments according to the time points at which the indexing 
variables ‘attained age’ and ‘time since diagnosis’ changed. This was achieved using the
SAS statistical software package (SAS Institute Inc., Cary, NC, USA) and a series of 
programs developed specifically for this task, based on the program Lexis.sas by 
Carstensen (2007). This approach is similar to that used when conducting survival 
analyses using the ‘period’ method, where cross-sectional person-time at risk is 
considered for a given calendar period (Brenner and Gefeller, 1997).
A Lexis diagram (Lexis, 1875) can be used to illustrate this process. This diagram – 
named after the German demographer Wilhelm Lexis (1837–1914) and an example of 
Stigler’s Law of Eponymy (Stigler, 1999; Vandeschrick, 2001) – is a simple chart that 
can be used to present population dynamics according to three demographic co-
ordinates: cohort of birth, calendar time and attained age. These co-ordinates are 
linearly dependent (since cohort of birth is defined as calendar time minus attained age)
and can therefore be represented on a two-dimensional chart. Lexis originally proposed 
a (cohort, age) co-ordinate system, but modern Lexis diagrams use a (calendar time, 
age) co-ordinate system with each person represented by a line segment starting at 
birth and ending at death, in such a way that the slope of the line is 1 (Keiding, 2006). 
A single trajectory in the Lexis diagram may be shared by more than one individual in 
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a population. Figure 3.1 depicts a Lexis diagram for four cancer survivors prevalent 
during 2006, with the line segments starting at the date of diagnosis (rather than birth)
and ending, where applicable, at death.









During the calendar year, each survivor has two possible anniversaries – the points at 
which either their discrete attained age or time since diagnosis in years increases by 
one. These anniversaries were used to classify their person-time of prevalence (see 
Figure 3.2). By summing the lengths of the person-time segments along the calendar 
time axis in the Lexis diagram, the total amount of person-time of prevalence in 2006 
for each cohort of survivors was calculated according to 5-year attained age group and 
single year since diagnosis.
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Figure 3.2. Illustrative survivor person-time segments for the year 2006, indexed 

















Using similar methods, the person-time of hospital activity among cancer survivors was
also calculated according to 5-year attained age group and single year since diagnosis. 
Day case episodes with the same start date and end date were considered to have a 
duration of one day – therefore, for consistency, the duration of an episode featuring 
overnight stays in hospital was calculated as the number of days between the start date
and end date, inclusive. The proportion of total person-time each cohort of survivors 
spent admitted to hospital, according to attained age and time since diagnosis, was 
then calculated by dividing the total population person-time of hospital activity by the 
total population person-time of prevalence. This quantity may be interpreted as the 
mean proportion of time in the analysis period spent admitted to hospital by a survivor
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of a given age and time since diagnosis sampled at random. Or, equivalently, as an 
estimate of the probability of that survivor being an admitted hospital patient on any 
given day in the period. It may be presented as the number of days spent admitted to 
hospital per 100 person-days, or as a percentage.
To formalise these methods, the following definitions are made for a cohort of N  
survivors prevalent for some portion of the time period (0, T ] (for example, a calendar 
year) where each individual is indexed by i, with i ∈ [1, N ]:
Xi,a,y,t =

1 B7 BM/BpB/mH i Bb  bm`pBpQ` ;2/ a M/ y v2`b





1 B7 BM/BpB/mH i Bb  bm`pBpQ` M/ M /KBii2/ ?QbTBiH TiB2Mi
;2/ a M/ y v2`b TQbi@/B;MQbBb i /Bb+`2i2 iBK2 t ∈ [1, T ]
0 Qi?2`rBb2
[3.2]
where y is measured discretely as the number of whole years that have passed since 
diagnosis.
Then, the number of time units (e.g. days) spent as a survivor of attained age a and y 




Therefore, summed over all individuals in the population, the total person-time of 







Similarly, the total person-time of hospital activity among survivors aged a and y years







Then, the proportion of all time spent admitted to hospital by survivors aged a and y 
years since diagnosis is given by:






This is also the mean proportion of time in the period (0, T ] spent admitted to hospital 
for an individual sampled at random from the prevalent population.
Suppose for a given survivor i, aged a and y years since diagnosis, that Xi,a,y,t = 1 for 
all t ∈ [t1, t2], and Xi,a,y,t = 0 for all t /∈ [t1, t2]. In other words, the person-time of 
prevalence segment starts at t1 and ends at t2. Let mi,a,y = t2 − t1 + 1 be the duration 
(in days) of the person-time segment. Then, the random variables {Hi,a,y,t : t ∈ [t1, t2]} 
form a sequence of mi,a,y Bernoulli trials and each follows the binomial distribution. 
However, these are not independent trials since days in hospital for an individual 
survivor are likely to be clustered together in episodes or spells of care, rather than 
randomly distributed in time. This situation is called positive serial dependence 
(Budescu, 1985) and must be accounted for when estimating confidence intervals for 
Ra,y.
Perhaps the simplest way to model this dependence is to assume that the random 
variables {Hi,a,y,t : t ∈ [t1, t2]} form a stationary first order Markov chain – i.e. the 
probability that Hi,a,y,t = 1 is independent of all preceding trials with the exception of 
that which immediately precedes it (the first order Markov condition), and this 
probability is independent of the trial number (the stationary condition) (Feller, 1971: 
p.94–99). The standard binomial model for independent trials is modified for the 
dependent situation by including an additional dependence parameter, 
λ = Pr(Hi,a,y,t = 1 | Hi,a,y,t−1 = 1) for t ∈ [t1 + 1, t2] (Klotz, 1973). Budescu (1985) gave 
a method for estimating λ using maximum likelihood estimates of the transition 
probabilities between consecutive Bernoulli trials, and provided an approximate 
confidence interval for the success probability (i.e. in this context, the probability of a 
day being spent in hospital) when estimated from a sample of N  individuals, where 
dependence exists within each subject’s trials but there is independence between 
subjects. This method was used to estimate confidence intervals for Ra,y, the proportion
of time spent in hospital activity by cancer survivors.
3.3.3 Survivorship states
To provide a means for further enriching the basic prevalence statistics, distinct 
temporal phases of survivorship were defined according to time since diagnosis and time
until death. Specifically, at a given point in time, distinctions were made between 
survivors who were in the first year after diagnosis and those who were not, and 
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survivors who were in the last year of their life and those who were not. Four temporal 
phases of survivorship, depicted in Figure 3.3, were thus defined:
• Phase A: less than one year before death and less than one year after diagnosis.
• Phase B: less than one year before death and more than one year after diagnosis.
• Phase C: more than one year before death and less than one year after diagnosis.
• Phase D: more than one year before death and more than one year after diagnosis.
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An analysis of these temporal phases requires dates of diagnosis and dates of death 
(data readily available in UK cancer registries) and, at a given point in time, every 
survivor will be in one, and only one, phase. They therefore provide a practical and 
useful way of sub-dividing the population of cancer survivors, and are largely 
comparable to the definitions used by Brown et al. (1999) and Mariotto et al. (2006) 
who both defined the ‘initial’ phase according to time since diagnosis (≤6 or ≤12 
months), the ‘end of life/terminal’ phase as the last year of life and the ‘continuing 
care/monitoring’ phase as everything in between.
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3.3.3.1 Analysis for England in 2006
Details of cancer diagnoses among residents of England made in the period 1990–2006, 
and the corresponding hospital activity data for these patients, were available in the 
linked cancer registry and hospital activity dataset. Death notifications (provided in 
England by the Oﬃce for National Statistics) were available for survivors in the cancer 
registry dataset up to the end of 2008, so it was possible to identify the points in time 
during 2006 at which any survivors entering the last year of their life did so. For each 
survivor, the person-time for which they were prevalent in 2006 (i.e. that which was 
post-diagnosis and pre-death and overlapped the calendar year 2006) was split into 
segments according to the time points at which they moved between temporal phases or
broad age groups (0–44, 45–64 and ≥65 years).
For each survivor, each segment of person-time was then indexed according to ‘intensity
of acute health service utilisation’ by calculating the combined duration of cancer 
related hospital episodes that occurred within it. ‘Intensity of acute health service 
utilisation’ was considered to be ‘high’ if hospital activity accounted for more than 10%
of the person-time segment; it was considered to be ‘low’ if hospital activity accounted 
for some, but no more than 10%, of the segment; and a separate category, ‘none’, was 
reserved for those segments of person-time which contained no hospital activity.
There were, therefore, 12 possible survivorship states defined according to temporal 
phase and intensity of acute health service utilisation (Table 3.1). The total amount of 
person-time spent by the population of cancer survivors in each of these states was 
calculated separately for each cancer type, sex and broad attained age group.
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Table 3.1. Twelve survivorship states.













Under certain assumptions, the proportion of total population person-time spent in 
each survivorship state is equal to the proportion of the prevalent population in that 
state at a given point in time during the analysis period (see Lemma 3.1 below). Using 
this fact, the summed population person-time described above was used to estimate the
proportion of survivors in each state at the end of 2006 in England.
Lemma 3.1
Consider a population of survivors, {i}, each of whose person-time of prevalence 
overlaps the time interval (0, T ]. The actual number of survivors will fluctuate during 
this period. But suppose that the number and attained age of survivors at a given point
in time in the period, say u ∈ (0, T ], is known, as is the total amount of person-time 
spent in each phase of survivorship and age group during the period.
Let t ∈ (0, T ] be the discrete time sampling point at which prevalence is evaluated;
Let Na,t be the number of survivors aged a at time t;




1 B7 bm`pBpQ` i Bb ;2/ a M/ BM T?b2 p i iBK2 t
0 Qi?2`rBb2 ;
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Let Sa be the total person-time of prevalence at age a, summed over all survivors in the
period 0 < t ≤ T ;
Let sa,p be the total person-time of prevalence spent in phase p at age a, summed over 
all survivors in the period 0 < t ≤ T ;
Then, if we assume that the distribution of Na,t is in steady state throughout the 
period 0 < t ≤ T , then the expected number of survivors aged a in phase p at time t 
sampled at random from the interval (0, T ] is estimated by the total number of 
survivors at time T  multiplied by the proportion of total person-time of prevalence at 










































































where N¯a,t is the expected value of Na,t sampled randomly at time t.
Dividing [3.8] by [3.10] gives












Since the distribution of the number of survivors aged a, Na,t, is assumed to be in 
steady state throughout the period 0 < t ≤ T , we may estimate the expected value N¯a,t 
by Na,u, where u is the point at which the number of survivors is known (0 < u ≤ T ). 
Then, letting u = T  and N¯a,t = Na,T in [3.12] gives the required result:
n¯a,p,t ≈ Na,T sa,pSa . [3.13]
3.3.3.2 Extrapolation to complete prevalence in the UK in 2008
In order to use the person-time analysis pertaining to England in 2006 (as described in 
the previous section) to estimate the proportion of survivors in each survivorship state 
in the UK at the end of 2008 (cf. Chapter 2), it was assumed that the distribution of 
survivors between states was the same for the whole of the UK as it was for England, 
and did not change between 2006 and 2008.
The cancer registry dataset contained diagnoses made in the period 1990–2006. The 
person-time analysis for 2006 therefore completely described only those survivors 
diagnosed up to 16 years previously (16-year prevalence). Some extrapolation was 
therefore required to extend the analysis to complete prevalence. By definition, 
survivors more than 16 years beyond diagnosis are in either temporal phase B or D. It 
was assumed that the distribution of survivors between these two phases was the same 
for those more than 16 years beyond diagnosis as it was for those between 15 and 16 
years beyond diagnosis. Figure 3.4 shows the estimated proportion of female cancer 
survivors in phase D, by time since diagnosis up to 16 years – it can be seen that this 
proportion is quite steady for time since diagnosis greater than 10 years in all age 
groups, and therefore the above assumption was considered reasonable.
It was also assumed that the relative numbers of survivors with an acute health service 
utilisation intensity of ‘high’, ‘low’, or ‘none’ in each temporal phase B or D were the 
same for survivors greater than 16 years beyond diagnosis as they were for those in that
phase no more than 16 years beyond diagnosis.
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As noted in section 2.4, the number of male lung cancer survivors at least 20 years 
beyond diagnosis at the end of 2008 was likely to have been overestimated (possibly by 
up to 8,000). For consistency, the analysis in this chapter used the same prevalence 
figures presented in Chapter 2, and so the number of male lung cancer survivors more 
than one year beyond diagnosis (phases B and D combined) is also likely to be an 
overestimate.
Figure 3.4. Proportion of female survivors (all malignant neoplasms) in temporal 


















3.4.1 Hospital activity among cancer survivors in England in 2006
Figures 3.5 and 3.6, and the corresponding Tables 3.2–3.9, display the mean number of 
days (per 100 person-days) spent admitted to hospital by cancer survivors in England 
during 2006, by attained age and time since diagnosis. Results are presented for cancer 
related and non-cancer related episodes of care separately, but are omitted if less than 
20 person-years of prevalence contributed to the estimate.
Figure 3.5 shows that, for each age group, the number of days spent admitted to 
hospital for cancer related episodes of care (per 100 person-days) was highest in the 
first year after diagnosis. For both male and female colorectal cancer survivors, it was 
approximately 7 times higher than in the period 1–5 years after diagnosis, and 35 times
higher than in the period ≥5 years after diagnosis. Similarly, for lung cancer survivors 
it was approximately 5 times higher than in the period 1–5 years after diagnosis, and 
40 times higher than in the period ≥5 years after diagnosis. Although the first year 
after diagnosis contained by far the highest levels of cancer related hospital activity, 
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cancer survivors also experienced a significant amount of hospitalisation between one 
and five years after diagnosis.
The number of days spent admitted to hospital for cancer related episodes of care (per 
100 person-days) in the first year after diagnosis was significantly higher among 
survivors over the age of 75, compared with younger survivors. This is most noticeable 
for survivors of prostate cancer – those aged at least 85 years spent around three times 
as many days admitted to hospital for cancer related care in the first year after 
diagnosis, compared with those aged between 70 and 74 years.
In the first five years after diagnosis, the number of days admitted to hospital for 
cancer related episodes of care (per 100 person-days) was highest among lung cancer 
survivors; it was lowest among prostate and female breast cancer survivors. In the 
period more than five years after diagnosis there was little diﬀerence in the proportion 
of time spent admitted to hospital for cancer related care between survivors of diﬀerent
cancer types.
Among prostate cancer survivors, the relatively young and relatively old age groups 
spent a higher proportion of time admitted to hospital for cancer related episodes in 
the first five years after diagnosis than the middle age groups (50–75 years). A similar 
trend was observed among female breast cancer survivors.
The number of days spent admitted to hospital for non-cancer related episodes of care 
(per 100 person-days) generally increased as attained age increased above 60 years, and
showed no definitive age association among younger survivors (Figure 3.6). It generally 
increased slightly as time since diagnosis decreased among survivors of colorectal and 
lung cancer, but there was little diﬀerence in each time since diagnosis band among 
survivors of prostate and female breast cancers.   
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Figure 3.5. Mean cancer related admitted patient hospital activity among cancer 
survivors, England, 2006. Number of days admitted to hospital per 100 person-days 













































































Results are not plotted if the total person-time of prevalence that contributed was less than 20 years. 
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Figure 3.6. Mean non-cancer related admitted patient hospital activity among 
cancer survivors, England, 2006. Number of days admitted to hospital per 100 person-
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Results are not plotted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.2. Mean cancer related admitted patient hospital activity among survivors of 
colon, rectum and anus cancers, England, 2006. Number of days in hospital per 100 
person-days (95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis






20–24 6.85 (5.44–8.25) 1.11 (0.08–2.15)
25–29 9.48 (8.36–10.60) 1.43 (0.64–2.22)
30–34 7.10 (6.11–8.09) 1.02 (0.34–1.70) 0.11 (0.00–1.43)
35–39 8.41 (7.78–9.04) 0.83 (0.50–1.15) 0.11 (0.00–0.58)
40–44 6.88 (6.42–7.34) 1.09 (0.84–1.34) 0.24 (0.00–0.59)
45–49 6.70 (6.39–7.00) 1.28 (1.09–1.47) 0.25 (0.00–0.51)
50–54 7.04 (6.81–7.28) 1.23 (1.09–1.37) 0.32 (0.13–0.50)
55–59 7.17 (7.00–7.34) 1.14 (1.05–1.24) 0.32 (0.21–0.42)
60–64 7.49 (7.34–7.65) 0.99 (0.91–1.06) 0.24 (0.16–0.32)
65–69 7.80 (7.65–7.94) 1.22 (1.14–1.29) 0.31 (0.24–0.38)
70–74 7.69 (7.55–7.84) 0.97 (0.90–1.04) 0.30 (0.24–0.35)
75–79 7.86 (7.70–8.03) 0.94 (0.88–1.01) 0.33 (0.27–0.38)
80–84 8.23 (7.99–8.47) 0.98 (0.89–1.07) 0.38 (0.32–0.44)






20–24 9.23 (7.07–11.39) 1.01 (0.00–2.06)
25–29 8.47 (7.21–9.72) 1.36 (0.59–2.14) 0.23 (0.00–1.28)
30–34 6.45 (5.51–7.40) 1.07 (0.60–1.54) 0.04 (0.00–0.57)
35–39 7.60 (6.97–8.24) 1.09 (0.69–1.49) 0.63 (0.00–1.47)
40–44 6.84 (6.44–7.24) 1.27 (1.00–1.54) 0.51 (0.03–0.99)
45–49 7.14 (6.81–7.47) 1.45 (1.21–1.69) 0.17 (0.00–0.38)
50–54 7.15 (6.88–7.42) 1.29 (1.12–1.46) 0.16 (0.00–0.32)
55–59 7.28 (7.08–7.49) 0.99 (0.88–1.10) 0.27 (0.14–0.40)
60–64 7.43 (7.24–7.63) 0.90 (0.80–0.99) 0.21 (0.12–0.31)
65–69 7.23 (7.05–7.41) 1.02 (0.92–1.11) 0.26 (0.18–0.35)
70–74 7.79 (7.60–7.97) 0.84 (0.75–0.92) 0.24 (0.17–0.31)
75–79 7.71 (7.52–7.91) 0.83 (0.74–0.91) 0.24 (0.18–0.31)
80–84 8.19 (7.93–8.46) 0.78 (0.68–0.89) 0.26 (0.19–0.34)
≥85 9.02 (8.66–9.38) 0.74 (0.61–0.88) 0.21 (0.14–0.27)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.3. Mean non-cancer related admitted patient hospital activity among survivors
of colon, rectum and anus cancers, England, 2006. Number of days in hospital per 100 
person-days (95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis






20–24 1.47 (0.51–2.44) 0.84 (0.20–1.48)
25–29 1.47 (0.82–2.13) 1.12 (0.78–1.47) 0.03 (0.00–0.17)
30–34 0.64 (0.31–0.97) 0.31 (0.11–0.51) 0.13 (0.00–0.37)
35–39 0.79 (0.55–1.04) 0.58 (0.42–0.73) 0.14 (0.03–0.26)
40–44 1.05 (0.79–1.30) 0.35 (0.27–0.43) 0.22 (0.12–0.32)
45–49 1.26 (1.06–1.46) 0.57 (0.48–0.65) 0.31 (0.23–0.40)
50–54 0.89 (0.77–1.01) 0.54 (0.48–0.59) 0.34 (0.27–0.41)
55–59 0.83 (0.75–0.92) 0.57 (0.53–0.61) 0.30 (0.26–0.34)
60–64 1.00 (0.92–1.08) 0.74 (0.70–0.77) 0.38 (0.35–0.42)
65–69 1.23 (1.15–1.31) 0.79 (0.75–0.82) 0.39 (0.36–0.42)
70–74 1.38 (1.30–1.45) 0.87 (0.84–0.90) 0.61 (0.57–0.64)
75–79 1.50 (1.42–1.58) 0.96 (0.93–1.00) 0.76 (0.72–0.79)
80–84 1.77 (1.66–1.88) 1.34 (1.29–1.39) 0.98 (0.93–1.02)






20–24 1.26 (0.47–2.05) 0.43 (0.00–0.89)
25–29 0.67 (0.18–1.16) 0.31 (0.11–0.51) 0.58 (0.21–0.95)
30–34 1.24 (0.69–1.79) 0.35 (0.16–0.54) 0.28 (0.05–0.51)
35–39 0.82 (0.54–1.09) 0.42 (0.30–0.55) 0.64 (0.38–0.91)
40–44 0.69 (0.49–0.89) 0.44 (0.33–0.54) 0.49 (0.36–0.62)
45–49 0.98 (0.81–1.16) 0.64 (0.55–0.72) 0.30 (0.23–0.38)
50–54 0.87 (0.73–1.01) 0.52 (0.46–0.58) 0.25 (0.20–0.30)
55–59 0.89 (0.79–1.00) 0.56 (0.51–0.61) 0.26 (0.22–0.31)
60–64 0.78 (0.69–0.88) 0.55 (0.51–0.59) 0.26 (0.23–0.30)
65–69 1.05 (0.96–1.14) 0.57 (0.53–0.61) 0.39 (0.36–0.43)
70–74 1.10 (1.01–1.18) 0.77 (0.73–0.81) 0.49 (0.45–0.53)
75–79 1.53 (1.43–1.63) 0.93 (0.88–0.97) 0.59 (0.55–0.63)
80–84 1.96 (1.84–2.08) 1.31 (1.25–1.37) 0.87 (0.82–0.92)
≥85 2.07 (1.91–2.23) 1.59 (1.51–1.67) 1.02 (0.96–1.07)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.4. Mean cancer related admitted patient hospital activity among survivors of 
lung, bronchus and trachea cancers, England, 2006. Number of days in hospital per 100 
person-days (95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis









35–39 9.02 (7.76–10.27) 1.81 (0.86–2.77) 0.21 (0.00–1.59)
40–44 9.12 (8.45–9.79) 1.60 (0.64–2.57) 0.10 (0.00–0.74)
45–49 9.15 (8.69–9.61) 2.43 (1.78–3.08) 0.07 (0.00–0.44)
50–54 9.46 (9.13–9.80) 1.72 (1.42–2.02) 0.16 (0.00–0.71)
55–59 9.40 (9.18–9.63) 1.93 (1.72–2.15) 0.43 (0.15–0.72)
60–64 8.83 (8.65–9.01) 1.98 (1.81–2.15) 0.29 (0.09–0.50)
65–69 9.58 (9.41–9.76) 1.95 (1.79–2.12) 0.29 (0.15–0.44)
70–74 9.32 (9.14–9.49) 1.77 (1.61–1.94) 0.31 (0.16–0.45)
75–79 9.76 (9.56–9.95) 1.99 (1.82–2.17) 0.39 (0.26–0.53)
80–84 10.04 (9.76–10.32) 2.05 (1.80–2.30) 0.35 (0.20–0.51)








30–34 1.01 (0.00–2.71) 0.11 (0.00–1.03)
35–39 9.30 (8.05–10.54) 1.15 (0.26–2.04) 0.04 (0.00–0.76)
40–44 7.50 (6.90–8.10) 1.56 (0.92–2.20) 0.17 (0.00–0.54)
45–49 7.63 (7.24–8.02) 2.04 (1.56–2.52) 0.26 (0.00–0.76)
50–54 9.03 (8.69–9.36) 1.54 (1.22–1.86) 0.38 (0.00–0.88)
55–59 9.07 (8.83–9.31) 1.92 (1.69–2.15) 0.26 (0.01–0.52)
60–64 9.07 (8.85–9.30) 1.96 (1.75–2.17) 0.28 (0.06–0.51)
65–69 9.28 (9.06–9.49) 1.53 (1.34–1.71) 0.45 (0.22–0.67)
70–74 9.35 (9.13–9.58) 1.84 (1.64–2.04) 0.40 (0.18–0.63)
75–79 9.60 (9.34–9.85) 1.81 (1.59–2.03) 0.33 (0.16–0.51)
80–84 11.08 (10.71–11.45) 2.23 (1.90–2.55) 0.43 (0.20–0.65)
≥85 12.81 (12.19–13.42) 2.23 (1.77–2.69) 0.17 (0.00–0.40)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.5. Mean non-cancer related admitted patient hospital activity among survivors
of lung, bronchus and trachea cancers, England, 2006. Number of days in hospital per 
100 person-days (95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis









35–39 1.05 (0.21–1.89) 0.04 (0.00–0.30) 0.04 (0.00–0.21)
40–44 0.52 (0.23–0.80) 0.08 (0.00–0.26) 0.25 (0.00–0.63)
45–49 0.64 (0.38–0.89) 0.22 (0.00–0.45) 0.28 (0.00–0.69)
50–54 1.24 (0.99–1.50) 0.19 (0.07–0.30) 0.27 (0.07–0.48)
55–59 0.85 (0.72–0.99) 0.44 (0.32–0.56) 0.39 (0.19–0.59)
60–64 0.88 (0.77–0.98) 0.63 (0.54–0.73) 0.47 (0.33–0.62)
65–69 0.77 (0.68–0.86) 0.62 (0.54–0.71) 0.38 (0.29–0.47)
70–74 1.00 (0.91–1.09) 0.66 (0.57–0.74) 0.44 (0.35–0.52)
75–79 1.02 (0.93–1.11) 0.75 (0.66–0.84) 0.55 (0.46–0.64)
80–84 1.54 (1.38–1.69) 0.95 (0.82–1.08) 0.53 (0.42–0.64)








30–34 0.20 (0.00–0.52) 0.06 (0.00–0.68)
35–39 0.66 (0.05–1.27) 0.14 (0.00–0.41) 0.09 (0.00–0.34)
40–44 0.51 (0.18–0.85) 0.57 (0.13–1.02) 0.10 (0.00–0.32)
45–49 0.50 (0.28–0.72) 0.61 (0.34–0.89) 0.41 (0.00–0.85)
50–54 0.73 (0.55–0.92) 0.25 (0.11–0.38) 0.32 (0.00–0.65)
55–59 0.66 (0.53–0.79) 0.38 (0.27–0.48) 0.16 (0.05–0.28)
60–64 0.61 (0.50–0.72) 0.47 (0.36–0.57) 0.45 (0.30–0.59)
65–69 0.77 (0.66–0.88) 0.46 (0.37–0.56) 0.49 (0.37–0.62)
70–74 0.98 (0.86–1.09) 0.76 (0.65–0.87) 0.40 (0.29–0.52)
75–79 1.22 (1.09–1.35) 0.92 (0.81–1.04) 0.60 (0.45–0.74)
80–84 1.52 (1.34–1.71) 0.88 (0.74–1.03) 0.72 (0.56–0.89)
≥85 1.75 (1.47–2.03) 1.19 (0.90–1.47) 0.39 (0.17–0.60)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.6. Mean cancer related admitted patient hospital activity among survivors of 
prostate cancer, England, 2006. Number of days in hospital per 100 person-days (95% 
confidence interval), by attained age and time since diagnosis.
Time since diagnosis










40–44 2.02 (1.13–2.92) 1.87 (0.92–2.81)
45–49 1.77 (1.46–2.08) 0.81 (0.43–1.20) 0.00 (0.00–0.03*)
50–54 1.78 (1.62–1.94) 0.52 (0.39–0.65) 0.20 (0.00–0.44)
55–59 1.34 (1.27–1.42) 0.36 (0.30–0.41) 0.37 (0.24–0.50)
60–64 1.38 (1.32–1.44) 0.39 (0.35–0.43) 0.39 (0.31–0.46)
65–69 1.38 (1.33–1.43) 0.45 (0.42–0.48) 0.46 (0.41–0.51)
70–74 1.44 (1.39–1.49) 0.58 (0.55–0.61) 0.55 (0.51–0.59)
75–79 1.72 (1.66–1.78) 0.84 (0.80–0.88) 0.68 (0.64–0.72)
80–84 2.63 (2.54–2.73) 1.13 (1.08–1.18) 0.93 (0.88–0.97)
≥85 4.57 (4.41–4.74) 1.75 (1.67–1.83) 1.15 (1.08–1.21)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
*Wilson (score) confidence interval. 
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Table 3.7. Mean non-cancer related admitted patient hospital activity among survivors
of prostate cancer, England, 2006. Number of days in hospital per 100 person-days 
(95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis










40–44 0.19 (0.00–0.44) 0.31 (0.00–0.86)
45–49 0.31 (0.18–0.44) 0.14 (0.02–0.25) 0.09 (0.00–0.89)
50–54 0.28 (0.21–0.36) 0.23 (0.17–0.30) 0.15 (0.00–0.33)
55–59 0.26 (0.22–0.31) 0.16 (0.13–0.19) 0.18 (0.11–0.26)
60–64 0.34 (0.30–0.38) 0.24 (0.22–0.26) 0.27 (0.23–0.32)
65–69 0.33 (0.30–0.36) 0.31 (0.29–0.33) 0.31 (0.27–0.34)
70–74 0.38 (0.34–0.41) 0.38 (0.36–0.40) 0.39 (0.37–0.42)
75–79 0.49 (0.45–0.53) 0.56 (0.53–0.58) 0.54 (0.52–0.57)
80–84 0.76 (0.70–0.83) 0.71 (0.68–0.74) 0.85 (0.81–0.88)
≥85 1.16 (1.05–1.26) 1.23 (1.18–1.29) 1.00 (0.96–1.04)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.8. Mean cancer related admitted patient hospital activity among female 
survivors of breast cancer, England, 2006. Number of days in hospital per 100 person-
days (95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis







25–29 3.43 (3.12–3.74) 1.41 (1.12–1.70) 1.33 (0.48–2.18)
30–34 3.57 (3.40–3.74) 0.95 (0.82–1.08) 0.51 (0.27–0.74)
35–39 3.27 (3.18–3.37) 0.79 (0.72–0.87) 0.46 (0.35–0.56)
40–44 3.14 (3.07–3.21) 0.56 (0.51–0.61) 0.36 (0.30–0.42)
45–49 3.01 (2.95–3.07) 0.47 (0.43–0.51) 0.34 (0.30–0.39)
50–54 2.53 (2.48–2.59) 0.38 (0.35–0.42) 0.28 (0.24–0.31)
55–59 2.49 (2.44–2.55) 0.35 (0.32–0.38) 0.23 (0.21–0.26)
60–64 2.21 (2.15–2.26) 0.34 (0.31–0.37) 0.25 (0.22–0.27)
65–69 2.16 (2.10–2.22) 0.34 (0.30–0.38) 0.25 (0.22–0.28)
70–74 2.31 (2.23–2.40) 0.45 (0.41–0.50) 0.28 (0.25–0.31)
75–79 2.52 (2.41–2.62) 0.53 (0.47–0.58) 0.34 (0.30–0.38)
80–84 2.69 (2.55–2.82) 0.61 (0.54–0.68) 0.36 (0.31–0.40)
≥85 2.83 (2.67–2.99) 0.88 (0.79–0.96) 0.43 (0.37–0.49)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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Table 3.9. Mean non-cancer related admitted patient hospital activity among female 
survivors of breast cancer, England, 2006. Number of days in hospital per 100 person-
days (95% confidence interval), by attained age and time since diagnosis.
Time since diagnosis







25–29 0.31 (0.08–0.54) 0.25 (0.10–0.41) 0.06 (0.00–0.26)
30–34 0.25 (0.12–0.37) 0.32 (0.24–0.39) 0.25 (0.09–0.42)
35–39 0.22 (0.15–0.30) 0.31 (0.27–0.35) 0.19 (0.13–0.26)
40–44 0.31 (0.26–0.37) 0.29 (0.26–0.32) 0.16 (0.13–0.20)
45–49 0.25 (0.20–0.29) 0.29 (0.27–0.32) 0.15 (0.12–0.17)
50–54 0.32 (0.27–0.36) 0.29 (0.27–0.31) 0.16 (0.14–0.18)
55–59 0.25 (0.22–0.29) 0.28 (0.26–0.30) 0.15 (0.13–0.16)
60–64 0.31 (0.27–0.35) 0.30 (0.28–0.32) 0.17 (0.15–0.18)
65–69 0.47 (0.42–0.52) 0.38 (0.36–0.41) 0.23 (0.22–0.25)
70–74 0.54 (0.48–0.60) 0.48 (0.46–0.51) 0.32 (0.30–0.34)
75–79 0.67 (0.60–0.74) 0.83 (0.79–0.87) 0.47 (0.45–0.50)
80–84 0.97 (0.87–1.07) 1.08 (1.04–1.13) 0.77 (0.73–0.80)
≥85 1.23 (1.11–1.35) 1.47 (1.40–1.53) 1.06 (1.02–1.11)
Results are omitted if the total person-time of prevalence that contributed was less than 20 years. 
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3.4.2 Survivorship states in the UK in 2008
Tables 3.10–3.14 present estimates of the number of UK cancer survivors in diﬀerent 
survivorship states at the end of 2008. Each table is for a diﬀerent cancer type. Tables 
3.15–3.19 present the same data as percentages. To aid interpretation of the results in 
these tables, Figures 3.9–3.13 are also included. These are bespoke graphics which 
represent cancer survivors by a set of square tiles, each with four horizontal divisions 
marking the proportion of survivors in each of the four temporal phases (defined 
according to time since diagnosis and time until death – see Figure 3.3), and three 
vertical divisions marking the proportion of survivors in each category of acute health 
service utilisation (none, low or high intensity – see section 3.3.3.1). In essence, these 
figures are a variation on the standard histogram chart and employ the same principle 
that the area of each block is proportional to the quantity represented. Each square tile
represents the survivors of a given cancer type, sex and broad age group, and the 
density of overlaid male or female person icons is approximately proportional to the 
total number of survivors represented by the tile – each person icon represents 1,000 
cancer survivors.
The design of Figures 3.9–3.13 was inspired by the work of the Dutch artist, Piet 
Mondrian (1872–1944). Mondrian was a founding contributor to the art review De Stijl 
(“The Style”) which was first published in the Netherlands in October 1917 and from 
which grew the neo-plasticism art movement (Elgar, 1968). Manifestos printed in early 
editions of De Stijl set out the principles of neo-plasticism:
“…‘painting must be made to submit to the horizontal-vertical order, which
excludes the diagonal and the curve; colours must be limited to the three
primary colours and the three non-colours white, black and grey, which
must never be either mixed or superimposed (cookery)…What we want is a
new aesthetic based on pure relationships of lines and pure colours, because
only pure relationships between pure constructive elements can result in
pure beauty.’ ”
(Elgar, 1968: p.93)
An example of a composition by Mondrian in the neo-plastic style is shown in Figure 
3.7. 
Mondrian’s ideas and philosophy have been adapted for this results section to provide a
visually attractive way of displaying a large amount of data in a clean and simple way, 
allowing for an immediate high level analysis, as well as facilitating in-depth study and 
easy comparison across cancer types, age groups and sexes. Figure 3.8 provides a 
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reference key for Figures 3.9–3.13, and indicates which temporal phase and health 
service utilisation categories correspond to each section of the tile. It should be noted 
that, in Figures 3.9–3.13, the proportion of survivors in temporal phase D and with a 
‘high’ level of acute health service utilisation (i.e. the rightmost area of the bottom 
row) may be too small to be visible. Similarly, the proportion of breast cancer survivors
in temporal phase A (i.e. the top row) may also be too small to be visible.
Figure 3.7. Composition with Red, Yellow, Blue and Black by Piet Mondrian (1921). 
Oil on canvas 59.5 × 59.5 cm. Gemeentemuseum, The Hague, Netherlands.

































At the end of 2008, approximately 81% of all male, and 87% of all female, cancer 
survivors were more than one year beyond diagnosis and more than one year from 
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death (Table 3.19). There was little variation in these proportions by attained age, 
except for male survivors aged under 45 years for whom this proportion rose to 90%. 
The proportion of lung cancer survivors who were more than one year beyond diagnosis
and more than one year from death was markedly lower (72% of male survivors and 
64% of female survivors), as shown in Table 3.16. There was little acute health service 
utilisation among cancer survivors in this temporal phase, regardless of attained age or 
type of cancer. Overall, 1.57 million of the 2 million cancer survivors in the UK at the 
end of 2008 (78%) were more than one year beyond diagnosis and more than one year 
from death, and had no cancer related hospital admissions in this temporal phase.
Of the estimated two million cancer survivors in the UK (Chapter 2), 240,000 were in 
the ‘low’ acute health service utilisation category (14.8% of male survivors and 10.0% of
female survivors) – see Tables 3.14 and 3.19. 61,000 (4.0% of male survivors and 2.4% 
of female survivors) were in the ‘high’ category. The proportion of lung cancer survivors
in the ‘high’ category was much larger (7.2% of males and 9.3% of females), 
particularly in the age group 45–64 years where the proportion rose to around 12% 
(Table 3.16). Conversely, only 1.2% of female breast cancer survivors had a ‘high’ level 
of acute health service utilisation (Table 3.18).
Table 3.14 also shows that 147,000 cancer survivors were in the last year of their life 
(9.0% of male survivors and 6.2% of female survivors). It was these survivors who had 
the highest intensity of cancer related acute health service utilisation, particularly those
who were also in the first year after diagnosis. 41% of the 41,000 cancer survivors who 
were less than one year beyond diagnosis and less than one year from death had a high 
intensity of acute health service utilisation, compared with 19% of the 106,000 survivors
who were in the last year of their life but more than one year beyond diagnosis.
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
Table 3.10. Number of colon, rectum and anus cancer survivors in the UK, 2008. By sex, attained age, temporal phase of survivorship* 
and intensity of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
Males
A <10 20 30 60 80 260 270 610 530 710 840 2,080 610 990 1,150 2,750
B 10 40 30 80 290 510 270 1,060 4,120 2,130 1,070 7,320 4,420 2,680 1,360 8,460
C 130 150 80 360 1,050 1,820 790 3,670 2,590 3,650 1,590 7,840 3,770 5,620 2,470 11,860
D 1,490 90 <10 1,590 18,760 1,430 160 20,350 72,400 4,700 410 77,520 92,650 6,220 580 99,450
Total 1,640 310 150 2,090 20,180 4,010 1,500 25,690 79,640 11,200 3,910 94,750 101,460 15,520 5,560 122,530
Females
A <10 10 30 50 50 140 190 390 510 500 750 1,750 570 650 970 2,180
B 20 30 30 80 180 300 200 680 4,010 1,470 820 6,300 4,210 1,800 1,060 7,060
C 110 150 70 330 710 1,260 540 2,510 2,310 2,790 1,190 6,290 3,130 4,200 1,800 9,120
D 1,550 110 10 1,680 15,140 910 100 16,150 73,780 3,010 310 77,090 90,470 4,030 420 94,910
Total 1,690 300 150 2,130 16,080 2,610 1,030 19,720 80,600 7,760 3,070 91,430 98,370 10,670 4,250 113,290
*†As defined in section 3.3.3.
   

Table 3.11. Number of lung, bronchus and trachea cancer survivors in the UK, 2008. By sex, attained age, temporal phase of 
survivorship* and intensity of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
Males
A <10 30 30 70 210 660 520 1,400 830 1,420 1,260 3,500 1,050 2,120 1,810 4,980
B <10 <10 <10 20 180 260 120 550 930 770 370 2,070 1,110 1,040 490 2,640
C 20 40 <10 70 320 630 130 1,090 830 1,090 220 2,130 1,180 1,750 360 3,290
D 280 10 <10 290 3,310 270 20 3,600 22,360 1,500 90 23,950 25,950 1,780 110 27,840
Total 310 90 50 440 4,030 1,820 790 6,640 24,950 4,780 1,940 31,660 29,280 6,690 2,770 38,740
Females
A <10 30 20 60 160 480 440 1,080 750 1,060 1,030 2,840 920 1,580 1,490 3,980
B <10 10 <10 20 150 220 120 500 760 520 290 1,570 920 760 420 2,090
C 30 30 <10 70 300 570 130 1,000 780 860 200 1,850 1,110 1,460 350 2,920
D 340 30 <10 370 3,040 260 20 3,320 11,320 740 40 12,090 14,700 1,020 60 15,780
Total 380 110 40 530 3,660 1,530 710 5,900 13,600 3,180 1,560 18,350 17,640 4,820 2,320 24,780
*†As defined in section 3.3.3.
   

Table 3.12. Number of prostate cancer survivors in the UK, 2008. By attained age, temporal phase of survivorship* and intensity of 
cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
A <10 <10 <10 <10 80 130 70 280 1,110 890 740 2,740 1,190 1,020 820 3,030
B <10 <10 <10 <10 220 350 180 750 7,800 5,860 3,210 16,880 8,020 6,210 3,390 17,630
C 20 10 <10 40 5,020 3,590 140 8,740 17,190 8,370 600 26,160 22,230 11,970 740 34,940
D 120 10 <10 130 22,830 1,830 80 24,740 152,850 18,960 1,150 172,970 175,810 20,800 1,230 197,840
Total 140 30 10 180 28,150 5,890 470 34,510 178,960 34,080 5,700 218,740 207,250 40,000 6,180 253,440
*†As defined in section 3.3.3.
Table 3.13. Number of female breast cancer survivors in the UK, 2008. By attained age, temporal phase of survivorship* and intensity of 
cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
A 30 60 30 120 130 250 140 520 830 480 360 1,670 990 790 530 2,310
B 150 370 190 710 1,260 2,110 1,020 4,390 11,200 4,390 2,400 17,990 12,610 6,870 3,620 23,100
C 1,430 3,060 210 4,700 7,610 11,430 610 19,660 8,250 7,020 500 15,770 17,290 21,520 1,320 40,120
D 17,950 1,870 80 19,890 174,890 8,240 380 183,510 268,030 11,200 840 280,070 460,870 21,300 1,300 483,470
Total 19,560 5,360 510 25,430 183,890 22,030 2,150 208,080 288,300 23,090 4,100 315,490 491,750 50,480 6,760 549,000
*†As defined in section 3.3.3.    
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Table 3.14. Number of survivors of all malignant neoplasms combined in the UK, 2008. By sex, attained age, temporal phase of 
survivorship* and intensity of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
Males
A 80 210 360 650 880 2,260 2,500 5,640 4,180 6,170 6,680 17,030 5,140 8,630 9,540 23,310
B 220 360 300 880 1,960 2,680 1,790 6,430 21,210 14,480 8,060 43,750 23,390 17,520 10,140 51,060
C 2,400 2,410 1,150 5,950 10,330 10,810 2,740 23,880 24,500 19,820 4,270 48,600 37,230 33,040 8,160 78,430
D 59,200 4,020 560 63,780 142,560 12,260 1,150 155,970 398,000 45,800 2,840 446,640 599,760 62,080 4,560 666,390
Total 61,890 6,990 2,370 71,250 155,730 28,010 8,180 191,920 447,890 86,270 21,850 556,020 665,520 121,270 32,400 819,190
Females
A 100 230 360 690 670 1,650 1,970 4,290 3,570 4,100 5,010 12,680 4,340 5,980 7,340 17,660
B 310 680 510 1,490 2,690 4,230 2,550 9,470 25,610 11,570 6,890 44,070 28,610 16,470 9,950 55,030
C 4,390 5,620 1,140 11,160 13,460 18,490 2,560 34,510 17,200 17,270 3,510 37,970 35,050 41,380 7,210 83,640
D 76,500 5,240 540 82,280 318,620 17,370 1,200 337,190 573,070 32,000 2,460 607,520 968,180 54,620 4,190 1,026,990
Total 81,300 11,770 2,550 95,620 335,440 41,730 8,280 385,460 619,440 64,940 17,870 702,250 1,036,180 118,440 28,700 1,183,330
*†As defined in section 3.3.3.
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Table 3.15. Percentage of colon, rectum and anus cancer survivors in the UK, 2008. By sex, attained age, temporal phase of survivorship*
and intensity of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
Males
A 0.4 1.2 1.5 3.1 0.3 1.0 1.1 2.4 0.6 0.8 0.9 2.2 0.5 0.8 0.9 2.2
B 0.7 1.9 1.2 3.8 1.1 2.0 1.1 4.1 4.3 2.2 1.1 7.7 3.6 2.2 1.1 6.9
C 6.2 7.3 3.8 17.3 4.1 7.1 3.1 14.3 2.7 3.9 1.7 8.3 3.1 4.6 2.0 9.7
D 71.1 4.3 0.5 75.8 73.0 5.5 0.6 79.2 76.4 5.0 0.4 81.8 75.6 5.1 0.5 81.2
Total 78.3 14.7 7.0 (100.0) 78.6 15.6 5.8 (100.0) 84.0 11.8 4.1 (100.0) 82.8 12.7 4.5 (100.0)
Females
A 0.2 0.6 1.5 2.4 0.3 0.7 1.0 2.0 0.6 0.5 0.8 1.9 0.5 0.6 0.9 1.9
B 1.0 1.3 1.4 3.7 0.9 1.5 1.0 3.5 4.4 1.6 0.9 6.9 3.7 1.6 0.9 6.2
C 5.2 7.0 3.4 15.5 3.6 6.4 2.7 12.7 2.5 3.0 1.3 6.9 2.8 3.7 1.6 8.1
D 72.6 5.2 0.6 78.5 76.8 4.6 0.5 81.9 80.7 3.3 0.3 84.3 79.9 3.6 0.4 83.8
Total 79.0 14.1 6.9 (100.0) 81.5 13.2 5.2 (100.0) 88.2 8.5 3.4 (100.0) 86.8 9.4 3.8 (100.0)
*†As defined in section 3.3.3.
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Table 3.16. Percentage of lung, bronchus and trachea cancer survivors in the UK, 2008. By sex, attained age, temporal phase of 
survivorship* and intensity of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
Males
A 1.7 7.6 7.0 16.3 3.2 10.0 7.9 21.1 2.6 4.5 4.0 11.1 2.7 5.5 4.7 12.8
B 0.7 1.4 1.5 3.6 2.7 3.9 1.8 8.4 2.9 2.4 1.2 6.5 2.9 2.7 1.3 6.8
C 5.0 7.9 2.1 15.0 4.9 9.5 2.0 16.4 2.6 3.4 0.7 6.7 3.0 4.5 0.9 8.5
D 62.4 2.6 0.2 65.1 49.9 4.0 0.2 54.2 70.6 4.7 0.3 75.7 67.0 4.6 0.3 71.9
Total 69.8 19.5 10.7 (100.0) 60.7 27.5 11.9 (100.0) 78.8 15.1 6.1 (100.0) 75.6 17.3 7.2 (100.0)
Females
A 1.8 6.1 4.3 12.2 2.8 8.2 7.4 18.4 4.1 5.8 5.6 15.5 3.7 6.4 6.0 16.1
B 1.1 2.7 0.7 4.5 2.6 3.7 2.1 8.4 4.1 2.9 1.6 8.6 3.7 3.1 1.7 8.4
C 5.1 6.4 1.6 13.1 5.2 9.6 2.3 17.0 4.2 4.7 1.1 10.1 4.5 5.9 1.4 11.8
D 64.7 5.2 0.3 70.2 51.4 4.4 0.3 56.2 61.7 4.0 0.2 65.9 59.3 4.1 0.3 63.7
Total 72.6 20.4 7.0 (100.0) 62.0 25.9 12.1 (100.0) 74.1 17.3 8.5 (100.0) 71.2 19.5 9.3 (100.0)
*†As defined in section 3.3.3.
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Table 3.17. Percentage of prostate cancer survivors in the UK, 2008. By attained age, temporal phase of survivorship* and intensity of 
cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
A 0.0 0.5 1.0 1.6 0.2 0.4 0.2 0.8 0.5 0.4 0.3 1.3 0.5 0.4 0.3 1.2
B 0.8 0.5 1.3 2.6 0.6 1.0 0.5 2.2 3.6 2.7 1.5 7.7 3.2 2.5 1.3 7.0
C 13.2 7.3 2.4 22.9 14.5 10.4 0.4 25.3 7.9 3.8 0.3 12.0 8.8 4.7 0.3 13.8
D 64.5 6.8 1.7 73.0 66.2 5.3 0.2 71.7 69.9 8.7 0.5 79.1 69.4 8.2 0.5 78.1
Total 78.5 15.2 6.4 (100.0) 81.6 17.1 1.4 (100.0) 81.8 15.6 2.6 (100.0) 81.8 15.8 2.4 (100.0)
*†As defined in section 3.3.3.
Table 3.18. Percentage of female breast cancer survivors in the UK, 2008. By attained age, temporal phase of survivorship* and intensity 
of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
A 0.1 0.2 0.1 0.5 0.1 0.1 0.1 0.2 0.3 0.2 0.1 0.5 0.2 0.1 0.1 0.4
B 0.6 1.5 0.8 2.8 0.6 1.0 0.5 2.1 3.5 1.4 0.8 5.7 2.3 1.3 0.7 4.2
C 5.6 12.0 0.8 18.5 3.7 5.5 0.3 9.4 2.6 2.2 0.2 5.0 3.1 3.9 0.2 7.3
D 70.6 7.3 0.3 78.2 84.1 4.0 0.2 88.2 85.0 3.5 0.3 88.8 83.9 3.9 0.2 88.1
Total 76.9 21.1 2.0 (100.0) 88.4 10.6 1.0 (100.0) 91.4 7.3 1.3 (100.0) 89.6 9.2 1.2 (100.0)
*†As defined in section 3.3.3.    
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Table 3.19. Percentage of survivors of all malignant neoplasms combined in the UK, 2008. By sex, attained age, temporal phase of 
survivorship* and intensity of cancer related health service utilisation†.
Age group
0–44 45–64 ≥65 All ages
Intensity of health service use Intensity of health service use Intensity of health service use Intensity of health service use
Temporal
phase None Low High Total None Low High Total None Low High Total None Low High Total
Males
A 0.1 0.3 0.5 0.9 0.5 1.2 1.3 2.9 0.8 1.1 1.2 3.1 0.6 1.1 1.2 2.8
B 0.3 0.5 0.4 1.2 1.0 1.4 0.9 3.4 3.8 2.6 1.4 7.9 2.9 2.1 1.2 6.2
C 3.4 3.4 1.6 8.3 5.4 5.6 1.4 12.4 4.4 3.6 0.8 8.7 4.5 4.0 1.0 9.6
D 83.1 5.6 0.8 89.5 74.3 6.4 0.6 81.3 71.6 8.2 0.5 80.3 73.2 7.6 0.6 81.3
Total 86.9 9.8 3.3 (100.0) 81.1 14.6 4.3 (100.0) 80.6 15.5 3.9 (100.0) 81.2 14.8 4.0 (100.0)
Females
A 0.1 0.2 0.4 0.7 0.2 0.4 0.5 1.1 0.5 0.6 0.7 1.8 0.4 0.5 0.6 1.5
B 0.3 0.7 0.5 1.6 0.7 1.1 0.7 2.5 3.6 1.6 1.0 6.3 2.4 1.4 0.8 4.7
C 4.6 5.9 1.2 11.7 3.5 4.8 0.7 9.0 2.4 2.5 0.5 5.4 3.0 3.5 0.6 7.1
D 80.0 5.5 0.6 86.0 82.7 4.5 0.3 87.5 81.6 4.6 0.3 86.5 81.8 4.6 0.4 86.8
Total 85.0 12.3 2.7 (100.0) 87.0 10.8 2.1 (100.0) 88.2 9.2 2.5 (100.0) 87.6 10.0 2.4 (100.0)
*†As defined in section 3.3.3.
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*Display suppressed due to very small numbers in this age group. 
   






























   































In this chapter, a person-time analysis of linked cancer registry and hospital activity 
data for England was presented. Attained age, time since diagnosis and time until 
death were anticipated to be important factors in the level of health service utilisation 
among cancer survivors, and so the analysis was disaggregated according to these 
variables. The linked dataset allowed an analysis of all recorded episodes of NHS 
hospital in-patient or day case health care among registered cancer survivors in 
England during 2006. The person-time approach made it possible to quantify the 
intensity of hospitalisation by considering the proportion of time spent in hospital – 
this was considered to be a better measure of the cancer burden to both survivors and 
the health service than simply the number of hospital admissions.
There were two main strands to the analysis. Firstly, methods were developed to 
classify person-time of prevalence and person-time of hospital activity and to estimate 
the mean proportion of time spent admitted to hospital in the year 2006 by an 
individual sampled at random from the prevalent population, and how this varied with 
attained age and time since diagnosis. Secondly, diﬀerent temporal phases of 
survivorship were identified and defined based on time since diagnosis and time until 
death. Time spent in these phases was described according to the intensity of cancer 
related acute health service utilisation that occurred, and from this the number of 
cancer survivors in the UK in diﬀerent states of survivorship at the end of 2008 was 
estimated. It should be noted that an implication of this methodology is that 
survivorship states at a given point in time are influenced by hospital admissions both 
in the recent past and near future.
These two analysis stages are complementary. In the first stage, person-time was pooled
for the whole population, allowing a precise assessment of the influence of attained age 
and time since diagnosis on the mean number of days (per 100 person-days) spent 
admitted to hospital by cancer survivors; but this approach provided a measure only of 
the average health service utilisation and not the underlying distribution. The second 
stage, however, explored this distribution by defining diﬀerent categories of intensity of 
health service utilisation for individual survivors. It was shown that the underlying 
distribution of hospital activity is skewed heavily towards cancer survivors with no 
hospital activity, particularly in the period more than one year after diagnosis. This 
should be kept in mind when considering the mean proportion of time spent in hospital
for the whole population.
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The hospital activity data from HES featured details of all types of in-patient and day 
case care delivered to cancer survivors, not just that which related to cancer. Each 
record had up to 14 diagnostic codes (using the ICD-10 classification) and 12 operation 
procedure codes (using the OPCS-4 clinical classification), with the first of each of 
these codes intended to indicate the primary diagnosis or intent of the treatment. For 
simplicity, episodes were categorised as ‘cancer related’ or ‘non-cancer related’ 
according to the diagnostic codes only – an episode was considered to be cancer related
if any of the diagnostic codes was between C00 and C97 (excluding C44). This was an 
intentionally broad categorisation, designed to take account of the wide range of health 
problems associated with cancer and the side eﬀects of its treatment, as well as to 
negate any possible institutional variation in coding of the primary diagnosis. Defined 
thus, ‘cancer related’ hospital activity may be considered as that directly or indirectly 
caused by, or associated with, a cancer diagnosis. Nonetheless the specificity of the 
definition is unproven and it is not possible to say exactly which kinds of treatment 
following a cancer diagnosis are included – a specific analysis of the types of recorded 
clinical procedures was considered to be beyond the scope of this work due to the 
extremely large number of diﬀerent operation codes contained in the data. However, 
analysis of the complementary ‘non-cancer related’ hospital activity (Figure 3.6) 
indicated that the cancer related definition achieved its goal of removing some of the 
background hospitalisation experienced by this population – the proportion of time 
spent by cancer survivors in hospital for non-cancer related care was much lower than 
for cancer related care, and, importantly, showed little variation with time since 
diagnosis.
Perhaps a more precise way of defining the health care burden directly attributable to 
cancer would be to compare hospitalisation of any kind among cancer survivors to that 
observed in a randomly selected age and sex-matched subset of the cancer-free 
population (or, more practically, the general population). This would allow some 
measure of the background hospitalisation experienced by the cancer-free or general 
population to be removed from the levels observed in cancer survivors. However, no 
such dataset was available for comparison – the Cancer Registries’ National HES 
extract contains only episodes of care for patients with at least one episode ‘for or with 
cancer’ – and so the broad cancer/non-cancer related distinction described above was 
considered the most practical.
Some survivors will be diagnosed with additional primary cancers some time after their 
first diagnosis. Indeed, many studies have shown elevated cancer incidence rates in 
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those previously diagnosed with cancer compared with the general population (Evans et
al., 2001, 2002) and the prevalence of multiple malignancies among cancer survivors has
been shown to be around 7% in the Netherlands (Liu et al., 2011). However, treatment 
received for subsequent cancers is indistinguishable in this analysis from that received 
for the initial cancer, a fact to be remembered when considering the ‘time since 
diagnosis’ dimension. Furthermore, a small number of survivors in the cancer registry 
data will have had a diagnosis pre-1990 as well as in the period 1990–2006. However, 
since details of diagnoses made before 1990 were not available in the linked dataset, it 
was necessary to assume that all survivors in the dataset who were alive during 2006 
had their first diagnosis in the period 1990–2006. The eﬀect of this assumption is a 
possible small re-distribution of survivors between the types of cancer studied, but is 
not considered to be a significant limitation.
Each day of hospitalisation was treated equally in this analysis, and it is a limitation 
that the variation in the burden presented by diﬀerent types of admission and diﬀerent 
clinical procedures is not taken into account. For example, some survivors will be 
admitted to hospital for routine observation and monitoring, whereas others will be 
admitted (possibly in an emergency) for complicated operations that consume large 
amounts of hospital resources and require intense periods of rehabilitation.
3.5.1 Hospital activity among cancer survivors
The majority of cancer related health service utilisation occurred during the first year 
after diagnosis, for survivors of all the cancer types studied. Most cancer patients 
receive some form of care or treatment as soon as possible after diagnosis, and thus it is
perhaps unsurprising that this period contained a large amount of hospital activity. 
However, there was also a significant amount of cancer related health service utilisation 
in the period 1–5 years after diagnosis, particularly among survivors of lung and 
colorectal cancers. This is no longer the initial treatment phase, but is indicative of the 
ongoing care needs of cancer survivors.
The highest levels of cancer related acute health service utilisation were observed in 
survivors of the relatively poor prognosis cancers, but these diﬀerences largely 
disappeared more than five years after diagnosis. This indicates that the worse 
prognosis cancers required more intensive treatment regimes (including end of life care) 
in the short to medium term after diagnosis, but not, for those surviving, in the long 
term.
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Prostate cancer survivors over the age of 60 and at least five years beyond diagnosis 
had higher levels of cancer related acute health service utilisation than comparable 
survivors of the other cancer types (see Figure 3.5 and Tables 3.2, 3.4, 3.6 and 3.8). 
This was despite prostate cancer survivors generally having relatively low levels of 
health service utilisation. A detailed investigation showed that these survivors 
experienced a large amount of hospital activity recorded in the HES data with a non-
cancer primary diagnosis code, but with prostate cancer recorded as one of the 
supplementary diagnoses, and it was largely these episodes that resulted in the 
relatively high number of days spent admitted to hospital (per 100 person-days) among
this group (Figure 3.14).
Figure 3.14. Mean cancer related admitted patient hospital activity among prostate 
cancer survivors five or more years after diagnosis, England, 2006. Number of days 






























In the analysis, these episodes were considered to be ‘cancer related’ because cancer 
was recorded as one of the supplementary diagnosis codes in the HES data. However, 
the recorded primary diagnosis codes, together with the operation procedure codes, 
indicated that these episodes were not generally related directly to prostate cancer. For 
example, the most common procedure codes were endoscopic examinations of the 
bladder and urethral catheterisations of the bladder, and the most common primary 
diagnosis codes were for disorders of the urinary system. There are several physiological
changes that occur in men as they get older and lead to alterations in lower urinary 
tract function, making urinary disorders in elderly men common (Dubeau, 2006; 
Griebling, 2008). Many prostate cancer survivors are likely to be closely monitored in 
urology clinics for many years after initial diagnosis – often an extended period of 
either ‘active surveillance’ or ‘watchful waiting’ is pursued, especially if the cancer is 
less aggressive and treatment is not immediately necessary (Parker, 2004). This may 
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explain the greater hospital activity, many years after diagnosis, among prostate cancer 
survivors over the age of 60, compared with male lung or colorectal cancer survivors – 
it is possible that the increased observation and monitoring of these survivors leads to a
high level of urological intervention which is only indirectly related to their prostate 
cancer diagnosis.
For all cancer types apart from female breast, acute health service utilisation in the 
first year after diagnosis was significantly higher for survivors aged over 70 compared 
with younger age groups. Initial cancer treatment can be physically very arduous, 
particularly for older patients who may be more frail and suﬀering a greater number of 
co-morbidities, resulting in more frequent and extended admissions to hospital. 
Particularly striking was the three-fold diﬀerence between cancer related acute health 
service utilisation in the first year after diagnosis among prostate cancer survivors aged 
at least 85 compared with those aged 65–69 (Figure 3.5). Since the early 1990s, the 
PSA test has increasingly been available (usually to men aged over 50) as a screening 
tool for prostate cancer, although in the UK no organised PSA screening programme is 
in place. This test is still controversial and considered to potentially result in over-
diagnosis and over-treatment of prostate cancers which would otherwise never have 
become symptomatic (Barry, 2009; van Leeuwen et al., 2010). Recorded incidence rates 
and survival have, accordingly, greatly increased since the test’s introduction (Evans 
and Møller, 2003; Cancer Research UK, 2010, 2011c), as have the number of prostate 
cancer survivors (Chapter 2). Men diagnosed with prostate cancer over the age of 70 
are more likely to have symptomatic disease requiring intensive initial treatment 
compared with those aged 50–70 years who are more likely to have been diagnosed via 
the PSA test. Similarly, the observed reduction in acute health service utilisation in 
recently diagnosed female breast cancer survivors aged 50–70 (the age range in which 
women are routinely invited to attend breast screening units in England (NHS Cancer 
Screening Programmes, 2011)) reflects some of the benefits of early detection oﬀered by
screening programmes.
Non-cancer related acute health service utilisation was shown to generally increase with
age, reflecting the greater number of morbidities likely to be found in the elderly 
compared with the young. Generally it varied little with time since diagnosis, but for 
lung and colorectal cancer survivors levels were slightly higher for shorter time since 
diagnosis. This may be explained by the fact that some survivors will have been 
diagnosed during an emergency admission to hospital. Also, some genuine cancer 
related hospital activity may not be coded as such in the HES data.
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3.5.2 Survivorship states
As described in section 3.3.3, and illustrated in Figure 3.3, four mutually exclusive 
temporal phases of survivorship were defined according to time since diagnosis and time
until death, as follows:
• Phase A: less than one year before death and less than one year after diagnosis.
• Phase B: less than one year before death and more than one year after diagnosis.
• Phase C: more than one year before death and less than one year after diagnosis.
• Phase D: more than one year before death and more than one year after diagnosis.
The first year following diagnosis is the time during which cancer patients receive  
initial treatment, the success of which may significantly aﬀect their subsequent health 
and well-being. The final year before death is also significant since, for many people 
who die from cancer, there is a period of health deterioration in the months beforehand.
For some survivors, post-diagnosis survival time is short enough that the first year 
following diagnosis and the final year of life overlap. Conversely, for those who live long 
enough after diagnosis, the period of survivorship which is more than one year after 
diagnosis and more than one year before death may be characterised by periods of 
remission, relapse, disease monitoring and/or eventual ‘cure’. The temporal phases of 
survivorship defined above therefore provide a broad but informative way of describing 
the population of cancer survivors, and at any given point in time every survivor is in 
precisely one of these phases.
Lung cancer has a universally poor prognosis (age-standardised 5-year relative survival 
in England and Wales is under 10% (Cancer Research UK, 2009b)) and accordingly a 
large proportion of lung cancer survivors were less than one year beyond diagnosis and 
also less than one year from death (phase A). On the other hand, one quarter of 
prostate cancer survivors aged 45–64 were less than one year beyond diagnosis but not 
less than one year from death (phase C), reflecting the relatively good prognosis of this 
disease and the rapidly increasing incidence rates brought about by the use of the PSA 
test since the early 1990s (Evans and Møller, 2003).
In recent years, the number of cancer survivors in the UK has grown steadily each year 
(Chapter 2: Figure 2.3). The distribution of survivors between temporal phases, and the
intensity of acute health service utilisation within them, provides an insight into what is
meant by the term ‘cancer survivor’, especially given the current national survivorship 
initiatives in the UK and the movement towards understanding cancer as a chronic 
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illness. For example, the majority of UK cancer survivors (1.69 million of the 2.00 
million as at 2008) are more than one year beyond diagnosis and more than one year 
from death, and the degree of acute health service utilisation in this phase is small – 
1.57 million are in a period characterised by no cancer related acute health service 
utilisation and these survivors account for 78% of all UK cancer survivors. 
Cancer survivors can now realistically expect to live longer beyond diagnosis, but this 
analysis suggests that the primary burden of cancer on the health service still comes 
from survivors in the first year following diagnosis and/or near the end of their life. The
term ‘cancer survivor’ was originally proposed by the US National Coalition for Cancer 
Survivorship in 1986 at a time when “cancer was a disease that people needed to learn 
to fight” but has, according to some, become “so muddy that…a new definition is 
needed” (Twombly, 2004). Alternative terms include people ‘living with or beyond 
cancer’ or ‘cancer patients’. However, this analysis has shown that the population of 
cancer survivors is heterogeneous, and finding a single term to usefully define everyone 
who has ever been diagnosed with cancer may not be possible.
A limitation of this work, brought about by the extent of the available hospital activity
data, is that it only considered admitted hospital episodes of care (i.e. in-patients and 
day cases). Visits to general practitioner surgeries and other out-patient clinics are not 
captured in this analysis, but much of the observation and monitoring of survivors 
(especially those who are more than one year beyond diagnosis and more than one year
from death) is carried out in such clinics (Khan et al., 2010). Neither does this analysis 
consider the personal psychosocial or general health burden of cancer on survivors – the
trauma of being diagnosed with a life-threatening illness such as cancer is associated 
with post traumatic stress disorder, depression, and other mental disorders (Smith et 
al., 1999; Gregurek et al., 2010) and cancer survivors have been found to have poorer 
general health outcomes than individuals who have not been diagnosed with cancer 
(Yabroﬀ et al., 2004). Cancer survivors are also likely to face day-to-day struggles (such
as financial, emotional, relationship and employment diﬃculties) even if they have no 
need for treatment in hospital (Short et al., 2008; Foster et al., 2009). These issues 
present significant burdens to cancer survivors and should be kept in mind when 
considering the distribution of survivors between the states defined in this analysis.
3.6 Summary
The extent to which the population of cancer survivors in the UK is receiving care and 
treatment in hospital is central to understanding the burden of cancer on society. The 
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work described in this chapter provides a detailed characterisation of cancer 
survivorship in the UK which greatly enriches the basic prevalence estimates of Chapter
2. The findings contained here will be of interest to health service providers keen to 
quantify the volume of acute health care administered to cancer survivors, and the 
associated financial burden, as well as to survivors themselves.
The previous two chapters focused on current cancer prevalence in the UK. What 
follows in the next three chapters is the derivation and application of a model for 
projecting cancer prevalence into the future.    
Chapter 3. Health service utilisation and phases of survivorship
89
Chapter 4. A model for projecting cancer prevalence
In the following three chapters a discrete time model of the dynamics of cancer 
prevalence is developed, tested and used to project cancer prevalence in the UK up to 
2040 under various scenarios of future incidence and survival.
The model is introduced in this chapter and described by a set of mathematical 
equations that allow continuous time data (from cancer registry sources) to be used as 
the inputs. A computer program implementation of the model is then briefly described 
and its potential applications discussed. Although the primary motivation is to provide 
projections of cancer prevalence, the model is generic enough to be applied to any 
disease which is considered to be prevalent in all individuals from the moment they are 
diagnosed until death.
Exercises were carried out to test the model and these are described, together with the 
extent of the required input data, in Chapter 5. Finally, results showing projections of 
cancer prevalence in the UK for the next 30 years are contained in Chapter 6.
4.1 Introduction
Projections of cancer prevalence can be used to estimate the future burden of cancer 
and inform the likely resources that will need to be allocated in order to meet the many
and varied needs of the population of survivors. They provide valuable intelligence to 
health service resource planners as well as those responsible for providing care and 
support in the community to people aﬀected by cancer and its treatment. Estimates of 
future cancer incidence and mortality are routinely produced by various bodies at local 
and national levels (NHS Scotland, 2004; Olsen et al., 2008; Parkin et al., 2008; 
Gatenby et al., 2011; Mistry et al., 2011; Thames Cancer Registry, 2011), but 
projections of cancer prevalence are less common. In part this may be due to the extra 
level of complexity involved in projecting prevalence compared with other vital 
statistics. For example, the definition of complete prevalence is such that data spanning
many years are required in order to estimate it (see Chapter 2). Additionally, although 
it may be intuitively obvious that increasing incidence and/or increasing survival will 
result in increasing prevalence, the exact mechanisms by which this occurs, and the 
extent of the eﬀect of each on the other, are not often investigated.
For these reasons, a flexible and general description of the dynamics of cancer 
prevalence is sought in order to produce projections of prevalence and to investigate the
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influence of incidence rates, survival and demographic changes on future prevalence in 
the UK.
4.2 Background and literature
Cancer prevalence is a function of cancer incidence and survival, since it increases as 
new diagnoses are made and decreases as people previously diagnosed die. 
Consequently, the task of projecting cancer prevalence consists of two exercises: 
a) defining appropriate equations which relate cancer prevalence to incidence and 
survival; and b) producing the required projections of cancer incidence and survival on 
which future prevalence depends. The first exercise describes the mathematical model 
of prevalence that will be used and the second produces the input data for this model. 
A small number of diﬀerent approaches to these exercises have been described in the 
literature. Various authors have diﬀered in their choice of input data (for example, 
incidence and survival, incidence and mortality or survival and mortality) and how 
these are modelled but, essentially, the mathematical relationships between prevalence, 
incidence, survival and mortality are a matter of fact.
In places where cancer registration provides complete coverage of the population, and a
long time series of data is available, estimates of current cancer prevalence can be made
directly. It is then possible to obtain future prevalence estimates by considering the 
future survival of those currently prevalent as well as the future survival of those yet to
be diagnosed (Phillips et al., 2002; Heinavaara and Hakulinen, 2006). However, if there 
are only sparse or incomplete cancer registry data available then this is not possible 
and both current and future cancer prevalence estimates must be entirely modelled (De
Angelis et al., 1994; Tabata et al., 2008). 
De Angelis et al. (1994) produced a computer program (called MIAMOD) which uses 
mortality and survival data to produce modelled estimates of incidence and prevalence 
in situations where these cannot be estimated directly using cancer registry data. 
Verdecchia et al. (2002) produced a similar program (PIAMOD) which does require 
cancer registry data and uses incidence and survival to calculate prevalence and 
mortality. Both of these programs are based on the equations relating disease incidence,
survival, mortality and prevalence described by Verdecchia et al. (1989) and can be 
used to estimate current complete prevalence, as well as to provide medium to long-
term projections. 
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In the literature, there are numerous examples of the application of these methods, 
particularly by investigators in Italy. Capocaccia et al. (1995) used mortality and 
survival data to estimate the prevalence of stomach cancer in Italy in the period 1970–
1990, and to project this to 2000. National mortality data were available, but survival 
was estimated based on cancer registry data from four Italian provinces. Despite 
decreasing incidence rates, stomach cancer prevalence was shown to have increased in 
the period 1980–1990 and was anticipated to continue increasing up to the year 2000. 
The same authors also produced a similar paper that focussed on colorectal cancer 
(Capocaccia et al., 1997); again, national mortality and regional survival data were 
used to describe and project cancer prevalence trends in Italy from 1970 to 2000. The 
number of colorectal cancer survivors was anticipated to double between 1990 and 2000
due, mainly, to rising cancer incidence and population ageing. These results were used 
to highlight the increasing burden presented by colorectal cancer to the health service 
in Italy, in terms of both short-term intensive care and long-term care aimed at 
preventing disease recurrence.
Verdecchia et al. (2001) used national estimates of cancer mortality, survival estimates 
from the ITACARE study (Verdecchia et al., 1997) and the MIAMOD program to 
project the prevalence of all cancers combined in Italy from 1990 to 2000. It was shown 
that cancer prevalence was increasing at a faster rate for males than for females. 
Overall, cancer prevalence was projected to be 70% higher in 2000 compared with 1970,
and 23% higher compared with 1990. These dramatic increases were found to be largely
due to population ageing. This work was extended by Grande et al. (2006) who 
projected the prevalence of all cancers combined up to the year 2010 at a regional level 
in Italy. These authors anticipated that the proportion of the population who were 
cancer survivors would increase by around 3.5% per annum between 1999 and 2010.
In the USA, Mariotto et al. (2006) used the PIAMOD program to project colorectal 
cancer prevalence from 2000 to 2020. Estimates of incidence and survival were made 
using data from the SEER group of regional cancer registries and, for the purposes of 
prevalence projection, assumed to be constant from 2000 to 2020. Under this 
assumption, the number of colorectal cancer survivors was projected to increase by 50%
from 1.0 million to 1.5 million over the period. In Japan, Tabata et al. (2008) described
a similar approach to that used in the PIAMOD program and produced estimates of 
national cancer prevalence using incidence and survival data from selected regional 
cancer registries. These authors estimated that national 5-year cancer prevalence would
increase by around 70% from 1.3 million in 1995 to 2.2 million in 2020.
Chapter 4. A model for projecting cancer prevalence
92
When building a model for cancer prevalence, many authors have parameterised cancer 
incidence using age-period-cohort models (De Angelis et al., 1994; Phillips et al., 2002; 
Verdecchia et al., 2002; Heinavaara and Hakulinen, 2006; Tabata et al., 2008). These 
can be specified in numerous ways but, generally, incidence rates are assumed to be a 
function of attained age and birth cohort with or without an additional calendar time 
eﬀect.
Survival from cancer and survival from other causes of death are often considered 
separately in models of cancer prevalence. Relative survival has been modelled using 
cure mixture models (Phillips et al., 2002; Verdecchia et al., 2002; Heinavaara and 
Hakulinen, 2006; Tabata et al., 2008). These assume that only a proportion of those 
diagnosed with cancer experience an excess risk of death attributable to cancer, 
whereas the rest (the cured proportion) do not – survival of the non-cured proportion is
then assumed to follow the Weibull distribution (Mudholkar and Srivastava, 1993). 
Heinavaara and Hakulinen (2006) developed this approach further by allowing the 
cured proportion to experience diﬀerent non-cancer risks of dying compared with the 
general population.
Before any of the previously described models for projecting cancer prevalence can be 
used, projections of the input data must be made. Age-period-cohort regression models 
of incidence are well-suited to medium-term projections since age and cohort eﬀects can
reasonably be assumed to persist into the near future. However, likely future trends in 
cancer survival have been treated slightly diﬀerently. Some authors have suggested 
considering two scenarios: one in which temporal trends in cancer survival are assumed 
to continue into the future, and another in which cancer survival is assumed to remain 
constant into the future (Capocaccia et al., 1995, 1997; Verdecchia et al., 2002; Tabata 
et al., 2008). The former may be considered the ‘optimistic’ scenario, since cancer 
survival is generally increasing in Western countries, and the latter as ‘pessimistic’ or 
‘conservative’. Heinavaara and Hakulinen (2006) produced projections of cancer 
prevalence using such scenarios for both survival and incidence.
In the following section, a model for projecting cancer prevalence is described. This was
developed in the context of national cancer registry data with a long time series being 
available. Current prevalence, estimated directly from these data (see Chapter 2), forms
the basis of the model.
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4.3 Model description
In this section, a discrete time model to describe prevalence as a function of disease 
incidence and mortality is derived. The approach is similar to that used by Fiorentino 
et al. (2011) but diﬀers in the choice of mortality, rather than survival, as an input – a 
choice made to reflect the nature of the available input data. In addition, the variables 
age at diagnosis and time of diagnosis, used by Fiorentino et al., are replaced by 
attained age at the index date and time since diagnosis, respectively.
The derivation of the model assumes that prevalence, according to attained age and 
time since diagnosis, is known for a given point in time, the goal being to express 
prevalence at some future point in time as a function of this known prevalence, future 
disease incidence and future mortality.
4.3.1 Discrete time definitions
The prevalence model is based in discrete time, i.e. variables such as age, time and time
since diagnosis may only take whole number values (0,1,2,… etc.). It is suﬃcient to use 
a time resolution of one year in what follows, but other resolutions are also possible; for
example, one month or one day. The practical implications of this, and methods for 
obtaining the required discrete time input data, are discussed after the derivation.
The following discrete time definitions of the model variables are made:
4.3.1.1 Inflow
Let the inflow, NT,a, be the number of newly diagnosed people who, in the model, enter
the prevalent population at time T  and are aged a at time T . Inflow is the discrete 
time equivalent of incidence (count) in the continuous time setting.
4.3.1.2 Prevalence
Let VT,y,a be the number of people alive aged a at time T  who entered the prevalent 
population at time T   y, for y ≥ 0 and a   y. The variable y is therefore referred to as
the time since entry, and is the discrete time equivalent of time since diagnosis in the 
continuous time setting. When considering limited duration prevalence there is an 
additional restriction of y  Y , for some Y ≥ 0. Since VT,y,a is defined for y ≥ 0, people 
entering the prevalent population at time T  are included in the prevalence count at 
time T  such that VT,0,a = NT,a.
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4.3.1.3 Mortality
Let MT,y,a be the probability of dying between time T  and time T + 1, for people alive 
aged a at time T  who entered the prevalent population at time T − y for y ≥ 0 and 
a ≥ y. Note that both VT,y,a and MT,y,a are defined only for a   y since nobody may 
enter the prevalent population before they are born, but the situation where age is zero
upon entry (a = y) is permitted.
4.3.2 Derivation of the model equations
Suppose that prevalence at time T1 is known. The principle of the model is that the 
prevalent population at time T2 (where T2 > T1) is the union of two sub-populations: 
a) the proportion of the prevalent population at time T1 that survives to at least time 
T2, and b) the proportion of those entering the prevalent population between times T1 
and T2 that survives to at least time T2. 
Sub-population (a) is estimated using the sets of prevalence and mortality variables 
{VT1,y,a : a ≥ y ≥ 0} and {MT,y,a : T1 ≤ T < T2, a ≥ y ≥ 0}, respectively, and (b) is 
estimated using the sets of inflow and mortality variables {NT,a : T1 < T ≤ T2} and 
{MT,y,a : T1 ≤ T < T2, a ≥ y ≥ 0}, respectively, as follows.
The probability that an individual who is prevalent at time T , aged a at time T  having
entered the prevalent population at time T − y, will survive from time T  to at least 
time T + 1 is given by 1−MT,y,a. Therefore the probability of such an individual 




(1−MT+i,y+i,a+i) , ∀a ≥ y ≥ 0 [4.1]
since, for every year that passes, age and time since entry to the prevalent population 
increase by one year, and the probability of surviving the entire interval is given by the 
product of the probabilities of surviving each consecutive year.
Using [4.1], and the principle stated above, an equation for prevalence VT2,γ2,α2, the 
number of people alive aged α2 at time T2 who entered the prevalent population at time
T2 − γ2, can be written down by considering the following three cases separately 
(Figure 4.1).
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Figure 4.1. Timelines showing three diﬀerent cases of time since entry to the prevalent
population.
Case 1: γ2 = 0. Then VT2,γ2,α2 is simply the number of new patients who entered the 
prevalent population at time T2, aged α2. Therefore
VT2,0,α2 = NT2,α2 , ∀α2 ≥ 0 . [4.2]
Case 2: 0 < γ2 < T2 − T1. Then VT2,γ2,α2 is the number of people who a) entered the 
prevalent population at time T2 − γ2, b) were aged α2 − γ2 at time T2 − γ2 and c) 
survived for a time interval of length at least γ2 (i.e. from time T2 − γ2 to at least time 




(1 MT2  2+i,i, 2  2+i) ,   2    2 B7 0 <  2 < T2   T1 .
[4.3]
Case 3: γ2 ≥ T2 − T1. Here VT2,γ2,α2 is a proportion of the known prevalence VT1,γ1,α1, 
where γ1 = γ2 − (T2 − T1) and α1 = α2 − (T2 − T1). More precisely, VT2,γ2,α2 is equal to 
VT1,γ1,α1 multiplied by the appropriate probability of surviving for a time interval of 
length at least T2 − T1, i.e. from time T1 to at least time T2. Therefore, substituting 
I = T2 − T1, T = T1, y = γ1 and a = α1 into [4.1] gives: 





(1 MT1+i, 1+i, 1+i) ,   2    2 B7  2   T2   T1 .
[4.4]





  2    2 B7  2   T2   T1 . [4.5]
So, combining [4.2], [4.3] and [4.5], the required expression for prevalence at time T2, 













(1−MT2−γ2+i,i,α2−γ2+i) B7 γ2 ≥ T2 − T1.
[4.6]
4.3.3 Limited duration and complete prevalence
Limited duration (Y+1)-year prevalence at age α2 is given by summing equation [4.6] 




Furthermore, limited duration (Y+1)-year prevalence in a given age group [AL, AU ] can







As Y  increases, the above two summations approach complete prevalence at age α2 and
in age group [AL, AU ], respectively; i.e. that which includes everyone ever diagnosed.
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It is also possible to segment limited duration prevalence at time T2 into a sum of the 
contributions from the prevalent population at time T1 and new entrants to the 















 B7 Y ≥ T2 − T1
0 Qi?2`rBb2
[4.10]
where, following the notation used by Fiorentino et al., AT1 (T2) and BT1 (T2) are the 
prevalence at time T2 of those who enter the prevalent population after and before (or 
at) time T1, respectively.
4.4 Input data
In order to use the model to estimate future disease prevalence, it is necessary to have 
a certain amount of input data. Cancer registry data are routinely used to estimate 
current and historical cancer incidence and prevalence, but it is also possible to use 
such data to estimate the required mortality probabilities for cancer survivors.
The model for projecting prevalence, as described above, was developed in the context 
of having a long time series of cancer registry data available, but the required input 
data may also be gathered from other sources. Either way, since the available data will 
only cover historical incidence and mortality, it is necessary to project these forward in 
time before using them as input to the model. Methods of projecting incidence and 
mortality are covered in Chapter 5.
The model is specified in discrete time, yet real world data are continuous; for example,
inflow is defined as the discrete time version of incidence – the number of people 
entering the prevalent population at a discrete time point – but incidence in continuous
time is usually reported over the course of a whole year and not all of those who are 
diagnosed in that year will survive long enough to be counted as prevalent at the end of
the year. So it is necessary to consider in detail the translation of continuous time data 
into the required discrete time data.
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4.4.1 Specification of discrete data inputs
The most convenient discrete time interval to consider is one year, and so in the 
following section the term ‘at time T ’ is intended to mean ‘at the first instant of year 
T ’. In the discrete time model, at each time point T  prevalence increases by ∑aNT,a 
and simultaneously decreases by the number of people who were prevalent at time 
T − 1 but who died between time T − 1 and time T . It is assumed that all these 
deaths, as well as the inflow of newly diagnosed people, occur at precisely the same 
instant, time T . The prevalence count VT,y,a incorporates the resultant net flow of 
survivors into or out of the prevalent population at time T .
4.4.1.1 Incidence and inflow
In the real world, new diagnoses, which increase the size of the prevalent population, 
may occur at any time between two discrete time points; i.e. the inflow to the prevalent
population at time T  is made up of people who were diagnosed at any point in the year
leading up to time T . However, not everyone diagnosed in this period will contribute to
the prevalence count at time T  since not everyone will survive to time T . For this 
reason, when specifying the model input data, NT,a should not be confused with the 
continuous time incidence in the year leading up to time T . Rather, NT,a should be 
estimated as the expected number of people diagnosed in the year leading up to time T
who survive to time T  and are aged a at time T , as follows:
Let eNT,a be the continuous time one year incidence count at age a in year T  – i.e. the 
total number of people diagnosed with cancer at age a between discrete time points T  
and T + 1. Then NT,a is comprised of a proportion of N˜T−1,a and a proportion of 
N˜T−1,a−1, since everyone who enters the prevalent population at time T  and is aged a 
at time T  must have been diagnosed in the previous year at age a or a− 1, depending 
on when in the year their birthday and date of diagnosis fall.
Let eN iT,a be the number of people diagnosed with cancer at age a on the ith day of year 





where ⌧  is the number of days in year T  (i.e. 365 or 366; we may assume τ = 365).
Let ⇢T,a,j be the probability of dying on the j th day after diagnosis for those diagnosed 
at age a in year T .
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Consider those who are diagnosed on the ith day of year T − 1. For this group, 




and, assuming that birthdays are distributed equally throughout the year, 
Pr (;2/ a i T | /B;MQb2/ i ;2 a BM v2` T − 1) = i
τ
[4.13]
since each person will not age between diagnosis and time T  if and only if their 
birthday falls earlier in the year than their date of diagnosis.
Therefore, the contribution to NT,a from N˜ iT−1,a is given by:
 N iT 1,a   Pr (;2/ a i T | /B;MQb2/ i ;2 a BM v2` T   1)
  Pr (HBp2 i T | /B;MQb2/ i ;2 a BM v2` T   1)
=  N iT 1,a i 
  i
j=0
(1   T 1,a,j) . [4.14]
Similarly, the contribution to NT,a from N˜ iT−1,a−1 is given by:
 N iT 1,a 1   Pr (;2/ a i T | /B;MQb2/ i ;2 a  1 BM v2` T   1)
  Pr (HBp2 i T | /B;MQb2/ i ;2 a  1 BM v2` T   1)
=  N iT 1,a 1  1  i 
    i
j=0
(1   T 1,a 1,j) . [4.15]
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Note that VT,y,a is defined for all y ≥ 0 and, from [4.6], VT,0,a = NT,a. So, a continuous 
time interpretation of NT,a is 1-year prevalence at age a and time T .
Counts of the historical numbers of incident cases of cancer, from which future counts 
can be extrapolated, are easily obtained from cancer registry data and therefore widely 
available. Similarly, the daily probabilities of death, ⇢T,a,j, may be estimated from 
cancer registry data using person-time methods (as described in the next section). 
Regression procedures for extrapolating future incidence and mortality from historical 
data are presented in Chapter 5.
4.4.1.2 Mortality probabilities
There are two types of mortality that must be estimated to provide input to the 
prevalence model. Use of equation [4.6] requires estimates of MT,y,a – the probability 
that a member of the prevalent population who is aged a at time T , and who entered 
at time T   y, will die before time T + 1. Use of equation [4.17] requires estimates of 
⇢T,a,j – the probability of death on the j th day after diagnosis for a person diagnosed in 
the period [T, T + 1], aged a at diagnosis.
Let pT,y,a be the daily probability of death in the period [T, T + 1] amongst those aged 
a who, in continuous time, were diagnosed in the year leading up to time T   y and 
therefore, in the discrete model, entered the prevalent population at time T   y. The 
primary distinction between ⇢T,a,j and pT,y,a is that the former is the daily probability 
of death in the calendar year of diagnosis and the latter is the daily probability of 
death in subsequent calendar years. Additionally, it is assumed that the latter is 
constant throughout the year; i.e. in each calendar year subsequent to the calendar year
of diagnosis, the risk of dying is the same on every day. This means that MT,y,a can be 
estimated, as described by Mayfield (1961, 1975) and Trent and Rongstad (1974), by:
M˜T,y,a = − (− pT,y,a)τ . [4.18]
A person-time analysis of cancer registry data was used to estimate the mortality 
probabilities MT,y,a. In each year T  and for each value of time since entry y and 
attained age a, the total number of deaths among survivors was calculated and divided 
by the appropriate total number of person-days of prevalence in the period to give an 
estimate of pT,y,a, from which an estimate of MT,y,a was made using equation [4.18].
The assumption that, among cancer survivors, the daily probability of dying is constant
throughout any given calendar year (but may vary between years) is used to estimate 
MT,y,a, where the time since entry variable y is specified with a resolution of one year. 
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For cancer patients in England, it was found that the daily probability of death is much
higher in the first few months following diagnosis than at other times, particularly 
among survivors aged 65 and over (see figure 4.2). Therefore, this assumption is not 
appropriate when estimating ⇢T,a,j since it describes the daily probability of dying up 
to 12 months after diagnosis only and requires a time since diagnosis resolution of one 
day (via the index j).
Figure 4.2. Daily probability of death among cancer survivors in England aged 65 and
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It is possible to estimate ⇢T,a,j directly using cancer registry data and the same person-
time method as for pT,y,a (described above). However, at the daily time since diagnosis 
resolution this method does not provide robust estimates since very small numbers are 
always involved. So instead, the daily mortality probabilities ⇢T,a,j were first calculated 
assuming that they were constant on each post-diagnosis day in the calendar year of 
diagnosis. They were then scaled using weights to represent the archetypal dependence 
of daily mortality on time since diagnosis in the months following diagnosis, as follows:
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Let ⇢T,a be the daily post-diagnosis probability of dying for people diagnosed at age a 
in the time period [T, T + 1], under the assumption that daily post-diagnosis mortality 
is constant from the point of diagnosis up to time T + 1; i.e. ⇢T,a is equivalent to ⇢T,a,j 
with the time since diagnosis dependence removed. Then ⇢T,a can be estimated using 
cancer registry data and the same person-time methods that were used to estimate 
pT,y,a (described above).















The role of these weights is to scale equation [4.17] to take account of the fine 
resolution dependence on time since diagnosis of the daily mortality probabilities in the
first months following diagnosis that is not robustly estimable from the data. For 
simplicity, they were assumed to be independent of time T  (as can be seen from the 
above definition), and were estimated using the most recent available 10 years of cancer
registry data. It was also assumed that they were constant in broad age groups and in 
each month post-diagnosis (see section 5.3.2 for full details).






   NT 1,a i (1   T 1,a)  i+1Wi,a
+  NT 1,a 1 (    i) (1   T 1,a 1)  i+1Wi,a 1 . [4.20]
4.5 Implementation
A computer program was written using Microsoft Visual Basic for Applications (VBA) 
in the Excel computer package in order to execute the large number of calculations 
required by the model equations [4.6] and [4.20]. Each input dataset – current 
prevalence, future incidence, future mortality and the mortality weights described 
above – is copied by the user into a separate worksheet. When executed, the program 
reads in all the input data, performs the calculations, and places the results in the 
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output worksheets. The required input data were gathered from an analysis of cancer 
registry data, and regression models were developed where necessary (see Chapter 5 for 
full details).
4.6 Applications
The model is designed to be flexible and as general as possible. Estimates of future 
prevalence can be produced for any chosen input data – examples of this are given in 
Chapter 6. The only requirements are that full datasets are provided for current 
prevalence, future incidence, future mortality and future demographics. The data 
themselves may pertain to any geographical region, cancer type, sex, or anticipated 
future scenario. 
One of the strengths of the model is in its ability to provide diﬀerent prevalence 
estimates based on diﬀerent scenarios relating to future incidence, mortality and 
demographics. The program may be run using future cancer statistics estimated from 
existing trends (perhaps incorporating various diﬀerent assumptions) or alternatively 
using a set of pre-defined target statistics. This may be particularly useful to test the 
eﬀect on prevalence of theoretical changes in survival. For example, cancer prevalence 
might be estimated under the assumption that cancer survival in the UK is to increase 
to a level comparable with that of another European population in the coming years.
However, the model equations require survival input data to be in the form of mortality
probabilities for survivors, according to time since diagnosis and attained age, rather 
than survival explicitly. It would be useful to be able to specify scenarios in terms of 
changes in survival using standard survival analysis techniques, rather than changes in 
these mortality probabilities. Therefore, a method for translating changes in survival to
changes in mortality probabilities for survivors is required.
4.6.1 Survival versus mortality
Proportional hazard models are often used to compare and analyse survival in two (or 
more) diﬀerent populations. Such models assume that the two survival functions S1(t) 
and S2(t) are related by a constant hazard ratio HR. As shown in Collett (2003: p.47), 
this implies that
S2 (t) = S1 (t)
HR . [4.21]
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Let M1 and M2 be the probabilities of dying between time t and time t+ δt under 
survival functions S1(t) and S2(t), respectively. Then 







= 1  (1 M1)HR . [4.22]
Equation [4.22] provides a method for translating changes in survival (under a 
proportional hazards model) to the equivalent changes in the required mortality inputs.
4.6.1.1 Example
Suppose that S1(t) represents the current cancer survival function for a particular 
cancer in the UK, and S2(t) represents a comparator or target survival function. The 
hazard ratio, HR, relating these survival functions can be estimated using standard 
proportional hazards regression techniques. The set of current mortality probabilities 
among survivors in the UK, {M1}, is known and so the set of mortality probabilities 
{M2} can be estimated using [4.22]. These can then be used as input to the model for 
projecting cancer prevalence.
4.7 Summary
In this chapter the mathematical relationships between incidence, mortality and 
prevalence were set out and used to define a model for projecting cancer prevalence. 
Careful consideration was given to the task of specifying the model inputs based on 
cancer registry data, and a strategy for doing this was described. A brief discussion of 
the possible applications of the model was also included.
The focus of the following chapter is the model input data – the extent of data that are
typically available in a cancer registry context is described and compared in detail to 
that which is required as input to the model. Methods for estimating future incidence 
and mortality, as required by the model, are developed and the performance of the 
model is then assessed. Finally, incidence and mortality projections for England up to 
the year 2039 are displayed. In Chapter 6, results showing projections of cancer 
prevalence in the UK up to the year 2040, under various diﬀerent scenarios of future 
incidence and survival, are displayed and discussed. 
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Chapter 5. Projection model input data and evaluation
In this chapter, the input data required to execute the model for projecting cancer 
prevalence (described in Chapter 4) are explored. These data are described in terms of 
‘parameter spaces’. In this context, a parameter space is the set of parameter values for
which a given input variable is required – for example, the ages and years for which it 
is necessary to provide cancer incidence counts. Parts of these parameter spaces 
(hereupon referred to simply as ‘spaces’) are readily available from an analysis of cancer
registry data. The remaining parts must be estimated, and for this task a series of 
regression models are developed. Exercises designed to test the prevalence model and 
evaluate its forecasting ability are then described. Finally, projections of incidence and 
mortality up to the year 2039 are displayed.
5.1 The parameter spaces
The model for projecting cancer prevalence described in Chapter 4 was developed in 
the context of a large volume of cancer registry data being available, and depends upon
a large amount of input data. These inputs are current prevalence counts, future 
incidence counts and future mortality probabilities for cancer survivors (see equations 
[4.6] and [4.20]).
Current prevalence may be counted directly using cancer registry data, with the only 
restriction being the length of the available data series. For example, in England cancer
registration has been active since the early 1960s and a national quality assured dataset
is available covering diagnoses made from 1971 onwards which, currently, allows 
estimates of almost 40-year limited duration prevalence to be made. Methods exist to 
adjust limited duration prevalence to account for survivors who were diagnosed before 
the start of the registry dataset (Capocaccia and De Angelis, 1997), but with such a 
long time series of data only small adjustments are needed (as in Chapter 2).
Future incidence counts and mortality probabilities must be estimated and this can be 
achieved by considering trends observed in the available data. Before designing 
appropriate methods for estimating future incidence and mortality, it is useful to 
consider in detail the space of available data and the space of data that is required to 
run the prevalence model.
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5.1.1 Extent of available data
The notation of variables used in this chapter follows the conventions set out in 
Chapter 4. There are two variables that index incidence – namely, calendar time T  and
age a. The extent of the incidence data can therefore be visualised in a two-dimensional
space (i.e. a plane) with axes {T, a}. Similarly, there are three variables that index 
cancer prevalence and survivor mortality probabilities – calendar time T , age a and 
time since diagnosis y – and therefore the extent of these data can be visualised in a 
three-dimensional space with axes {T, a, y}.
Suppose that the available cancer registry data cover all diagnoses made from year T0 
to year T1 − 1 (inclusive) and that the maximum possible attainable age of members of 
the population is amax. Then the space of available incidence data (Figure 5.1) is given 
by: {
N˜T,a : T ∈ [T0, T1 − 1], a ∈ [0, amax]
}
[5.1]
where T  and a are discrete integer variables and N˜T,a is the count of the number of 
cancers diagnosed in year T  at age a. 
The extent of the available daily mortality probabilities among survivors in the 
calendar year of diagnosis, ρT,a, is the same as for the incidence counts:
{ρT,a : T ∈ [T0, T1 − 1], a ∈ [0, amax]} . [5.2]
Figure 5.1. Extent of available incidence and mortality in the calendar year of 
diagnosis data.
Now let’s consider the extent of the available prevalence, VT,y,a. The cancer registry 
data contain a total of Y  years of diagnoses, where Y  is defined as T1 − T0. From these 
data, estimates of Y -year limited duration prevalence at the start of year T1, given by ∑Y−1
y=0 VT1,y,a in the discrete time formulation, are possible. In general, at an 
intermediate discrete time point T ∈ [T0 + 1, T1], the restriction on y (the time since 
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entry to the prevalent population) in the available prevalence data is y ∈ [0, T − T0 − 1].
Additionally, since no person may enter the prevalent population within the model 
before they are born, the age variable is restricted such that a   y. These conditions 
lead to the following space of available prevalence estimates:
{VT,y,a : T ∈ [T0 + 1, T1], y ∈ [0, T − T0 − 1], a ∈ [y, amax]} . [5.3]
Figure 5.2 shows cross sections of this space in each of the planes {T, a}, {y, a} and 
{T, y}. In the three dimensional space {T, a, y}, the extent of the data forms a shape 
similar to a wedge of cheese but with a tapered underside (Figure 5.3). 
Figure 5.2. Cross-sectional planar extents of available prevalence data.




Finally, the extent of the available daily mortality probabilities pT,y,a, which are used to
estimate the yearly mortality probabilities MT,y,a, is very similar to that of the 
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available prevalence data. The only diﬀerence is that there are no data from which to 
calculate pT1,y,a and so the restriction on T  becomes T ∈ [T0 + 1, T1 − 1] and the space 
of the available daily mortality estimates (Figure 5.4) is given by:
{pT,y,a : T ∈ [T0 + 1, T1 − 1], y ∈ [0, T − T0 − 1], a ∈ [y, amax]} . [5.4]




5.1.2 Extent of required data
In order to describe the space of required input data, suppose that Y -year limited 
duration prevalence at the start of year T1 is known and that the model is to be used to
project this to some later time T2. Then equation [4.6] (restated below as equation [5.5]
for convenience) must be evaluated for all γ2 ∈ [0, Y − 1] and α2 ∈ [γ2, aKt]. By 
considering this equation, together with equation [4.20] (restated as [5.6]), the spaces of
required input incidence, mortality and prevalence can be found.
VT2,γ2,α2 =










(1−MT2−γ2+i,i,α2−γ2+i) B7 γ2 ≥ T2 − T1.
[5.5]







   NT 1,a i (1   T 1,a)  i+1Wi,a
+  NT 1,a 1 (    i) (1   T 1,a 1)  i+1Wi,a 1 . [5.6]
In equation [5.5], the required known prevalence term is VT,y,a, where T = T1, 
y = γ2 − T2 + T1 and a = α2 − T2 + T1, for γ2 ≥ T2 − T1. Let’s assume that 
T2 ≤ Y − 1 + T1, since otherwise the length of the projection period is such that none 
of the survivors prevalent at time T1 can contribute to Y -year limited duration 
prevalence at time T2 and the known prevalence term is not required at all. 
Then the lower bound for the second index of VT,y,a is 0, since y = γ2 − T2 + T1 and 
γ2 ≥ T2 − T1; the upper bound is Y − 1− T2 + T1, since γ2 ≤ Y − 1 for Y -year limited 
duration prevalence. The lower and upper bounds for the third index of VT,y,a are y 
and amax − T2 + T1, respectively, since a = α2 − T2 + T1 and α2 ∈ [γ2, aKt]. Intuitively, 
the lower bound on the age index a is determined by the fact that nobody may enter 
the prevalent population in the model before they are born; the upper bound is 
determined by the fact that those above a certain age at time T1 will exceed the 
maximum age amax at time T2 and therefore will not be counted as prevalent.
Therefore, the space of required prevalence data is:
{VT,y,a : T = T1, y ∈ [0, Y − 1− T2 + T1], a ∈ [y, amax − T2 + T1]} . [5.7]
This is shown and compared to the space of available prevalence data in Figure 5.5.




Inflow terms NT2−γ2,α2−γ2 are required in equation [5.5] for all γ2 ∈ [0, T2 − T1 − 1] and 
α2 ∈ [γ2, amax]. Therefore, the required space of inflow data is:
{NT,a : T ∈ [T1 + 1, T2], a ∈ [0, amax + T − T2]} . [5.8]
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As explained in section 4.4.1, inflow NT,a is the number of people who join the 
prevalent population at discrete time T  and age a, and it can be estimated using 
continuous time data via equation [5.6]. Consideration of this equation, together with 
equation [5.8], shows that the required spaces of continuous time incidence counts N˜T,a,
death probabilities ρT,a and weights Wi,a (as defined in equation [4.19]) are given by:{
N˜T,a : T ∈ [T1, T2 − 1], a ∈ [0, amax + T + 1− T2]
}
[5.9]
{ρT,a : T ∈ [T1, T2 − 1], a ∈ [0, amax + T + 1− T2]} [5.10]
{Wi,a : i ∈ [1, τ ], a ∈ [0, amax]}. [5.11]
The spaces of required incidence counts and death probabilities are compared to the 
available spaces in Figure 5.6.
Figure 5.6. Comparison of required and available extents of continuous time data 




The final terms required to evaluate equation [5.5] are the yearly mortality probabilities
MT,y,a. As before, let’s assume that T2 ≤ Y − 1 + T1 so that all lines of equation [5.5] 
need to be evaluated. Then MT,y,a is required for all T ∈ [T1, T2 − 1], 
y ∈ [0, T + Y − 1− T2] and a ∈ [y, amax + T − T2]. As stated previously, equation [4.18] 
is used to estimate MT,y,a via pT,y,a, the daily mortality probabilities in calendar years 
subsequent to the year of diagnosis. The above conditions therefore lead to the 
following space of required daily mortality probabilities:
{pT,y,a : T ∈ [T1, T2 − 1], y ∈ [0, T + Y − 1− T2], a ∈ [y, amax + T − T2]} . [5.12]
Cross-sectional planar and three-dimensional views of this space are shown in Figure 
5.7, and compared to the available space of daily mortality data in Figure 5.8.
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Figure 5.7. Extent of required daily mortality data.

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5.2 Available data sources
In the previous section the theoretical extent of data available from a generic cancer 
registry dataset, and the extent of the input data required to make projections of 
cancer prevalence using the model of Chapter 4, were described. In practice, cancer 
registry data from the National Cancer Data Repository (National Cancer Intelligence 
Network, 2011a) were used. This dataset is an amalgamation of data from all eight 
regional cancer registries in England and as such provides complete geographical 
coverage of the country. Details of all registered diagnoses of cancer among residents of 
England in the period 1971 to 2008 (inclusive) were available. In the notation of the 
previous section, this corresponds to T0 = 1971, T1 = 2009 and Y = 38. It is always 
possible for a small number of cancer registrations never to receive a death notification,
leading to so-called ‘immortals’ in the dataset. The impact of these immortals was 
minimised by imposing a maximum possible attainable age for all registered cancer 
patients of 99 years; i.e. in the notation of the previous section, amax = 99.
Consistent with previous chapters, the data were analysed using cohorts of survivors 
defined by sex and type of cancer – colon, rectum and anus (ICD-10 C18–C21), lung, 
bronchus and trachea (ICD-10 C33–C34), prostate (ICD-10 C61) and female breast 
Chapter 5. Projection model input data and evaluation
113
(ICD-10 C50), as well as all other malignant neoplasms combined (ICD-10 C00–C97 
excluding C44 and those codes mentioned previously).
Historical and estimated future national population data were supplied by ONS. The 
‘principal’ (i.e. the most likely) 2008-based projections of the size of the population of 
England and the UK, by age, sex and year up to 2040, were used (Oﬃce for National 
Statistics, 2011b). A population pyramid showing the size and age structure of the 
population of England in 2009 and the projected population for 2040 is shown in Figure
5.9. It can be seen that the population is anticipated to increase in almost all age 
groups, for both sexes, with the largest increases in the oldest age groups; i.e. the 
population is both growing and ageing. Specifically, the size of the population of the 
UK is anticipated to grow by almost 20% from 62 million in 2009 to 74 million in 2040,
and the median age to increase from approximately 37 to 41 years (males) and from 40 
to 43 years (females). The proportion of the population at least 65 years of age is 
expected to increase from 16% in 2009 to 24% in 2040.


































All required prevalence input data are known if it is assumed that the cancer registry 
data contain Y  years of cancer registrations prior to year T1 and that the task is to 
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project Y -year limited duration prevalence from the start of year T1 to the start of year
T2. Future incidence rates and mortality probabilities are not known but can be 
estimated from the available data by extrapolating from existing empirical trends. 
Regression models were designed for this purpose.
Using the cancer registry dataset described above, 38-year prevalence at the start of 
2009 was known, and this was to be projected to the year 2040; i.e. T1 = 2009, Y = 38 
and T2 = 2040. With these parameters, the extents of the available and required input 
data can be seen in the figures of section 5.1.2 and these visualisations informed the 
design of the regression models.
The following models were chosen for their simplicity and general applicability to all 
cancer type and sex combinations. Similar models were chosen for both incidence and 
mortality and, in all cases, age groups under 30 years were excluded from the regression
due to problems surrounding small numbers – incidence rates and mortality 
probabilities were assumed to be constant in these age groups from 2009 to 2040. This 
assumption was considered to be reasonable given the types of cancer being studied 
(prostate, breast, colorectal and lung) for which the majority of disease is diagnosed in 
the older age groups. The ‘all other’ category does contain a variety of cancer types for 
which this assumption would not be appropriate (bone cancers, lymphoma, leukaemia, 
etc.), but since these are not being studied individually the eﬀect of the assumption in 
this category is minimal.
The regression models were initially evaluated on a sub-set of the available cancer 
registry data as part of an exercise to test the prevalence projection model; this is 
described in section 5.4. Only after this exercise was considered to be complete was the 
whole dataset used, and at this point it was necessary to make an alteration to the 
incidence regression model, as described in section 5.5.
5.3.1 Incidence
Incidence rates were projected in 5-year age groups and 5-year calendar time periods 
using an age-period-cohort Poisson regression model with a log link function. This is a 
log-linear regression model commonly used to project incidence counts and rates, as 
well as other epidemiological statistics (Clayton and Schiﬄers, 1987). The number of 
incident cases of disease is assumed to follow the Poisson distribution and the logarithm
of its expected value is modelled as a linear combination of the explanatory variables 
age, period and cohort. If a rate is being modelled then the logarithm of the population
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at risk is also included as an explanatory variable in the regression equation with a 
fixed coeﬃcient of 1 – this is known as the ‘oﬀset’ variable.
Age-period-cohort models can be constructed in a variety of ways – for example, the 
cohort or period term may be omitted, and a linear ‘drift’ term may or may not be 
included (Clayton and Schiﬄers, 1987). A drift term is used to model the general trend 
in the response variable over time that applies equally in the period and cohort 
dimensions – it may therefore be specified as either a period-drift or a cohort-drift. In 
many instances, diﬀerent constructions result in diﬀerent parameterisations of the exact
same model; this is known as the identifiability problem and is caused by the fact that 
age, period and cohort are not linearly independent variables. When modelling cancer 
incidence rates, the cohort term is often preferred to the period term since long-term 
habits and historical exposures to risk factors are likely to vary by birth cohort rather 
than time period (Robertson et al., 1999). For this reason, age group and birth cohort 
(defined as period minus age group) were used as categorical explanatory variables. To 
allow projections of incidence rates beyond the most recent year of available data in all 
age groups, period was also included as a linear explanatory variable (the period-drift 
term). The coeﬃcients of the regression equation were estimated using the proc 
genmod procedure in the SAS statistical programming package (SAS Institute Inc., 
Cary, NC, USA).
The variables used in the incidence regression were at a resolution of five years in order 
to minimise any issues with small numbers that may have caused unstable projections. 
The model for projecting cancer prevalence, however, operates at a 1-year resolution 
and so linear interpolation was used to convert the projected incidence rates in 5-year 
periods and age groups to incidence rates in 1-year periods and age groups. Projected 
populations for England, as supplied by ONS, were then used to convert the projected 
incidence rates to numbers for use in the prevalence projection model.
5.3.2 Mortality
The daily probability of death among survivors of a given age and time since diagnosis 
in a given time period was estimated using a person-time analysis of the cancer registry
data which calculated the total number of deaths and divided this by the total number 
of person-days at risk. Two separate Poisson regression models were then used to 
project the daily mortality probabilities ρT,a and pT,y,a into the required spaces defined 
by equations [5.10] and [5.12], respectively. In both cases, the response variable was the 
number of deaths and the logarithm of the number of person-days at risk was the oﬀset
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variable. An arbitrary number of person-days at risk was used where no empirical data 
were available (i.e. in the projected period) – this was appropriate since only the 
probability of death is required to be projected, not the actual number of deaths. The 
choice of explanatory variables was diﬀerent in each of the two models, as explained 
below.
The daily mortality probability in the calendar year of diagnosis, ρT,a, was projected 
using an age-period model; 10-year age group and 5-year period were the explanatory 
variables, with the latter being a linear drift term as in the incidence model. The 
weights Wi,a that are required to scale ρT,a (as per equation [4.19]) were estimated for 
each cancer type and sex combination using the most recent 10 years of cancer registry 
data, i.e. diagnoses made between 1999 and 2008 (inclusive), under the assumption that
the weights themselves remain constant over calendar time. They were also assumed to 
be constant within broad age groups (0–44, 45–64 and ≥65 years) and within each 
month post-diagnosis.
The daily mortality probabilities in years subsequent to the year of diagnosis, pT,y,a, 
were projected using 10-year age group, 5-year period (again as a linear drift) and 1-
year time since diagnosis as the explanatory variables. In addition, an age–time since 
diagnosis interaction term was included to account for the fact that, as time since 
diagnosis increases beyond the initial phase of the disease, the eﬀect of general 
background mortality becomes more pronounced in the older age groups than in the 
younger age groups – i.e. the risk of dying from a non-cancer cause increases with age. 
The interaction groups were defined following an empirical investigation; time since 
diagnosis was grouped in one year intervals up to 5 years, then 5–9 years and ≥10 
years, and age was grouped as <60, 60–69, 70–79 and ≥80 years. Once again, the 
coeﬃcients of the regression equation were estimated using the proc genmod 
procedure in the SAS statistical programming package (SAS Institute Inc., Cary, NC, 
USA).
Mortality data were grouped at various resolutions for the purposes of regression 
analysis (1-year time since diagnosis bands, 5-year calendar time periods and 10-year 
age groups), and therefore some interpolation was required to transform the output to 
the 1-year resolution required by the prevalence projection model. As with the 
incidence data, linear interpolation was used for this task.
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5.4 Evaluation exercises
Exercises were undertaken to test the prevalence projection model and to explore its 
forecasting ability. During this evaluation stage, it was desirable to maintain the 
integrity of both the model and the data, so that no changes were made based on 
specific features of the data that would result in over-fitting of the model. A sub-set of 
the cancer registry data for England was therefore created for testing purposes only. 
This consisted of a 50% random sample of all male colon cancers (ICD-10 C18) 
diagnosed in the period 1972–2006 (inclusive), approximately 122,000 records. 
The first exercise tested the construction of the prevalence projection model, and its 
implementation using cancer registry data as input. Using the test data, 20-year 
prevalence at the start of 1997 was estimated and the model was used to project this 10
years forward to 2007 using empirical incidence and mortality data from the period 
1997–2006. Since all required input data was available empirically, and the intent was 
to test the construction of the projection model, no regression was carried out. An 
empirical estimate of 20-year prevalence at the start of 2007 was then calculated using 
the test data, and compared with the results of the model projections.
No discrepancies were found that indicated a structural or systematic error in the VBA
code used to implement the model, and the two estimates of prevalence were in very 
close agreement. Table 5.1 shows the absolute and percentage diﬀerences between the 
projected and empirical estimates of the number of survivors. The largest percentage 
diﬀerences were observed in the youngest age group (0–44 years), due largely to the 
small numbers involved, but, nonetheless, overall the diﬀerence was very small (1.94%). 
In the other age groups, the diﬀerences were negligible: 0.28% overall in the 45–64 years
age group and 0.32% overall in the ≥65 years age group.
Table 5.1. Results of exercise 1. Absolute and percentage diﬀerences between 
projected and empirical number of survivors, by attained age and time since diagnosis.
Age group
0–44 45–64 ≥65 All ages
Years since 
diagnosis Absolute % Absolute % Absolute % Absolute %
<1 1 0.94 0 0.00 31 1.15 32 0.85
1–5 -1 -0.46 9 0.44 28 0.41 36 0.40
5–20 10 5.21 5 0.26 4 0.04 19 0.15
All (0–20) 10 1.94 14 0.28 63 0.32 87 0.35
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Projecting prevalence 10 years forward in time using true incidence and mortality data 
for the projected period resulted in almost exactly the same prevalence estimates as 
were obtained by a count of empirical data. The results of this exercise therefore 
showed that the discrete time mechanics of the model for projecting cancer prevalence, 
and its handling of real world continuous time data input, worked well.
Having established this, the exercise was then repeated using projected incidence and 
mortality for the period 1997–2006, rather than the empirical data. Incidence and 
mortality in the period 1972–1996 were projected forward to 2006 using the regression 
models described in section 5.3. The absolute and percentage diﬀerences between the 
projected and empirical number of survivors in 2007 using these input data are shown 
in Table 5.2.
Table 5.2. Results of exercise 2. Absolute and percentage diﬀerences between 
projected and empirical number of survivors, by attained age and time since diagnosis.
Age group
0–44 45–64 ≥65 All ages
Years since 
diagnosis Absolute % Absolute % Absolute % Absolute %
<1 -21 -19.81 -18 -1.92 381 14.07 342 9.12
1–5 -37 -17.05 -120 -5.81 611 9.03 454 5.02
5–20 -14 -7.29 28 1.43 287 2.82 301 2.45
All (0–20) -72 -13.98 -110 -2.22 1,279 6.51 1,097 4.37
The diﬀerences are now much greater than when using only empirical input data. This 
was to be expected, since the regression models provide only an estimate of incidence 
and mortality in the period 1997–2006 based on the trends observed in the period 
1972–1996. However, this exercise does give a measure of the predictive power of the 
model for this particular test set of data when using the regression procedures 
described. 
Once again, it was in the youngest age group (0–44 years) that the percentage 
diﬀerences between the projected and empirical estimates of prevalence were greatest; 
overall the projected number was 14% lower than the empirical. This is partly due to 
the small numbers involved in this age group, since the instability in the empirical 
incidence and mortality cannot be captured by the regression models (which produce 
smooth estimates). It is also a direct result of the assumption that incidence rates and 
mortality probabilities remained constant in the very youngest age groups, the under 
30s.
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Of note is the apparent age structure to the percentage diﬀerences in Table 5.2 – 
prevalence in the youngest age groups was underestimated, and in the oldest age groups
it was overestimated. This was shown to be not a structural problem with the 
prevalence model, but a result of the success or failure of each regression procedure (or 
assumption of constancy for the under 30s) to correctly predict the input data for the 
period 1997–2006. Substituting the projected incidence data for the empirical incidence 
data, and running the model, removed the underestimation of prevalence in the 
youngest age groups, but the overestimation in the oldest age groups remained. 
Conversely, running the model with projected incidence and empirical mortality 
removed the overestimation of prevalence in the oldest age groups whilst leaving the 
underestimation in the youngest age groups. The mortality regression model had 
underestimated the death rates in the oldest age groups, particularly those over 80 
years, and this is what caused the increasing overestimation of prevalence as age 
increased.
It was therefore shown that, unsurprisingly, the accuracy of the model’s projections of 
future cancer prevalence was dependent upon the performance of the regression models 
used to estimate the input data (future incidence and mortality). However, this 
performance can only be assessed retrospectively with the type of exercises and 
historical data described above. It is, of course, impossible to predict exactly what 
future incidence and mortality will be, but the regression models used here resulted in a
projected total number of survivors (all age and time since diagnosis groups combined) 
that was within 5% of the empirical number (Table 5.2).
5.5 Incidence and mortality projections 2009–2039
Having completed the testing and evaluation exercises, the input data required to 
project cancer prevalence in England from 2009 to 2040 was prepared. The full extent 
of the available cancer registry data (as described in section 5.2) was analysed, and 
incidence and mortality in the period 1974–2008 was projected to 2039 using the 
regression models described in section 5.3. Data pertaining to the period 1971–1973 
were excluded from the regression since they did not cover a complete five year period.
The incidence regression model was, however, found to be inappropriate for such long-
term projections. During the testing and evaluation exercises, incidence was projected 
no more than 10 years forward, but for the main analysis 30 year projections were 
required. It was found that the inclusion of the categorical cohort term resulted in 
unstable projections because for many cancer types the regression procedure resulted in
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cohort eﬀects acting in one direction and a period drift eﬀect acting in the opposite 
direction – for example, for male lung cancer the best fit to the data was obtained with 
all cohort coeﬃcients being negative, but the period-drift coeﬃcient being positive. 
This is problematic for long-term projections since coeﬃcients for cohorts not present in
the empirical data are not estimable and must therefore be ignored or remain constant 
based on the nearest estimable cohort parameter; this can result in an undesirable false 
reversal of trends many years into the future, based not on any empirical evidence, but 
on a failure of the regression model. For this reason, the incidence regression model was
simplified and the cohort term was removed so that all cohort and period eﬀects were 
condensed and estimated by a single period-drift coeﬃcient.
5.5.1 Incidence results
Figure 5.10 shows the results of the incidence regression described above, for each 
cancer type and sex combination. The outlines of graphs for age groups which 
(individually) contained less than 10% of the total number of registered cancer 
diagnoses in the period 2004–2008 for each cancer type and sex combination have been 
greyed out – this is to provide an indication of the performance of the regression model 
in the age groups for which the inflow to the prevalent population is likely to be 
greatest.
The majority of incidence rates increased in the period 1974–2008 and, accordingly, the
regression model extended these increasing trends to 2039. The notable exceptions were
male lung cancer which showed a decreasing trend – primarily as a result of 
dramatically decreasing smoking prevalence among men in the UK since the 1970s 
(Davy, 2006) – and female colorectal cancer which had largely stable incidence rates in 
most age groups.
The largest increases in incidence rates were seen for prostate cancer. For example, in 
the age group 70–74 years, incidence rates rose from 200 cases per 100,000 population 
in the period 1974–1978 to 625 per 100,000 in 2004–2008; a more than three-fold 
increase in 30 years. Naively extending this trend with the log-linear period-drift 
resulted in an estimated incidence rate of almost 3,000 per 100,000 by 2039. This is 
certainly an overestimate of the likely future incidence rates of prostate cancer. Much of
the historical increase in prostate cancer incidence is attributable to the introduction in
the early 1990s of the PSA test as a screening tool for prostate cancer. This test 
essentially re-framed the definition of the disease, but its eﬀect on incidence rates 
cannot realistically be expected to continue in the same way until 2039. This is a 
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limitation of the described approach to projecting incidence rates – it simply extends 
existing trends into the future and in some cases this may be clearly unrealistic. Other 
methods for projecting incidence rates are possible – for example, by including explicit 
assumptions regarding the eﬀects of screening programmes, as in Mistry et al. (2011) – 
but for the purposes of this work a model was sought that could easily and reasonably 
be applied to all cancer types. Additionally, instead of assuming existing trends will 
continue unabated, other authors have advocated applying arbitrary or empirically 
motivated attenuation factors to recent trends in order to project cancer incidence into 
the future (Møller et al., 2002; Mistry et al., 2011). This approach was not used in this 
thesis, however, since alternative scenarios for future incidence (and mortality), and 
their eﬀect on projections of prevalence, are considered separately in Chapter 6.
The residuals of the regression procedure (not displayed here) were analysed to assess 
the goodness of fit of the model to the empirical data. For all cancer type and sex 
combinations the standardised residuals were quite well normally distributed and 
showed little correlation with the explanatory variables. Residuals were largest for 
incidence of lung cancer. The female lung cancer results illustrate a limitation imposed 
by the simplicity of the regression model. The empirical data show that incidence rates 
generally increased in the period 1974–2008 for all age groups older than 65 years, were
quite steady in the age groups 50–64, and decreased slightly in the age groups under 45.
However, the regression model is unable to account for such diﬀerent period trends in 
each age group since there is only one period-drift parameter and no period-age 
interaction term. This results in female lung cancer incidence rates being projected to 
increase in all age groups, even though the empirical trends do not support this. The 
eﬀect of this limitation on projections of overall cancer prevalence is likely to be small, 
however, since a large majority of cancers are diagnosed in older age groups for which 
the regression model performed satisfactorily. This problem is much less significant for 
the other types of cancer, and is accepted as a limitation brought about by the desire 
to use the same regression model for every cancer type and sex combination. 
Nonetheless, an area of further study would be to develop individual regression models 
for each sex and type of cancer.
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Figure 5.10. Empirical and projected incidence rates, England, 1974–2039; by cancer 






















































































































































































































































































































*Outlines of graphs for age groups that contain less than 10% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.10 (continued). Empirical and projected incidence rates, England, 1974–












































































































































































































































































*Outlines of graphs for age groups that contain less than 10% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.10 (continued). Empirical and projected incidence rates, England, 1974–









































































































































































































































































*Outlines of graphs for age groups that contain less than 10% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.10 (continued). Empirical and projected incidence rates, England, 1974–







































































































































































































































































*Outlines of graphs for age groups that contain less than 10% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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5.5.2 Mortality results
Figure 5.11 shows the empirical and projected average daily probability of death in the 
calendar year of diagnosis for cancer survivors (i.e. ρT,a), by 10-year age group and 5-
year period. Similarly to Figure 5.10, the outlines of graphs for age groups which 
contained the smallest numbers of registered cancer diagnoses have been greyed out – 
this time, since the age bands are wider, the criterion for being greyed out is less than 
20% of the total number of registered cancer diagnoses in the period 2004–2008.
In all age groups, for every cancer type and sex combination, ρT,a showed a decreasing 
trend. This reflects the great improvements in cancer treatment that have been made in
the last 40 years, as well as the eﬀects of earlier diagnosis, both of which have 
contributed to increasing cancer survival particularly in the first year following 
diagnosis (Rachet et al., 2009). The fit of the regression model to the data was observed
to be reasonably good in most instances, with small residuals.
Figure 5.12 shows the results of the second mortality regression model which projected 
the average daily probability of death in calendar years subsequent to the year of 
diagnosis (i.e. pT,y,a), in 10-year age groups, 5-year time periods and 1-year time since 
diagnosis bands. Plotted are the yearly mortality probabilities, MT,y,a, calculated from 
the daily probabilities using equation [4.18]. In order to maintain the readability of the 
graphs, only values for y = 0 (solid lines) and y = 5 (dashed lines) are displayed. As in 
Figure 5.11, the outlines of graphs for age groups which contained less than 20% of the 
total number of registered cancer diagnoses in the period 2004–2008, for each cancer 
type and sex, have been greyed out.
As with the mortality probabilities in the calendar year of diagnosis, these probabilities 
decreased over time for all cancer type, sex and time since diagnosis combinations, 
reflecting the general lengthening of cancer survival time in England since the 1970s. 
For the majority of cancers, the fit of the regression model to the observed data was 
acceptable and the projections plausible. Residuals were larger than those produced by 
the incidence regression, mainly due to the necessary inclusion of the time since 
diagnosis term (y) at a 1-year resolution which resulted in rather small numbers and 
unstable estimates; for example, for prostate cancer in the relatively young age groups. 
In the period 1974–2008, mortality probabilities for breast cancer survivors decreased at
a much faster rate in the younger age groups compared with the older age groups, and 
this was a characteristic that was particularly hard for the regression model to account 
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for. The inclusion of the age–time since diagnosis interaction term did, however, 
improve the fit to the empirical data in this case.
Figure 5.11. Empirical and projected average death probabilities in the calendar year 




























































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.11 (continued). Empirical and projected average death probabilities in the 




















































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.11 (continued). Empirical and projected average death probabilities in the 



























































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.11 (continued). Empirical and projected average death probabilities in the 




















































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.12. Empirical and projected average yearly death probabilities for cancer 

























































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.12 (continued). Empirical and projected average yearly death probabilities 
for cancer survivors, England, 1974–2039; by cancer type, sex, age group* and time 




























































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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Figure 5.12 (continued). Empirical and projected average yearly death probabilities 
for cancer survivors, England, 1974–2039; by cancer type, sex, age group* and time 
























































































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
Chapter 5. Projection model input data and evaluation
134
Figure 5.12 (continued). Empirical and projected average yearly death probabilities 
for cancer survivors, England, 1974–2039; by cancer type, sex, age group* and time 


























































































































































































*Outlines of graphs for age groups that contain less than 20% of the total number of cancer diagnoses in 
the period 2004–2008 have been greyed out.
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5.5.3 Discussion
Regression models were chosen that would be generally applicable to all cancer types so
that the production of prevalence projections was not unnecessarily complex. The fit of 
the regression models to the observed data could be improved; for example, by tailoring
the regression procedures based on characteristics and trends observed in the data 
particular to each cancer type. However, in most cases, the fit to the observed data was
acceptable and the projected incidence and mortality estimates were plausible. Indeed, 
for the purposes of projecting cancer prevalence, it is more important to provide 
roughly plausible estimates of future incidence and mortality than it is to have a good 
fit to the observed data, since it is only the future estimates that are required by the 
prevalence projection model (see Figures 5.6 and 5.8).
5.6 Summary
In this chapter the extent of input data necessary for projecting cancer prevalence was 
explored. Regression models were developed to provide the required estimates of future 
incidence and mortality based on empirical trends. Using a test dataset, evaluation 
exercises were conducted and revealed that the mechanics of the discrete time 
prevalence model worked properly, dealt with continuous time data inputs 
appropriately and were coded in the Excel VBA computer program correctly.
National cancer registry data for England (covering all diagnoses made in the period 
1971–2008) were used to generate input data that would allow projections of cancer 
prevalence up to the year 2040. The results of these projections are detailed and 
discussed in the next chapter. Alternative scenarios of future incidence and mortality 
(i.e. not based on existing trends), and their eﬀect on future cancer prevalence, are also 
considered.
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Chapter 6. Projections of cancer prevalence to 2040
Using the model and input data described in the previous two chapters, projections of 
cancer prevalence in the UK up to the year 2040 were made under various scenarios of 
future incidence and survival. This chapter contains a detailed presentation and 
discussion of the results.
6.1 Background and literature
It is important to anticipate changes in cancer prevalence for the reasons set out in 
Chapter 4. But it is also of interest to explore the influence of each of the underlying 
elements that eﬀect changes in cancer prevalence. Various factors should be considered: 
trends in incidence rates and survival, population growth and changes in the age 
structure of a population can each have a significant impact on cancer prevalence. In 
the literature, there are a number of examples of attempts to quantify each of these 
influences.
In general, cancer prevalence is increasing in Western countries. Stenbeck et al. (1999) 
used 35 years of national cancer registry data to show that cancer prevalence in Sweden
increased between 1961 and 1995. By comparing, on a logarithmic scale, the observed 
trends in age-standardised incidence and age-standardised and crude prevalence, they 
estimated the proportion of the increases that could be attributable to trends in 
incidence rates and survival, population growth and population ageing. It was found 
that the largest proportion of observed increases in overall cancer prevalence was due to
population dynamics – 40% and 47% for males and females, respectively. The second 
biggest influence was increasing cancer survival, accounting for 30% of the increases in 
cancer prevalence. The authors suggested that the increases in cancer prevalence were 
therefore primarily a consequence of increased life expectancy in the general population
and better chances of surviving cancer – what they call “good forces”.
Other studies have looked at individual types of cancer separately. Merrill (2001) found 
that the observed increases in prostate cancer prevalence in the USA between 1988 and 
1997 were almost entirely due to increased incidence rates resulting from the 
introduction of PSA testing. Colonna et al. (2000) considered the ratio between 
prevalence proportions in France in 1992 and those in 1987, with and without age-
standardisation, and concluded that ageing of the population was not one of the main 
factors acting to increase cancer prevalence. In another paper, some of the same 
authors claimed that changes in incidence rates and survival were the main factors 
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eﬀecting changes in cancer prevalence in France between 1993 and 2002 (Colonna et al.,
2008). In this later study, the influence of population dynamics was found to vary 
greatly across diﬀerent cancer types; population ageing was responsible for increases in 
cancer prevalence of between 0.1% and 17.2%, and population growth was responsible 
for increases of between 4.7% and 13.5%.
De Angelis et al. (2009) projected breast cancer prevalence in the USA up to 2015 and 
gave specific consideration to the causes of geographical variation in prevalence across 
diﬀerent states. The number of breast cancer survivors was projected to increase by 1 
million between 2005 and 2015, from 2.4 million to 3.4 million. Breast cancer prevalence
varied greatly between states but this was largely explained by the diﬀering age 
structures of the population in each state as well as diﬀerent state-specific incidence 
rates.
When producing projections of cancer prevalence, many authors have advocated using 
multiple diﬀerent assumptions regarding future incidence rates and survival 
(Capocaccia et al., 1995, 1997; Verdecchia et al., 2002; Heinavaara and Hakulinen, 
2006; Tabata et al., 2008). Primarily, the purpose of such a set of diﬀerent assumptions 
is to provide a plausible range of estimates of future cancer prevalence, but they also 
provide a way of independently assessing the likely influences of underlying trends in 
incidence, survival or population demographics on future cancer prevalence.
The factors driving trends and regional variations in cancer prevalence largely depend 
on the specific circumstances under study (e.g. country, cancer type etc.). In this 
chapter, projections of cancer prevalence in the UK are presented. By considering 
diﬀerent scenarios of future incidence rates and survival in detail, the influence of each 
is assessed independently from the influence of population dynamics.
6.2 Projection scenarios
Projections of cancer prevalence are highly dependent on the assumptions surrounding 
future incidence and survival that are made. In the previous chapter, regression 
procedures were described to provide estimates of future incidence and mortality under 
the assumption that existing trends in each will continue. These data provided input to
the model that allowed the basic projections shown in this chapter to be made.
The model is, however, flexible in the sense that a wide range of assumptions can be 
used to specify the input data – the output is then the anticipated prevalence based on 
those assumptions. Long-term projections of cancer prevalence in the UK were sought 
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for the next three decades, up to the year 2040, a time period over which the 
assumption that existing trends will continue may not be realistic. For example, recent 
decades have seen advances in medicine that have, together with other factors, led to 
generally increasing survival for most types of cancer – it is perhaps optimistic to 
expect such increases to continue in the same way for the next 30 years. Other factors, 
such as the introduction of a breast cancer screening programme in the UK or the PSA 
test for prostate cancer, have caused rapid increases in recorded cancer incidence rates 
and changes to case-mix which cannot realistically be extrapolated to 2040 since they 
are clearly the result of specific interventions. By the same token, it is not possible to 
anticipate the eﬀect of any new public health initiative or screening programme that 
might be introduced in the future.
For these reasons, it is desirable to provide a range of estimates of future cancer 
prevalence based on diﬀerent assumptions regarding future incidence rates, survival and
population demographics. Two diﬀerent assumptions were used: a) the dynamic 
assumption (denoted  in figures) that specified existing trends would continue in the 
period 2009–2040; and b) the static assumption (denoted  in figures) that specified 
input data would remain constant from the most recent data year (2008) all the way to 
2040. The model for projecting cancer prevalence was then run multiple times by 
applying each assumption to each of the inputs in turn, thereby defining a set of 
scenarios for which future cancer prevalence was estimated – see Table 6.1.
Table 6.1. Scenarios for which cancer prevalence was projected.
Scenario number
Input data 1* 2 3* 4
Incidence rates Dynamic Static Dynamic Static 
Survival Dynamic Static Static Dynamic 
Population demographics Dynamic Dynamic Dynamic Dynamic 
*Incidence rates for prostate cancer were assumed to be static under scenarios 1 and 3, due to the 
unreliability of the projected prostate cancer incidence rates (see discussion in section 5.5.1). Scenarios 3 
and 4 are therefore the same as scenarios 2 and 1, respectively, for prostate cancer, and as such are omitted
from results tables and figures.
Population demographics were always assumed to be dynamic, based on projections 
provided by ONS (see section 5.2). These do, however, incorporate assumptions about 
general population mortality rates (including those for cancer survivors) which are 
separate from, and potentially inconsistent with, the static/dynamic assumptions used 
here.
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The model for projecting cancer prevalence is specified in terms of mortality 
probabilities for survivors at diﬀerent time points after diagnosis, rather than explicitly 
in terms of survival probabilities (see Chapter 4). Nonetheless, changes in one 
correspond directly to changes in the other and so, in practice, future survival scenarios
were specified in terms of the mortality probabilities ρT,a and pT,y,a. These are defined 
in section 4.4.1.2.
Incidence rates and survival under the dynamic assumption were specified using the 
results described in section 5.5. Under the static assumption, age and sex-specific 
incidence rates and survival were calculated for the year 2008 and applied to all 
subsequent years.
6.3 Materials and methods
Cancer registry data for England were available covering diagnoses in the period 1971–
2008, as described in section 5.2. The model was therefore able to produce estimates of 
limited duration 38-year cancer prevalence in England up to 2040, according to 
attained age, time since diagnosis, cancer type and sex, for each of the four scenarios in
Table 6.1. These were then adjusted to account for survivors diagnosed more than 38 
years previously (i.e. to give estimates of complete prevalence), using completeness 
indices previously calculated as part of the work described in Chapter 2 – see Table 6.2.
It was assumed that these completeness indices (calculated based on prevalence data 
for 2005) applied for all years in the period 2009–2040; this was considered to be 
reasonable given that the required adjustments were small, although (as noted in 
section 2.4) completeness indices for male lung cancer may have been underestimated. 
In addition to counts, prevalence proportions (per 100,000 population) in broad age 
groups were also calculated using the same projected national population figures for 
England supplied by ONS.
Estimates for England were then generalised to the UK population by assuming that 
prevalence proportions for the UK were the same as those for England in each broad 
age group and time since diagnosis band – a reasonable assumption given that, 
currently, the population of England accounts for approximately 84% of the UK 
population (Oﬃce for National Statistics, 2011a).  
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Table 6.2. 38-year completeness indices for cancer prevalence in England, 2005, by 




Colon, rectum and anus 1.0000 0.9980 0.9795
Lung, bronchus and trachea* 1.0000 0.9955 0.8032
Prostate 1.0000 1.0000 0.9978
All other malignant neoplasms 0.9958 0.9672 0.9422
Females
Colon, rectum and anus 0.9997 0.9946 0.9576
Lung, bronchus and trachea 1.0000 0.9976 0.9371
Breast 1.0000 0.9983 0.9214
All other malignant neoplasms 0.9970 0.9673 0.8757
*Possibly underestimated in older age groups, see discussion in section 2.4.
6.4 Results
Results are displayed in Figures 6.1–6.10 and tabulated in Tables 6.3–6.28. Figure 6.1 
shows the projected increases in the total number of survivors of all malignant 
neoplasms (excluding non-melanoma skin cancer) in the UK under projection scenario 
1. Figures 6.2–6.7 show the projected number of survivors (complete prevalence) in the 
UK from 2009 to 2040 under each of the scenarios described in Table 6.1, according to 
cancer type, sex and broad attained age group (0–44, 45–64 and ≥65 years). Due to the
unrealistically high projections of prostate cancer incidence rates that were produced by
the regression model (as discussed in section 5.5.1), the dynamic assumption was not 
used for prostate cancer incidence and therefore only two scenarios are included in 
Figure 6.4 and Tables 6.9 and 6.10.
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Figure 6.1. Total number of survivors of all malignant neoplasms combined (excluding



















*Dynamic incidence rates (for all cancer types except prostate), dynamic survival and dynamic population 
demographics.
Figures 6.8–6.10 display results under projection scenario 1. Figure 6.8 shows projected 
changes in the age distribution of cancer survivors for each sex and cancer type. Figure 
6.9 shows projected changes in the proportion of survivors in each of the time since 
diagnosis groups <1, 1–5 and ≥5 years. Finally, Figure 6.10 shows projected changes in 
the proportion of the total number of survivors accounted for by each type of cancer.
Tables 6.3–6.28 are arranged in pairs – the first of each pair contains projected cancer 
prevalence counts and proportions (per 100,000 population) for the years 2010, 2020, 
2030 and 2040; the second contains the corresponding average annual percentage 
change in cancer prevalence in the decades 2010–2020, 2020–2030 and 2030–2040. 
Tables 6.3 and 6.4 contain results for complete prevalence in all age groups combined 
under projection scenario 1. Tables 6.5–6.16 contain results for all projection scenarios, 
disaggregated according to attained age group. Finally, Tables 6.17–6.28 contain results
for all projection scenarios, disaggregated according to time since diagnosis.
Considering the results for projection scenario 1, the total number of survivors in the 
UK (all malignant neoplasms combined) is estimated to grow by approximately 1 
million every decade – from 2.1 million in 2010 to 2.9, 4.0 and 5.3 million in 2020, 2030 
and 2040, respectively. Not only will there be more cancer survivors under this scenario,
but they will account for a larger proportion of the population – from 2.8% of the male 
population in 2010 to 6.2% in 2040, and from 3.9% to 8.5% of the female population 
(Table 6.3). However, the growth rate of prevalence is projected to slow down over the 
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30 year period. The average annual percentage change in the number of survivors 
(proportion of the population) is projected to decrease from 3.7 (3.0) in the 2010s to 
2.7 (2.4) in the 2040s for males, and from 3.3 (2.7) to 2.9 (2.6) for females – see Table 
6.4. 
The number of survivors, and the proportion of the population that they comprise, are 
also projected to increase substantially under this scenario for each of the individual 
cancer types studied, with one exception: male lung cancer prevalence is projected to 
exhibit only modest increases in terms of numbers (0.3%, 0.3% and 0.1% per year in 
each decade) and to decrease slightly in terms of the proportion of the population 
(-0.5%, -0.3% and -0.2% per year in each decade) – see Table 6.4. This is in contrast to 
the prevalence of female lung cancer which is projected to increase by 4.7%, 4.6% and 
4.1% (count) and by 4.0%, 4.0% and 3.8% (proportion of the population) in each 
decade – these are the largest projected proportional increases of any cancer apart from
prostate cancer in the 2010s. Despite this, however, the number of female lung cancer 
survivors will remain relatively modest under this scenario, accounting for just 3.1% of 
all female cancer survivors by 2040 (Figure 6.10). It is prostate cancer prevalence which
is projected to increase at the fastest rate among males, despite this scenario assuming 
static prostate cancer incidence rates from 2009 onwards – by 2040 the total number of 
prostate cancer survivors will have more than trebled to around 830,000, accounting for
approximately 2.3% of the male population overall (and considerably more than this in 
the older age groups).
Currently, a large majority of cancer survivors are aged 65 years and over. In 2009, the 
proportion was 66.7% among male cancer survivors and 59.4% among females. Under 
projection scenario 1 this will rise to 82.3% and 73.1% in 2040, for males and females 
respectively (Figure 6.8). In the youngest age group, 0–44 years, the proportion of the 
population who are cancer survivors (all malignant neoplasms combined) is projected to
increase modestly between 2010 and 2040 – from just under 0.4% to just over 0.4% for 
males, and from 0.5% to 0.7% for females. In the age group 45–64 years these increases 
are also relatively modest, from 2.7% to 3.6% of the male population and from 5.0% to 
8.4% of the female population. However, more dramatic increases are projected for the 
oldest age group; the proportion of the population aged at least 65 years who are 
cancer survivors will almost double to 23.3% (males) and 24.9% (females) by 2040 
under this scenario (Table 6.15). By far the largest contributing cancer types in this age
group are prostate and female breast – under this projection scenario, in 2040, 10.0% of
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the male population will be prostate cancer survivors (Table 6.9), and 13.3% of the 
female population will be breast cancer survivors (Table 6.11).
Still considering the same projection scenario, Figure 6.9 shows the projected changes 
in the distribution of cancer survivors between diﬀerent time since diagnosis bands. A 
large majority of all cancer survivors are currently at least five years beyond diagnosis, 
and this proportion is projected to increase from 55.2% in 2009 to 65.5% in 2040 for 
males and from 66.0% to 70.9% for females. Accordingly, the proportion of all survivors
who are less than five years beyond diagnosis is projected to decrease. Nonetheless, the 
actual number of survivors who are less than five years beyond diagnosis will more than
double from 2010 to 2040, from around 800,000 to around 1.7 million (Table 6.27). 
Projected prevalence counts for individual cancer types show similar patterns. Lung, 
bronchus and trachea cancer is the only type studied here for which the number of 
survivors who were less than one year beyond diagnosis in 2009 exceeded the number 
who were between one and five years beyond diagnosis. For males, this is projected to 
remain true for the whole period up to 2040 (Table 6.19), but for females the number of
lung cancer survivors between one and five years beyond diagnosis is projected to 
surpass the number less than one year beyond diagnosis from 2026 onwards. The 
number of prostate cancer survivors who are at least five years beyond diagnosis will 
reach 578,000 in 2040 under this scenario and will account for 69.6% of all prostate 
cancer survivors, a sizeable increase compared with the proportion in 2009 (42.2%). 
Scenario 1 (i.e. dynamic incidence rates, survival and population demographics) 
generally resulted in the highest projected cancer prevalence, and scenario 2 (i.e. static 
incidence rates and survival, dynamic population demographics) in the lowest. For all 
malignant neoplasms and ages combined, the number of cancer survivors in 2040 was 
projected to be 5.3 million under scenario 1, and 3.5 million under scenario 2 (Table 
6.15). By comparison, scenarios 3 and 4 gave projections of 4.1 million and 4.5 million, 
respectively.
All projection scenarios for the majority of cancer types, sexes and age groups resulted 
in generally increasing cancer prevalence. The notable exception was, however, male 
lung cancer prevalence which exhibited quite diﬀerent patterns to that of the other 
cancer types studied (Figure 6.3 and Table 6.7). In the youngest age group (0–44 years)
it was scenario 2 that resulted in the highest projected male lung cancer prevalence, 
although the number of survivors in this age group is very small (less than 1,000). In 
the age groups 45–64 and ≥65 years, scenario 4 (i.e. dynamic survival and population 
demographics) gave the highest projected prevalence and scenario 3 (i.e. dynamic 
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incidence rates and population demographics) the lowest. Overall, for all age groups 
combined, the number of male lung cancer survivors is projected to remain roughly 
constant under projection scenario 1 (i.e. dynamic incidence rates, survival and 
population demographics).
In most cases, each projection scenario resulted in substantially diﬀerent prevalence 
projections. Perhaps the most notable exception was for female colon, rectum and anus 
cancer. In the age groups 45–64 and ≥65 years, there was little diﬀerence between the 
projections made under scenarios 2 and 3, and similarly between those made under 
scenarios 1 and 4.
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Figure 6.2. Complete prevalence of colon, rectum and anus cancer in the UK, 2009–
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Figure 6.3. Complete prevalence of lung, bronchus and trachea cancer in the UK, 
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Figure 6.4. Complete prevalence of prostate cancer in the UK, 2009–2040, by attained













































*Scenarios 3 and 4 are omitted for prostate cancer due to being the same as scenarios 2 and 1, respectively;
see Table 6.1 for details.    
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Figure 6.5. Complete prevalence of female breast cancer in the UK, 2009–2040, by 
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Figure 6.6. Complete prevalence of all other malignant neoplasms (excluding non-
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Figure 6.7. Complete prevalence of all malignant neoplasms (excluding non-melanoma
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Figure 6.8. Age distribution of cancer survivors in the UK, 2009–2040, by cancer 
type* and sex, under projection scenario 1†. Proportion of total number of survivors in 












































































*ICD-10 codes as follows: Colorectal = C18–C21; Lung = C33–C34; Prostate = C61; Breast = C50; Other 
= C00–C97 excluding C44 and those mentioned previously; All = C00–C96 excluding C44. †Dynamic 
incidence rates (for all cancer types except prostate), dynamic survival and dynamic population 
demographics.
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Figure 6.9. Time since diagnosis distribution of cancer survivors in the UK, 2009–
2040, by cancer type* and sex, under projection scenario 1†. Proportion of total 
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*ICD-10 codes as follows: Colorectal = C18–C21; Lung = C33–C34; Prostate = C61; Breast = C50; Other 
= C00–C97 excluding C44 and those mentioned previously; All = C00–C97 excluding C44. †Dynamic 
incidence rates (for all cancer types except prostate), dynamic survival and dynamic population 
demographics.
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Figure 6.10. Distribution between cancer types of cancer survivors in the UK, 2009–
2040, by attained age and sex, under projection scenario 1*. Proportion of total number












































































*Dynamic incidence rates (for all cancer types except prostate), dynamic survival and dynamic population 
demographics.
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Table 6.3. Complete prevalence in the UK, 2010–2040, by cancer type* and sex, under
projection scenario 1†. Number of survivors (proportion of the population per 100,000).
Year
2010 2020 2030 2040
Males
Colorectal 127,076 (415) 188,354 (572) 273,966 (783) 377,200 (1,048)
Lung 38,827 (127) 39,825 (121) 41,208 (118) 41,612 (116)
Prostate 255,431 (835) 416,104 (1,264) 619,544 (1,771) 830,533 (2,306)
Other 428,680 (1,401) 578,810 (1,759) 761,941 (2,178) 966,396 (2,684)
All 850,014 (2,777) 1,223,093 (3,717) 1,696,659 (4,850) 2,215,742 (6,153)
Females
Colorectal 116,439 (368) 151,599 (451) 199,710 (561) 254,956 (697)
Lung 25,649 (81) 40,477 (120) 63,607 (179) 95,381 (261)
Breast 569,883 (1,803) 840,460 (2,500) 1,212,319 (3,406) 1,682,737 (4,598)
Other 516,737 (1,635) 672,070 (1,999) 866,271 (2,434) 1,091,560 (2,983)
All 1,228,708 (3,887) 1,704,606 (5,071) 2,341,907 (6,579) 3,124,634 (8,538)
*ICD-10 codes as follows: Colorectal=C18–C21; Lung=C33–C34; Prostate=C61; Breast=C50; Other=
C00–C97 excluding C44 and those mentioned previously; All=C00–C96 excluding C44. †Dynamic 
incidence rates (for all cancer types except prostate), dynamic survival and dynamic population 
demographics.
Table 6.4. Rate of change of complete prevalence in the UK, 2010–2040, by cancer 
type* and sex, under projection scenario 1†. Average annual percentage change in 




Colorectal 4.0 (3.3) 3.8 (3.2) 3.2 (3.0)
Lung 0.3 (-0.5) 0.3 (-0.3) 0.1 (-0.2)
Prostate 5.0 (4.2) 4.1 (3.4) 3.0 (2.7)
Other 3.0 (2.3) 2.8 (2.2) 2.4 (2.1)
All 3.7 (3.0) 3.3 (2.7) 2.7 (2.4)
Females
Colorectal 2.7 (2.0) 2.8 (2.2) 2.5 (2.2)
Lung 4.7 (4.0) 4.6 (4.0) 4.1 (3.8)
Breast 4.0 (3.3) 3.7 (3.1) 3.3 (3.0)
Other 2.7 (2.0) 2.6 (2.0) 2.3 (2.1)
All 3.3 (2.7) 3.2 (2.6) 2.9 (2.6)
*ICD-10 codes as follows: Colorectal=C18–C21; Lung=C33–C34; Prostate=C61; Breast=C50; Other=
C00–C97 excluding C44 and those mentioned previously; All=C00–C96 excluding C44. †Dynamic 
incidence rates (for all cancer types except prostate), dynamic survival and dynamic population 
demographics.
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Table 6.5. Complete prevalence of colon, rectum and anus cancer in the UK, 2010–
2040, by attained age, sex and projection scenario. Number of survivors (proportion of 
the population per 100,000).
Year
Age Scenario 2010 2020 2030 2040
Males
0–44 1 2,236 (12) 2,652 (14) 3,334 (17) 3,482 (18)
2 2,270 (12) 2,798 (15) 3,312 (17) 3,243 (16)
3 2,249 (12) 2,655 (14) 3,200 (16) 3,238 (16)
4 2,257 (12) 2,784 (15) 3,406 (17) 3,429 (17)
45–64 1 25,925 (333) 32,402 (393) 39,608 (483) 44,511 (527)
2 25,938 (333) 28,364 (344) 30,541 (373) 30,018 (355)
3 26,106 (335) 31,780 (386) 36,528 (446) 38,739 (459)
4 25,759 (331) 28,876 (351) 33,020 (403) 34,354 (407)
≥65 1 98,915 (2,186) 153,301 (2,653) 231,024 (3,248) 329,207 (4,205)
2 98,133 (2,169) 133,966 (2,318) 164,931 (2,319) 187,377 (2,394)
3 98,338 (2,174) 137,774 (2,384) 180,276 (2,535) 219,793 (2,808)
4 98,689 (2,181) 148,401 (2,568) 210,082 (2,954) 279,462 (3,570)
All 1 127,076 (415) 188,354 (572) 273,966 (783) 377,200 (1,048)
2 126,342 (413) 165,128 (502) 198,784 (568) 220,637 (613)
3 126,693 (414) 172,209 (523) 220,005 (629) 261,769 (727)
4 126,704 (414) 180,061 (547) 246,508 (705) 317,245 (881)
Females
0–44 1 2,202 (12) 2,384 (13) 2,751 (15) 2,745 (15)
2 2,199 (12) 2,401 (13) 2,653 (14) 2,560 (14)
3 2,195 (12) 2,274 (13) 2,511 (13) 2,448 (13)
4 2,205 (12) 2,488 (14) 2,865 (15) 2,835 (15)
45–64 1 21,067 (261) 24,493 (286) 27,397 (329) 28,237 (335)
2 21,317 (264) 24,199 (283) 25,273 (303) 24,244 (288)
3 21,180 (263) 24,133 (282) 25,409 (305) 24,752 (294)
4 21,203 (263) 24,552 (287) 27,217 (327) 27,577 (327)
≥65 1 93,171 (1,621) 124,722 (1,811) 169,562 (2,028) 223,974 (2,436)
2 92,716 (1,613) 114,998 (1,670) 139,449 (1,668) 158,976 (1,729)
3 92,638 (1,611) 113,594 (1,650) 137,860 (1,649) 158,604 (1,725)
4 93,248 (1,622) 125,944 (1,829) 170,928 (2,045) 223,398 (2,430)
All 1 116,439 (368) 151,599 (451) 199,710 (561) 254,956 (697)
2 116,232 (368) 141,599 (421) 167,374 (470) 185,780 (508)
3 116,013 (367) 140,000 (416) 165,780 (466) 185,804 (508)
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Table 6.6. Rate of change of complete prevalence of colon, rectum and anus cancer in 
the UK, 2010–2040, by attained age, sex and projection scenario. Average annual 
percentage change in number of survivors (proportion of the population).
Period
Age Scenario 2010–2020 2020–2030 2030–2040
Males
0–44 1 1.7 (1.4) 2.3 (1.9) 0.4 (0.4)
2 2.1 (1.8) 1.7 (1.3) -0.2 (-0.2)
3 1.7 (1.4) 1.9 (1.5) 0.1 (0.1)
4 2.1 (1.8) 2.0 (1.6) 0.1 (0.0)
45–64 1 2.3 (1.7) 2.0 (2.1) 1.2 (0.9)
2 0.9 (0.3) 0.7 (0.8) -0.2 (-0.5)
3 2.0 (1.4) 1.4 (1.5) 0.6 (0.3)
4 1.1 (0.6) 1.4 (1.4) 0.4 (0.1)
≥65 1 4.5 (2.0) 4.2 (2.0) 3.6 (2.6)
2 3.2 (0.7) 2.1 (0.0) 1.3 (0.3)
3 3.4 (0.9) 2.7 (0.6) 2.0 (1.0)
4 4.2 (1.6) 3.5 (1.4) 2.9 (1.9)
All 1 4.0 (3.3) 3.8 (3.2) 3.2 (3.0)
2 2.7 (2.0) 1.9 (1.3) 1.0 (0.8)
3 3.1 (2.4) 2.5 (1.9) 1.8 (1.5)
4 3.6 (2.8) 3.2 (2.6) 2.6 (2.3)
Females
0–44 1 0.8 (0.6) 1.4 (1.1) 0.0 (0.0)
2 0.9 (0.7) 1.0 (0.6) -0.4 (-0.4)
3 0.4 (0.2) 1.0 (0.6) -0.3 (-0.3)
4 1.2 (1.0) 1.4 (1.0) -0.1 (-0.1)
45–64 1 1.5 (0.9) 1.1 (1.4) 0.3 (0.2)
2 1.3 (0.7) 0.4 (0.7) -0.4 (-0.5)
3 1.3 (0.7) 0.5 (0.8) -0.3 (-0.4)
4 1.5 (0.9) 1.0 (1.3) 0.1 (0.0)
≥65 1 3.0 (1.1) 3.1 (1.1) 2.8 (1.8)
2 2.2 (0.4) 1.9 (0.0) 1.3 (0.4)
3 2.1 (0.2) 2.0 (0.0) 1.4 (0.5)
4 3.1 (1.2) 3.1 (1.1) 2.7 (1.7)
All 1 2.7 (2.0) 2.8 (2.2) 2.5 (2.2)
2 2.0 (1.4) 1.7 (1.1) 1.0 (0.8)
3 1.9 (1.3) 1.7 (1.1) 1.1 (0.9)
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Table 6.7. Complete prevalence of lung, bronchus and trachea cancer in the UK, 2010–
2040, by attained age, sex and projection scenario. Number of survivors (proportion of 
the population per 100,000).
Year
Age Scenario 2010 2020 2030 2040
Males
0–44 1 476 (3) 410 (2) 408 (2) 351 (2)
2 497 (3) 677 (4) 832 (4) 847 (4)
3 505 (3) 561 (3) 591 (3) 529 (3)
4 467 (3) 479 (3) 575 (3) 590 (3)
45–64 1 7,076 (91) 7,315 (89) 6,790 (83) 5,693 (67)
2 6,753 (87) 7,201 (87) 7,697 (94) 7,515 (89)
3 7,128 (92) 6,989 (85) 6,071 (74) 4,808 (57)
4 6,709 (86) 7,550 (92) 8,639 (105) 8,940 (106)
≥65 1 31,275 (691) 32,101 (556) 34,011 (478) 35,568 (454)
2 32,299 (714) 34,231 (592) 38,653 (543) 43,120 (551)
3 31,639 (699) 29,036 (502) 26,952 (379) 24,594 (314)
4 31,882 (705) 37,542 (650) 48,354 (680) 62,087 (793)
All 1 38,827 (127) 39,825 (121) 41,208 (118) 41,612 (116)
2 39,549 (129) 42,109 (128) 47,182 (135) 51,482 (143)
3 39,271 (128) 36,586 (111) 33,614 (96) 29,931 (83)
4 39,059 (128) 45,571 (138) 57,568 (165) 71,618 (199)
Females
0–44 1 561 (3) 695 (4) 938 (5) 1,073 (6)
2 497 (3) 590 (3) 694 (4) 671 (4)
3 558 (3) 808 (4) 1,038 (6) 1,111 (6)
4 494 (3) 500 (3) 598 (3) 602 (3)
45–64 1 6,756 (84) 10,498 (123) 14,410 (173) 17,939 (213)
2 6,262 (78) 6,791 (79) 7,097 (85) 6,784 (81)
3 6,852 (85) 9,552 (112) 11,753 (141) 13,309 (158)
4 6,180 (77) 7,468 (87) 8,666 (104) 9,070 (108)
≥65 1 18,331 (319) 29,284 (425) 48,259 (577) 76,369 (831)
2 18,486 (322) 23,138 (336) 27,601 (330) 31,320 (341)
3 18,450 (321) 26,195 (380) 36,088 (432) 47,695 (519)
4 18,386 (320) 26,261 (381) 37,638 (450) 51,315 (558)
All 1 25,649 (81) 40,477 (120) 63,607 (179) 95,381 (261)
2 25,244 (80) 30,518 (91) 35,392 (99) 38,774 (106)
3 25,859 (82) 36,555 (109) 48,879 (137) 62,115 (170)
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Table 6.8. Rate of change of complete prevalence of lung, bronchus and trachea cancer
in the UK, 2010–2040, by attained age, sex and projection scenario. Average annual 
percentage change in number of survivors (proportion of the population).
Period
Age Scenario 2010–2020 2020–2030 2030–2040
Males
0–44 1 -1.5 (-1.8) 0.0 (-0.4) -1.5 (-1.5)
2 3.1 (2.8) 2.1 (1.7) 0.2 (0.2)
3 1.1 (0.7) 0.5 (0.1) -1.1 (-1.1)
4 0.2 (-0.1) 1.9 (1.4) 0.3 (0.2)
45–64 1 0.3 (-0.2) -0.7 (-0.7) -1.7 (-2.0)
2 0.6 (0.1) 0.7 (0.7) -0.2 (-0.5)
3 -0.2 (-0.8) -1.4 (-1.3) -2.3 (-2.6)
4 1.2 (0.6) 1.4 (1.4) 0.3 (0.0)
≥65 1 0.3 (-2.2) 0.6 (-1.5) 0.4 (-0.5)
2 0.6 (-1.8) 1.2 (-0.9) 1.1 (0.1)
3 -0.9 (-3.3) -0.7 (-2.8) -0.9 (-1.9)
4 1.6 (-0.8) 2.6 (0.5) 2.5 (1.6)
All 1 0.3 (-0.5) 0.3 (-0.3) 0.1 (-0.2)
2 0.6 (-0.1) 1.1 (0.5) 0.9 (0.6)
3 -0.7 (-1.4) -0.8 (-1.4) -1.2 (-1.4)
4 1.6 (0.8) 2.4 (1.7) 2.2 (1.9)
Females
0–44 1 2.2 (2.0) 3.0 (2.6) 1.4 (1.3)
2 1.7 (1.5) 1.6 (1.2) -0.3 (-0.4)
3 3.8 (3.6) 2.5 (2.1) 0.7 (0.7)
4 0.1 (-0.1) 1.8 (1.4) 0.1 (0.1)
45–64 1 4.5 (3.9) 3.2 (3.5) 2.2 (2.1)
2 0.8 (0.2) 0.4 (0.7) -0.5 (-0.6)
3 3.4 (2.8) 2.1 (2.4) 1.3 (1.1)
4 1.9 (1.3) 1.5 (1.8) 0.5 (0.3)
≥65 1 4.8 (2.9) 5.1 (3.1) 4.7 (3.7)
2 2.3 (0.4) 1.8 (-0.2) 1.3 (0.3)
3 3.6 (1.7) 3.3 (1.3) 2.8 (1.9)
4 3.6 (1.8) 3.7 (1.7) 3.1 (2.2)
All 1 4.7 (4.0) 4.6 (4.0) 4.1 (3.8)
2 1.9 (1.3) 1.5 (0.9) 0.9 (0.6)
3 3.5 (2.9) 2.9 (2.4) 2.4 (2.1)
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Table 6.9. Complete prevalence of prostate cancer in the UK, 2010–2040, by attained 
age and projection scenario*. Number of survivors (proportion of the population per 
100,000).
Year
Age Scenario 2010 2020 2030 2040
0–44 1 193 (1) 187 (1) 232 (1) 232 (1)
2 200 (1) 213 (1) 273 (1) 281 (1)
3
4
45–64 1 37,291 (479) 43,016 (522) 49,459 (604) 46,470 (550)
2 38,103 (490) 45,157 (548) 49,858 (609) 45,356 (537)
3
4
≥65 1 217,947 (4,817) 372,901 (6,453) 569,854 (8,012) 783,831 (10,013)
2 217,736 (4,813) 335,265 (5,802) 427,151 (6,006) 492,931 (6,297)
3
4
All 1 255,431 (835) 416,104 (1,264) 619,544 (1,771) 830,533 (2,306)
2 256,039 (836) 380,635 (1,157) 477,282 (1,364) 538,568 (1,496)
3
4
*Scenarios 3 and 4 are omitted for prostate cancer due to being the same as scenarios 2 and 1, respectively;
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Table 6.10. Rate of change of complete prevalence of prostate cancer in the UK, 2010–
2040, by attained age and projection scenario*. Average annual percentage change in 
number of survivors (proportion of the population).
Period
Age Scenario 2010–2020 2020–2030 2030–2040
0–44 1 -0.4 (-0.7) 2.2 (1.8) 0.0 (0.0)
2 0.6 (0.3) 2.5 (2.1) 0.3 (0.3)
3
4
45–64 1 1.4 (0.9) 1.4 (1.5) -0.6 (-0.9)
2 1.7 (1.1) 1.0 (1.1) -0.9 (-1.2)
3
4
≥65 1 5.5 (3.0) 4.3 (2.2) 3.2 (2.3)
2 4.4 (1.9) 2.5 (0.3) 1.4 (0.5)
3
4
All 1 5.0 (4.2) 4.1 (3.4) 3.0 (2.7)
2 4.0 (3.3) 2.3 (1.7) 1.2 (0.9)
3
4
*Scenarios 3 and 4 are omitted for prostate cancer due to being the same as scenarios 2 and 1, respectively;
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Table 6.11. Complete prevalence of female breast cancer in the UK, 2010–2040, by 
attained age and projection scenario. Number of survivors (proportion of the 
population per 100,000).
Year
Age Scenario 2010 2020 2030 2040
0–44 1 23,023 (129) 28,037 (154) 38,653 (205) 43,816 (232)
2 22,029 (124) 19,481 (107) 22,546 (120) 21,485 (114)
3 23,029 (129) 27,390 (151) 36,850 (195) 41,055 (217)
4 22,025 (124) 19,987 (110) 23,735 (126) 23,044 (122)
45–64 1 208,626 (2,588) 272,938 (3,188) 342,897 (4,116) 417,920 (4,960)
2 208,338 (2,584) 236,170 (2,759) 238,501 (2,863) 232,085 (2,755)
3 209,741 (2,602) 273,953 (3,200) 331,103 (3,974) 388,665 (4,613)
4 207,224 (2,570) 235,271 (2,748) 247,194 (2,967) 250,074 (2,968)
≥65 1 338,234 (5,883) 539,484 (7,835) 830,769 (9,937) 1,221,001 (13,281)
2 335,283 (5,832) 471,637 (6,850) 588,921 (7,044) 662,563 (7,207)
3 335,958 (5,844) 497,549 (7,226) 696,934 (8,336) 915,927 (9,962)
4 337,556 (5,872) 510,858 (7,420) 703,210 (8,411) 890,974 (9,691)
All 1 569,883 (1,803) 840,460 (2,500) 1,212,319 (3,406) 1,682,737 (4,598)
2 565,649 (1,789) 727,288 (2,164) 849,967 (2,388) 916,133 (2,503)
3 568,728 (1,799) 798,892 (2,377) 1,064,887 (2,992) 1,345,647 (3,677)
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Table 6.12. Rate of change of complete prevalence of female breast cancer in the UK, 
2010–2040, by attained age and projection scenario. Average annual percentage change 
in number of survivors (proportion of the population).
Period
Age Scenario 2010–2020 2020–2030 2030–2040
0–44 1 2.0 (1.8) 3.3 (2.9) 1.3 (1.2)
2 -1.2 (-1.4) 1.5 (1.1) -0.5 (-0.5)
3 1.7 (1.5) 3.0 (2.6) 1.1 (1.1)
4 -1.0 (-1.2) 1.7 (1.3) -0.3 (-0.3)
45–64 1 2.7 (2.1) 2.3 (2.6) 2.0 (1.9)
2 1.3 (0.7) 0.1 (0.4) -0.3 (-0.4)
3 2.7 (2.1) 1.9 (2.2) 1.6 (1.5)
4 1.3 (0.7) 0.5 (0.8) 0.1 (0.0)
≥65 1 4.8 (2.9) 4.4 (2.4) 3.9 (2.9)
2 3.5 (1.6) 2.2 (0.3) 1.2 (0.2)
3 4.0 (2.1) 3.4 (1.4) 2.8 (1.8)
4 4.2 (2.4) 3.2 (1.3) 2.4 (1.4)
All 1 4.0 (3.3) 3.7 (3.1) 3.3 (3.0)
2 2.5 (1.9) 1.6 (1.0) 0.8 (0.5)
3 3.5 (2.8) 2.9 (2.3) 2.4 (2.1)
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Table 6.13. Complete prevalence of all other malignant neoplasms (excluding non-
melanoma skin cancer) in the UK, 2010–2040, by attained age, sex and projection 
scenario. Number of survivors (proportion of the population per 100,000).
Year
Age Scenario 2010 2020 2030 2040
Males
0–44 1 66,849 (365) 70,634 (374) 79,430 (404) 80,786 (410)
2 67,564 (369) 73,602 (390) 81,383 (414) 80,667 (410)
3 67,337 (368) 73,038 (387) 82,075 (418) 83,001 (421)
4 67,072 (367) 71,209 (377) 78,847 (401) 78,610 (399)
45–64 1 137,394 (1,765) 167,457 (2,033) 187,509 (2,289) 210,096 (2,487)
2 138,585 (1,781) 169,458 (2,057) 179,390 (2,190) 185,316 (2,194)
3 138,789 (1,783) 172,809 (2,098) 187,851 (2,293) 202,253 (2,395)
4 137,199 (1,763) 164,064 (1,991) 178,434 (2,178) 191,396 (2,266)
≥65 1 224,437 (4,961) 340,718 (5,896) 495,003 (6,959) 675,515 (8,629)
2 222,612 (4,921) 302,523 (5,235) 376,877 (5,299) 430,750 (5,502)
3 224,432 (4,961) 319,633 (5,531) 416,193 (5,851) 497,992 (6,361)
4 222,693 (4,922) 322,476 (5,581) 446,881 (6,283) 580,454 (7,415)
All 1 428,680 (1,401) 578,810 (1,759) 761,941 (2,178) 966,396 (2,684)
2 428,760 (1,401) 545,583 (1,658) 637,649 (1,823) 696,732 (1,935)
3 430,558 (1,407) 565,481 (1,718) 686,119 (1,961) 783,247 (2,175)
4 426,965 (1,395) 557,749 (1,695) 704,162 (2,013) 850,460 (2,362)
Females
0–44 1 67,712 (381) 71,769 (395) 81,221 (431) 82,748 (438)
2 68,367 (384) 74,368 (410) 81,966 (435) 80,385 (425)
3 68,112 (383) 73,475 (405) 82,777 (439) 83,672 (443)
4 67,965 (382) 72,578 (400) 80,345 (426) 79,350 (420)
45–64 1 162,811 (2,019) 198,429 (2,318) 223,348 (2,681) 245,298 (2,911)
2 163,540 (2,029) 194,527 (2,272) 206,441 (2,478) 209,782 (2,490)
3 164,310 (2,038) 204,215 (2,385) 224,347 (2,693) 237,988 (2,825)
4 162,070 (2,010) 189,056 (2,208) 205,090 (2,462) 215,287 (2,555)
≥65 1 286,214 (4,979) 401,872 (5,837) 561,701 (6,719) 763,514 (8,305)
2 285,868 (4,973) 374,719 (5,442) 457,417 (5,471) 523,443 (5,693)
3 285,939 (4,974) 383,355 (5,568) 490,441 (5,866) 591,804 (6,437)
4 286,168 (4,978) 393,051 (5,709) 523,953 (6,267) 674,372 (7,335)
All 1 516,737 (1,635) 672,070 (1,999) 866,271 (2,434) 1,091,560 (2,983)
2 517,775 (1,638) 643,614 (1,915) 745,824 (2,095) 813,610 (2,223)
3 518,360 (1,640) 661,045 (1,967) 797,565 (2,241) 913,463 (2,496)
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Table 6.14. Rate of change of complete prevalence of all other malignant neoplasms 
(excluding non-melanoma skin cancer) in the UK, 2010–2040, by attained age, sex and 
projection scenario. Average annual percentage change in number of survivors 
(proportion of the population).
Period
Age Scenario 2010–2020 2020–2030 2030–2040
Males
0–44 1 0.6 (0.2) 1.2 (0.8) 0.2 (0.1)
2 0.9 (0.5) 1.0 (0.6) -0.1 (-0.1)
3 0.8 (0.5) 1.2 (0.8) 0.1 (0.1)
4 0.6 (0.3) 1.0 (0.6) 0.0 (0.0)
45–64 1 2.0 (1.4) 1.1 (1.2) 1.1 (0.8)
2 2.0 (1.5) 0.6 (0.6) 0.3 (0.0)
3 2.2 (1.6) 0.8 (0.9) 0.7 (0.4)
4 1.8 (1.2) 0.8 (0.9) 0.7 (0.4)
≥65 1 4.3 (1.7) 3.8 (1.7) 3.2 (2.2)
2 3.1 (0.6) 2.2 (0.1) 1.3 (0.4)
3 3.6 (1.1) 2.7 (0.6) 1.8 (0.8)
4 3.8 (1.3) 3.3 (1.2) 2.6 (1.7)
All 1 3.0 (2.3) 2.8 (2.2) 2.4 (2.1)
2 2.4 (1.7) 1.6 (1.0) 0.9 (0.6)
3 2.8 (2.0) 2.0 (1.3) 1.3 (1.0)
4 2.7 (2.0) 2.4 (1.7) 1.9 (1.6)
Females
0–44 1 0.6 (0.4) 1.2 (0.9) 0.2 (0.2)
2 0.8 (0.6) 1.0 (0.6) -0.2 (-0.2)
3 0.8 (0.6) 1.2 (0.8) 0.1 (0.1)
4 0.7 (0.5) 1.0 (0.6) -0.1 (-0.1)
45–64 1 2.0 (1.4) 1.2 (1.5) 0.9 (0.8)
2 1.8 (1.1) 0.6 (0.9) 0.2 (0.0)
3 2.2 (1.6) 0.9 (1.2) 0.6 (0.5)
4 1.6 (0.9) 0.8 (1.1) 0.5 (0.4)
≥65 1 3.5 (1.6) 3.4 (1.4) 3.1 (2.1)
2 2.7 (0.9) 2.0 (0.1) 1.4 (0.4)
3 3.0 (1.1) 2.5 (0.5) 1.9 (0.9)
4 3.2 (1.4) 2.9 (0.9) 2.6 (1.6)
All 1 2.7 (2.0) 2.6 (2.0) 2.3 (2.1)
2 2.2 (1.6) 1.5 (0.9) 0.9 (0.6)
3 2.5 (1.8) 1.9 (1.3) 1.4 (1.1)
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Table 6.15. Complete prevalence of all malignant neoplasms (excluding non-melanoma
skin cancer) in the UK, 2010–2040, by attained age, sex and projection scenario. 
Number of survivors (proportion of the population per 100,000).
Year
Age Scenario 2010 2020 2030 2040
Males
0–44 1 69,754 (381) 73,882 (391) 83,403 (424) 84,850 (431)
2 70,531 (385) 77,289 (409) 85,800 (436) 85,038 (432)
3 70,291 (384) 76,467 (405) 86,139 (438) 87,049 (442)
4 69,989 (382) 74,658 (395) 83,060 (423) 82,861 (421)
45–64 1 207,686 (2,669) 250,189 (3,037) 283,366 (3,459) 306,771 (3,632)
2 209,378 (2,690) 250,180 (3,037) 267,485 (3,265) 268,205 (3,175)
3 210,125 (2,700) 256,735 (3,116) 280,308 (3,421) 291,155 (3,447)
4 206,958 (2,659) 243,507 (2,956) 269,552 (3,290) 281,161 (3,329)
≥65 1 572,574 (12,656) 899,021 (15,558) 1,329,891 (18,698) 1,824,121 (23,301)
2 570,780 (12,616) 805,986 (13,948) 1,007,612 (14,167) 1,154,177 (14,743)
3 572,145 (12,647) 821,708 (14,220) 1,050,573 (14,771) 1,235,310 (15,780)
4 571,211 (12,626) 881,320 (15,252) 1,275,170 (17,928) 1,705,835 (21,790)
All 1 850,014 (2,777) 1,223,093 (3,717) 1,696,659 (4,850) 2,215,742 (6,153)
2 850,689 (2,779) 1,133,455 (3,444) 1,360,897 (3,890) 1,507,419 (4,186)
3 852,561 (2,785) 1,154,910 (3,510) 1,417,020 (4,051) 1,613,514 (4,481)
4 848,158 (2,771) 1,199,485 (3,645) 1,627,782 (4,653) 2,069,857 (5,748)
Females
0–44 1 93,498 (525) 102,886 (567) 123,563 (655) 130,382 (690)
2 93,092 (523) 96,840 (533) 107,858 (572) 105,100 (556)
3 93,894 (528) 103,947 (573) 123,176 (653) 128,286 (679)
4 92,689 (521) 95,552 (526) 107,543 (570) 105,833 (560)
45–64 1 399,260 (4,952) 506,357 (5,914) 608,052 (7,299) 709,393 (8,419)
2 399,456 (4,955) 461,687 (5,393) 477,312 (5,729) 472,895 (5,613)
3 402,082 (4,987) 511,853 (5,979) 592,612 (7,113) 664,714 (7,889)
4 396,678 (4,920) 456,348 (5,330) 488,167 (5,860) 502,008 (5,958)
≥65 1 735,950 (12,801) 1,095,362 (15,909) 1,610,292 (19,261) 2,284,859 (24,852)
2 732,353 (12,739) 984,492 (14,298) 1,213,387 (14,514) 1,376,301 (14,970)
3 732,985 (12,750) 1,020,693 (14,824) 1,361,323 (16,283) 1,714,030 (18,643)
4 735,358 (12,791) 1,056,114 (15,339) 1,435,729 (17,173) 1,840,060 (20,014)
All 1 1,228,708 (3,887) 1,704,606 (5,071) 2,341,907 (6,579) 3,124,634 (8,538)
2 1,224,900 (3,875) 1,543,019 (4,590) 1,798,557 (5,053) 1,954,297 (5,340)
3 1,228,961 (3,887) 1,636,493 (4,868) 2,077,111 (5,836) 2,507,030 (6,850)
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Table 6.16. Rate of change of complete prevalence of all malignant neoplasms 
(excluding non-melanoma skin cancer) in the UK, 2010–2040, by attained age, sex and 
projection scenario. Average annual percentage change in number of survivors 
(proportion of the population).
Period
Age Scenario 2010–2020 2020–2030 2030–2040
Males
0–44 1 0.6 (0.3) 1.2 (0.8) 0.2 (0.2)
2 0.9 (0.6) 1.1 (0.6) -0.1 (-0.1)
3 0.8 (0.5) 1.2 (0.8) 0.1 (0.1)
4 0.6 (0.3) 1.1 (0.7) 0.0 (0.0)
45–64 1 1.9 (1.3) 1.3 (1.3) 0.8 (0.5)
2 1.8 (1.2) 0.7 (0.7) 0.0 (-0.3)
3 2.0 (1.4) 0.9 (0.9) 0.4 (0.1)
4 1.6 (1.1) 1.0 (1.1) 0.4 (0.1)
≥65 1 4.6 (2.1) 4.0 (1.9) 3.2 (2.2)
2 3.5 (1.0) 2.3 (0.2) 1.4 (0.4)
3 3.7 (1.2) 2.5 (0.4) 1.6 (0.7)
4 4.4 (1.9) 3.8 (1.6) 3.0 (2.0)
All 1 3.7 (3.0) 3.3 (2.7) 2.7 (2.4)
2 2.9 (2.2) 1.8 (1.2) 1.0 (0.7)
3 3.1 (2.3) 2.1 (1.4) 1.3 (1.0)
4 3.5 (2.8) 3.1 (2.5) 2.4 (2.1)
Females
0–44 1 1.0 (0.8) 1.8 (1.5) 0.5 (0.5)
2 0.4 (0.2) 1.1 (0.7) -0.3 (-0.3)
3 1.0 (0.8) 1.7 (1.3) 0.4 (0.4)
4 0.3 (0.1) 1.2 (0.8) -0.2 (-0.2)
45–64 1 2.4 (1.8) 1.8 (2.1) 1.6 (1.4)
2 1.5 (0.9) 0.3 (0.6) -0.1 (-0.2)
3 2.4 (1.8) 1.5 (1.8) 1.2 (1.0)
4 1.4 (0.8) 0.7 (1.0) 0.3 (0.2)
≥65 1 4.1 (2.2) 3.9 (1.9) 3.6 (2.6)
2 3.0 (1.2) 2.1 (0.1) 1.3 (0.3)
3 3.4 (1.5) 2.9 (0.9) 2.3 (1.4)
4 3.7 (1.8) 3.1 (1.1) 2.5 (1.5)
All 1 3.3 (2.7) 3.2 (2.6) 2.9 (2.6)
2 2.3 (1.7) 1.5 (1.0) 0.8 (0.6)
3 2.9 (2.3) 2.4 (1.8) 1.9 (1.6)
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Table 6.17. Prevalence of colon, rectum and anus cancer in the UK, 2010–2040, by 
time since diagnosis, sex and projection scenario. Number of survivors (proportion of 
the population per 100,000).
Year
Years since
diagnosis Scenario 2010 2020 2030 2040
Males
<1 1 16,788 (55) 23,105 (70) 30,811 (88) 37,671 (105)
2 16,411 (54) 19,785 (60) 23,335 (67) 25,097 (70)
3 16,758 (55) 21,770 (66) 27,554 (79) 32,324 (90)
4 16,420 (54) 20,954 (64) 26,010 (74) 29,106 (81)
1–5 1 40,497 (132) 58,746 (179) 82,668 (236) 107,168 (298)
2 40,595 (133) 50,038 (152) 58,238 (166) 63,358 (176)
3 40,595 (133) 53,721 (163) 67,237 (192) 78,780 (219)
4 40,497 (132) 54,465 (166) 71,123 (203) 85,412 (237)
≥5 1 69,791 (228) 106,503 (324) 160,486 (459) 232,361 (645)
2 69,336 (227) 95,305 (290) 117,212 (335) 132,183 (367)
3 69,340 (227) 96,718 (294) 125,214 (358) 150,665 (418)
4 69,786 (228) 104,642 (318) 149,375 (427) 202,728 (563)
Females
<1 1 12,635 (40) 15,526 (46) 19,236 (54) 22,146 (61)
2 12,749 (40) 14,623 (44) 16,949 (48) 18,227 (50)
3 12,534 (40) 14,549 (43) 17,094 (48) 18,861 (52)
4 12,848 (41) 15,580 (46) 19,028 (53) 21,284 (58)
1–5 1 32,612 (103) 40,827 (121) 52,834 (148) 64,151 (175)
2 32,801 (104) 38,297 (114) 44,048 (124) 47,805 (131)
3 32,801 (104) 37,736 (112) 43,939 (123) 48,396 (132)
4 32,612 (103) 41,270 (123) 52,632 (148) 62,712 (171)
≥5 1 71,193 (225) 95,246 (283) 127,640 (359) 168,659 (461)
2 70,682 (224) 88,679 (264) 106,377 (299) 119,748 (327)
3 70,678 (224) 87,715 (261) 104,747 (294) 118,548 (324)
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Table 6.18. Rate of change of prevalence of colon, rectum and anus cancer in the UK, 
2010–2040, by time since diagnosis, sex and projection scenario. Average annual 
percentage change in number of survivors (proportion of the population).
Period
Years since
 diagnosis Scenario 2010–2020 2020–2030 2030–2040
Males
<1 1 3.2 (2.5) 2.9 (2.3) 2.0 (1.7)
2 1.9 (1.2) 1.7 (1.0) 0.7 (0.4)
3 2.7 (1.9) 2.4 (1.8) 1.6 (1.3)
4 2.5 (1.7) 2.2 (1.6) 1.1 (0.8)
1–5 1 3.8 (3.0) 3.5 (2.8) 2.6 (2.3)
2 2.1 (1.4) 1.5 (0.9) 0.8 (0.6)
3 2.8 (2.1) 2.3 (1.6) 1.6 (1.3)
4 3.0 (2.3) 2.7 (2.1) 1.8 (1.6)
≥5 1 4.3 (3.6) 4.2 (3.6) 3.8 (3.5)
2 3.2 (2.5) 2.1 (1.5) 1.2 (0.9)
3 3.4 (2.6) 2.6 (2.0) 1.9 (1.6)
4 4.1 (3.4) 3.6 (3.0) 3.1 (2.8)
Females
<1 1 2.1 (1.5) 2.2 (1.6) 1.4 (1.1)
2 1.4 (0.8) 1.5 (0.9) 0.7 (0.4)
3 1.5 (0.9) 1.6 (1.0) 1.0 (0.7)
4 1.9 (1.3) 2.0 (1.4) 1.1 (0.8)
1–5 1 2.3 (1.6) 2.6 (2.0) 2.0 (1.7)
2 1.6 (0.9) 1.4 (0.8) 0.8 (0.5)
3 1.4 (0.8) 1.5 (1.0) 1.0 (0.7)
4 2.4 (1.8) 2.5 (1.9) 1.8 (1.5)
≥5 1 3.0 (2.3) 3.0 (2.4) 2.8 (2.5)
2 2.3 (1.7) 1.8 (1.3) 1.2 (0.9)
3 2.2 (1.6) 1.8 (1.2) 1.2 (1.0)
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Table 6.19. Prevalence of lung, bronchus and trachea cancer in the UK, 2010–2040, by
time since diagnosis, sex and projection scenario. Number of survivors (proportion of 
the population per 100,000).
Year
Years since
diagnosis Scenario 2010 2020 2030 2040
Males
<1 1 9,235 (30) 9,613 (29) 9,628 (28) 8,941 (25)
2 9,741 (32) 11,869 (36) 14,065 (40) 15,183 (42)
3 9,592 (31) 9,105 (28) 8,372 (24) 7,176 (20)
4 9,349 (31) 12,528 (38) 16,211 (46) 19,034 (53)
1–5 1 7,967 (26) 8,289 (25) 8,550 (24) 8,292 (23)
2 8,139 (27) 9,786 (30) 11,295 (32) 12,167 (34)
3 8,139 (27) 8,173 (25) 7,368 (21) 6,255 (17)
4 7,967 (26) 9,912 (30) 13,170 (38) 16,360 (45)
≥5 1 21,625 (71) 21,922 (67) 23,030 (66) 24,380 (68)
2 21,669 (71) 20,453 (62) 21,822 (62) 24,132 (67)
3 21,541 (70) 19,308 (59) 17,873 (51) 16,500 (46)
4 21,743 (71) 23,131 (70) 28,186 (81) 36,224 (101)
Females
<1 1 8,131 (26) 12,083 (36) 17,530 (49) 23,720 (65)
2 7,727 (24) 8,868 (26) 10,158 (29) 10,769 (29)
3 8,343 (26) 11,103 (33) 14,573 (41) 17,973 (49)
4 7,541 (24) 9,706 (29) 12,353 (35) 14,402 (39)
1–5 1 7,074 (22) 11,621 (35) 18,075 (51) 26,387 (72)
2 7,178 (23) 8,587 (26) 9,625 (27) 10,230 (28)
3 7,178 (23) 10,957 (33) 14,127 (40) 17,399 (48)
4 7,074 (22) 9,233 (27) 12,592 (35) 15,991 (44)
≥5 1 10,444 (33) 16,774 (50) 28,002 (79) 45,274 (124)
2 10,339 (33) 13,064 (39) 15,609 (44) 17,775 (49)
3 10,338 (33) 14,495 (43) 20,179 (57) 26,743 (73)
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Table 6.20. Rate of change of prevalence of lung, bronchus and trachea cancer in the 
UK, 2010–2040, by time since diagnosis, sex and projection scenario. Average annual 
percentage change in number of survivors (proportion of the population).
Period
Years since
 diagnosis Scenario 2010–2020 2020–2030 2030–2040
Males
<1 1 0.4 (-0.3) 0.0 (-0.6) -0.7 (-1.0)
2 2.0 (1.3) 1.7 (1.1) 0.8 (0.5)
3 -0.5 (-1.2) -0.8 (-1.4) -1.5 (-1.8)
4 3.0 (2.2) 2.6 (2.0) 1.6 (1.3)
1–5 1 0.4 (-0.3) 0.3 (-0.3) -0.3 (-0.6)
2 1.9 (1.1) 1.4 (0.8) 0.7 (0.5)
3 0.0 (-0.7) -1.0 (-1.6) -1.6 (-1.9)
4 2.2 (1.5) 2.9 (2.3) 2.2 (1.9)
≥5 1 0.1 (-0.6) 0.5 (-0.1) 0.6 (0.3)
2 -0.6 (-1.3) 0.6 (0.0) 1.0 (0.7)
3 -1.1 (-1.8) -0.8 (-1.4) -0.8 (-1.1)
4 0.6 (-0.1) 2.0 (1.4) 2.5 (2.2)
Females
<1 1 4.0 (3.4) 3.8 (3.2) 3.1 (2.8)
2 1.4 (0.8) 1.4 (0.8) 0.6 (0.3)
3 2.9 (2.3) 2.8 (2.2) 2.1 (1.8)
4 2.6 (1.9) 2.4 (1.9) 1.5 (1.3)
1–5 1 5.1 (4.4) 4.5 (3.9) 3.9 (3.6)
2 1.8 (1.2) 1.1 (0.6) 0.6 (0.3)
3 4.3 (3.7) 2.6 (2.0) 2.1 (1.8)
4 2.7 (2.1) 3.2 (2.6) 2.4 (2.1)
≥5 1 4.9 (4.2) 5.3 (4.7) 4.9 (4.6)
2 2.4 (1.7) 1.8 (1.2) 1.3 (1.0)
3 3.4 (2.8) 3.4 (2.8) 2.9 (2.6)








Chapter 6. Projections of cancer prevalence to 2040
171
Table 6.21. Prevalence of prostate cancer in the UK, 2010–2040, by time since 




diagnosis Scenario 2010 2020 2030 2040
<1 1 33,373 (109) 41,680 (127) 50,228 (144) 54,925 (153)
2 33,377 (109) 40,597 (123) 47,810 (137) 51,455 (143)
3
4
1–5 1 106,161 (347) 133,296 (405) 169,580 (485) 197,181 (548)
2 107,436 (351) 126,851 (385) 148,294 (424) 161,248 (448)
3
4
≥5 1 115,898 (379) 241,128 (733) 399,736 (1,143) 578,427 (1,606)
2 115,226 (376) 213,187 (648) 281,179 (804) 325,865 (905)
3
4
*Scenarios 3 and 4 are omitted for prostate cancer due to being the same as scenarios 2 and 1, respectively;
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Table 6.22. Rate of change of prevalence of prostate cancer in the UK, 2010–2040, by 
time since diagnosis and projection scenario*. Average annual percentage change in 
number of survivors (proportion of the population).
Period
Years since
diagnosis Scenario 2010–2020 2020–2030 2030–2040
<1 1 2.2 (1.5) 1.9 (1.3) 0.9 (0.6)
2 2.0 (1.2) 1.6 (1.0) 0.7 (0.4)
3
4
1–5 1 2.3 (1.6) 2.4 (1.8) 1.5 (1.2)
2 1.7 (0.9) 1.6 (1.0) 0.8 (0.5)
3
4
≥5 1 7.6 (6.8) 5.2 (4.5) 3.8 (3.5)
2 6.3 (5.6) 2.8 (2.2) 1.5 (1.2)
3
4
*Scenarios 3 and 4 are omitted for prostate cancer due to being the same as scenarios 2 and 1, respectively;
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Table 6.23. Prevalence of female breast cancer in the UK, 2010–2040, by time since 




diagnosis Scenario 2010 2020 2030 2040
<1 1 45,892 (145) 60,881 (181) 80,136 (225) 101,636 (278)
2 42,874 (136) 47,386 (141) 52,293 (147) 54,907 (150)
3 45,898 (145) 60,118 (179) 78,195 (220) 98,190 (268)
4 42,869 (136) 47,999 (143) 53,607 (151) 56,842 (155)
1–5 1 143,834 (455) 201,689 (600) 271,911 (764) 354,410 (968)
2 144,222 (456) 160,835 (478) 174,831 (491) 184,322 (504)
3 144,222 (456) 195,669 (582) 252,011 (708) 314,908 (860)
4 143,834 (455) 165,720 (493) 188,652 (530) 207,460 (567)
≥5 1 380,157 (1,203) 577,889 (1,719) 860,271 (2,417) 1,226,691 (3,352)
2 378,553 (1,197) 519,067 (1,544) 622,843 (1,750) 676,903 (1,850)
3 378,609 (1,198) 543,105 (1,616) 734,682 (2,064) 932,550 (2,548)
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Table 6.24. Rate of change of prevalence of female breast cancer in the UK, 2010–
2040, by time since diagnosis and projection scenario. Average annual percentage 
change in number of survivors (proportion of the population).
Period
Years since
diagnosis Scenario 2010–2020 2020–2030 2030–2040
<1 1 2.9 (2.2) 2.8 (2.2) 2.4 (2.1)
2 1.0 (0.4) 1.0 (0.4) 0.5 (0.2)
3 2.7 (2.1) 2.7 (2.1) 2.3 (2.0)
4 1.1 (0.5) 1.1 (0.5) 0.6 (0.3)
1–5 1 3.4 (2.8) 3.0 (2.4) 2.7 (2.4)
2 1.1 (0.5) 0.8 (0.3) 0.5 (0.3)
3 3.1 (2.5) 2.6 (2.0) 2.3 (2.0)
4 1.4 (0.8) 1.3 (0.7) 1.0 (0.7)
≥5 1 4.3 (3.6) 4.1 (3.5) 3.6 (3.3)
2 3.2 (2.6) 1.8 (1.3) 0.8 (0.6)
3 3.7 (3.0) 3.1 (2.5) 2.4 (2.1)
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Table 6.25. Prevalence of all other malignant neoplasms (excluding non-melanoma 
skin cancer) in the UK, 2010–2040, by time since diagnosis, sex and projection scenario.
Number of survivors (proportion of the population per 100,000).
Year
Years since
diagnosis Scenario 2010 2020 2030 2040
Males
<1 1 49,273 (161) 65,614 (199) 85,185 (244) 103,028 (286)
2 49,295 (161) 58,004 (176) 66,612 (190) 71,266 (198)
3 50,982 (167) 63,234 (192) 76,660 (219) 87,449 (243)
4 47,664 (156) 60,185 (183) 73,985 (211) 83,822 (233)
1–5 1 110,838 (362) 148,274 (451) 196,500 (562) 246,453 (684)
2 111,215 (363) 132,805 (404) 148,969 (426) 159,545 (443)
3 111,215 (363) 142,058 (432) 167,922 (480) 189,618 (527)
4 110,838 (362) 138,390 (421) 173,615 (496) 205,983 (572)
≥5 1 268,569 (877) 364,921 (1,109) 480,256 (1,373) 616,916 (1,713)
2 268,250 (876) 354,774 (1,078) 422,068 (1,207) 465,921 (1,294)
3 268,361 (877) 360,189 (1,095) 441,537 (1,262) 506,179 (1,406)
4 268,463 (877) 359,174 (1,091) 456,562 (1,305) 560,654 (1,557)
Females
<1 1 46,388 (147) 58,420 (174) 73,429 (206) 87,675 (240)
2 47,656 (151) 53,540 (159) 59,827 (168) 63,312 (173)
3 48,208 (152) 57,278 (170) 67,792 (190) 76,584 (209)
4 45,884 (145) 54,657 (163) 64,869 (182) 72,474 (198)
1–5 1 118,127 (374) 146,461 (436) 187,401 (526) 230,531 (630)
2 118,750 (376) 136,611 (406) 149,903 (421) 157,964 (432)
3 118,750 (376) 144,544 (430) 167,658 (471) 187,036 (511)
4 118,127 (374) 138,499 (412) 167,551 (471) 194,459 (531)
≥5 1 352,222 (1,114) 467,189 (1,390) 605,441 (1,701) 773,354 (2,113)
2 351,369 (1,111) 453,463 (1,349) 536,094 (1,506) 592,334 (1,619)
3 351,402 (1,112) 459,223 (1,366) 562,114 (1,579) 649,844 (1,776)
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Table 6.26. Rate of change of prevalence of all other malignant neoplasms (excluding 
non-melanoma skin cancer) in the UK, 2010–2040, by time since diagnosis, sex and 
projection scenario. Average annual percentage change in number of survivors 
(proportion of the population).
Period
Years since
 diagnosis Scenario 2010–2020 2020–2030 2030–2040
Males
<1 1 2.9 (2.2) 2.6 (2.0) 1.9 (1.6)
2 1.6 (0.9) 1.4 (0.8) 0.7 (0.4)
3 2.2 (1.4) 1.9 (1.3) 1.3 (1.0)
4 2.4 (1.6) 2.1 (1.5) 1.3 (1.0)
1–5 1 3.0 (2.2) 2.9 (2.2) 2.3 (2.0)
2 1.8 (1.1) 1.2 (0.5) 0.7 (0.4)
3 2.5 (1.7) 1.7 (1.1) 1.2 (0.9)
4 2.2 (1.5) 2.3 (1.7) 1.7 (1.4)
≥5 1 3.1 (2.4) 2.8 (2.2) 2.5 (2.2)
2 2.8 (2.1) 1.8 (1.1) 1.0 (0.7)
3 3.0 (2.2) 2.1 (1.4) 1.4 (1.1)
4 3.0 (2.2) 2.4 (1.8) 2.1 (1.8)
Females
<1 1 2.3 (1.7) 2.3 (1.7) 1.8 (1.5)
2 1.2 (0.6) 1.1 (0.5) 0.6 (0.3)
3 1.7 (1.1) 1.7 (1.1) 1.2 (0.9)
4 1.8 (1.1) 1.7 (1.1) 1.1 (0.8)
1–5 1 2.2 (1.5) 2.5 (1.9) 2.1 (1.8)
2 1.4 (0.8) 0.9 (0.4) 0.5 (0.2)
3 2.0 (1.4) 1.5 (0.9) 1.1 (0.8)
4 1.6 (1.0) 1.9 (1.3) 1.5 (1.2)
≥5 1 2.9 (2.2) 2.6 (2.0) 2.5 (2.2)
2 2.6 (2.0) 1.7 (1.1) 1.0 (0.7)
3 2.7 (2.1) 2.0 (1.5) 1.5 (1.2)
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Table 6.27. Prevalence of all malignant neoplasms (excluding non-melanoma skin 
cancer) in the UK, 2010–2040, by time since diagnosis, sex and projection scenario. 
Number of survivors (proportion of the population per 100,000).
Year
Years since
diagnosis Scenario 2010 2020 2030 2040
Males
<1 1 108,669 (355) 140,013 (425) 175,851 (503) 204,564 (568)
2 108,823 (356) 130,255 (396) 151,821 (434) 163,001 (453)
3 110,708 (362) 134,705 (409) 160,395 (459) 178,404 (495)
4 106,806 (349) 135,348 (411) 166,434 (476) 186,888 (519)
1–5 1 265,462 (867) 348,606 (1,059) 457,299 (1,307) 559,094 (1,553)
2 267,385 (874) 319,480 (971) 366,796 (1,049) 396,318 (1,101)
3 267,385 (874) 330,802 (1,005) 390,821 (1,117) 435,901 (1,211)
4 265,462 (867) 336,062 (1,021) 427,489 (1,222) 504,936 (1,402)
≥5 1 475,884 (1,555) 734,474 (2,232) 1,063,509 (3,040) 1,452,083 (4,033)
2 474,481 (1,550) 683,720 (2,078) 842,281 (2,408) 948,100 (2,633)
3 474,469 (1,550) 689,403 (2,095) 865,804 (2,475) 999,208 (2,775)
4 475,890 (1,555) 728,074 (2,213) 1,033,859 (2,955) 1,378,033 (3,827)
Females
<1 1 113,046 (358) 146,910 (437) 190,331 (535) 235,178 (643)
2 111,006 (351) 124,417 (370) 139,227 (391) 147,215 (402)
3 114,983 (364) 143,049 (426) 177,654 (499) 211,608 (578)
4 109,142 (345) 127,942 (381) 149,856 (421) 165,003 (451)
1–5 1 301,647 (954) 400,598 (1,192) 530,221 (1,490) 675,479 (1,846)
2 302,951 (958) 344,329 (1,024) 378,407 (1,063) 400,321 (1,094)
3 302,951 (958) 388,906 (1,157) 477,736 (1,342) 567,737 (1,551)
4 301,647 (954) 354,721 (1,055) 421,427 (1,184) 480,623 (1,313)
≥5 1 814,015 (2,575) 1,157,097 (3,442) 1,621,355 (4,555) 2,213,978 (6,050)
2 810,943 (2,565) 1,074,272 (3,196) 1,280,923 (3,599) 1,406,761 (3,844)
3 811,027 (2,565) 1,104,538 (3,286) 1,421,722 (3,994) 1,727,684 (4,721)
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Table 6.28. Rate of change of prevalence of all malignant neoplasms (excluding non-
melanoma skin cancer) in the UK, 2010–2040, by time since diagnosis, sex and 
projection scenario. Average annual percentage change in number of survivors 
(proportion of the population).
Period
Years since
 diagnosis Scenario 2010–2020 2020–2030 2030–2040
Males
<1 1 2.6 (1.8) 2.3 (1.7) 1.5 (1.2)
2 1.8 (1.1) 1.5 (0.9) 0.7 (0.4)
3 2.0 (1.2) 1.8 (1.1) 1.1 (0.8)
4 2.4 (1.7) 2.1 (1.5) 1.2 (0.9)
1–5 1 2.8 (2.0) 2.8 (2.1) 2.0 (1.7)
2 1.8 (1.1) 1.4 (0.8) 0.8 (0.5)
3 2.2 (1.4) 1.7 (1.1) 1.1 (0.8)
4 2.4 (1.6) 2.4 (1.8) 1.7 (1.4)
≥5 1 4.4 (3.7) 3.8 (3.1) 3.2 (2.9)
2 3.7 (3.0) 2.1 (1.5) 1.2 (0.9)
3 3.8 (3.1) 2.3 (1.7) 1.4 (1.2)
4 4.3 (3.6) 3.6 (2.9) 2.9 (2.6)
Females
<1 1 2.7 (2.0) 2.6 (2.0) 2.1 (1.9)
2 1.1 (0.5) 1.1 (0.6) 0.6 (0.3)
3 2.2 (1.6) 2.2 (1.6) 1.8 (1.5)
4 1.6 (1.0) 1.6 (1.0) 1.0 (0.7)
1–5 1 2.9 (2.2) 2.8 (2.3) 2.5 (2.2)
2 1.3 (0.7) 0.9 (0.4) 0.6 (0.3)
3 2.5 (1.9) 2.1 (1.5) 1.7 (1.5)
4 1.6 (1.0) 1.7 (1.2) 1.3 (1.0)
≥5 1 3.6 (2.9) 3.4 (2.8) 3.2 (2.9)
2 2.9 (2.2) 1.8 (1.2) 0.9 (0.7)
3 3.1 (2.5) 2.6 (2.0) 2.0 (1.7)
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6.5 Discussion
The results presented in this chapter provide a detailed set of projections of cancer 
prevalence in the UK for the next three decades, up to 2040. Four of the major cancer 
types in the UK – prostate, female breast, colorectal and lung – were considered 
separately, and a final category for all other cancers (excluding non-melanoma skin 
cancer) allowed estimates of prevalence to be produced for all malignant neoplasms 
combined. Prevalence counts and proportions (the number of survivors per 100,000 
population) were calculated according to three attained age groups (0–44, 45–64 and 
≥65 years) and three time since diagnosis bands (<1, 1–5 and ≥5 years), as well as by 
sex and cancer type.
These projections covered a 31 year period from 2009 to 2040 and, given the inherent 
uncertainty involved in such long-term forecasting, four diﬀerent scenarios of future 
cancer incidence rates, cancer survival and population demographics – the three factors
which directly influence cancer prevalence – were considered separately (Table 6.1). 
These scenarios allowed the eﬀects on cancer prevalence of projected cancer incidence 
rates and survival to be examined separately to that of projected changes in population
demographics.
In section 6.4, the results for scenario 1 were given special consideration. This was the 
scenario under which empirical trends in cancer incidence rates and survival were 
extrapolated, without attenuation, from 2009 up to 2040. (Prostate cancer incidence 
rates were kept static, since the extrapolation results were considered to be extremely 
unrealistic in this instance.) Projections of cancer prevalence under this scenario 
provided estimates based on the simplistic, and in places optimistic, assumption that 
existing trends in cancer incidence rates and survival will continue unabated for the 
next 30 years, and this should be kept in mind when considering the results. 
Nonetheless, this scenario is the most empirically motivated of those presented, and 
could therefore be considered to be the most likely.
Of course, it is impossible to anticipate precisely the future events and interventions 
that may eﬀect changes in cancer prevalence – e.g. new screening programmes, public 
awareness campaigns or cancer treatments. If the prevalence estimates are viewed 
together with the results of the incidence and mortality regression models of section 
5.5, then a greater understanding of the factors that influenced the scenario 1 
projections can be gained. These diﬀer for each cancer type, sex and age group, and so 
in certain instances alternative scenarios to projection scenario 1 may be considered 
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more likely based on other intelligence. For example, Mistry et al. (2011) estimated the 
separate eﬀects on prostate cancer incidence of a) the introduction of the PSA test, and
b) the underlying trend. They were then able to project prostate cancer incidence based
on the explicit assumption that PSA testing levels would remain at current levels whilst
the underlying trend would continue. A similar approach was used by these authors to 
project female breast cancer incidence taking into account the eﬀect of breast cancer 
screening.
In the UK, cancer incidence rates are generally increasing. Of the cancers studied here, 
it was only male lung cancer incidence rates that exhibited a decreasing trend in the 
period 1974–2008 (Chapter 5: Figure 5.10). Cancer survival is also generally increasing, 
as can be seen from the decreasing mortality probabilities for survivors displayed in 
Chapter 5 (Figures 5.11 and 5.12). The reasons for these observed trends vary 
according to the cancer type in question. For example, recorded prostate cancer 
incidence rates have increased rapidly since the introduction of the PSA test as a 
screening tool and, since many cancers are now being diagnosed earlier, recorded 
survival has also increased (Cancer Research UK, 2010; Evans and Møller, 2003); 
recorded female breast cancer incidence rates have increased due to greater public 
awareness of the early symptoms and the introduction of a national screening 
programme in England (NHS Cancer Screening Programmes, 2011); and male lung 
cancer incidence rates have declined due, mainly, to a reduction in the prevalence of 
smoking among men in England since the 1970s (Davy, 2006). General increases in 
cancer survival have been brought about by advances in cancer treatment as well as a 
greater focus on earlier diagnosis. Each of these factors – increasing cancer incidence 
rates and increasing cancer survival – acts to increase cancer prevalence, since the 
former means that more cancers are being diagnosed and the latter that people are 
living longer with cancer. 
Furthermore, the population of the UK is growing in size and also ageing (Oﬃce for 
National Statistics, 2011c). Combined, these demographic changes lead to increasing 
cancer prevalence since there are more people to be diagnosed with cancer and a 
greater proportion of these are in the older age groups for which cancer incidence rates 
are highest.
So trends in each of the three epidemiological factors that directly control cancer 
prevalence – incidence rates, survival and population demographics – are, in general in 
the UK, acting to increase it. For this reason, projection scenario 1 resulted in the 
highest estimates of cancer prevalence for almost all cancer types, sexes and age groups.
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The main exception to this was male lung cancer, incidence rates of which have been 
decreasing in recent years. By considering the other three scenarios, the extents to 
which changes in cancer incidence rates, survival or population demographics are likely 
to aﬀect cancer prevalence, if existing trends continue, can be quantified separately.
For example, consider the average annual percentage change in prevalence of all 
malignant neoplasms combined – Table 6.16. For females in all age groups combined, 
projection scenarios 3 (dynamic incidence rates and static survival) and 4 (static 
incidence rates and dynamic survival) resulted in almost identical rates of increase in 
the number of cancer survivors: 2.9% for scenario 3 and 2.8% for scenario 4 in the 
2010s, 2.4% for both scenarios in the 2020s and 1.9% for both scenarios in the 2030s. 
This implies that, overall, the projected increase in female cancer prevalence due to 
increasing incidence rates is roughly the same as that due to increasing survival. By 
considering the projections of cancer prevalence under scenario 2 it can be seen that, 
even if incidence rates and survival were to remain constant from 2009 onwards, the 
number of survivors would still increase by between 0.8% and 2.3% per year. This is 
partly due to the increasing and ageing population. However, the prevalence proportions
in each age group will also increase under scenario 2, implying that static incidence 
rates and survival by themselves would act to increase cancer prevalence. This 
illustrates that it is not necessary for incidence and survival to be increasing for cancer 
prevalence to be increasing – for example, if incidence and survival are both static in 
the future, but are at such levels that the inflow to the prevalent population is greater 
than the outflow, then cancer prevalence will increase; historical changes in incidence 
and survival would take many years to wash through before cancer prevalence could 
ever reach a steady state.
Whilst for all female cancers combined the eﬀects on cancer prevalence of increasing 
incidence rates and survival are roughly of the same magnitude, this is not the case for 
every type of cancer. For example, the diﬀerence between the rate of change of male 
colorectal cancer prevalence under scenarios 2 (static incidence rates and survival) and 
4 (static incidence rates and dynamic survival) is roughly twice that between scenarios 
2 and 3 (dynamic incidence rates and static survival) (Table 6.6), with the number of 
survivors projected to increase to 221,000 in 2040 under scenario 2, 262,000 under 
scenario 3 and 317,000 under scenario 4 (Table 6.5). This implies that, if existing trends
in cancer incidence and survival are to persist, then it will be higher cancer survival 
that is responsible for the largest proportion of the projected increases in male 
colorectal cancer prevalence. Similarly, prevalence of female colorectal cancer is 
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projected to be roughly the same under scenarios 2 and 3 since incidence rates are 
projected to be quite stable; it is therefore the increases in cancer survival which are 
responsible for the majority of the increases in female colorectal cancer prevalence as 
projected under scenario 1.
The age structure of the population of cancer survivors will, under projection scenario 
1, become increasingly dominated by the oldest age groups: in 2040, 77% of all cancer 
survivors will be aged at least 65 years under this scenario. Perhaps even more notably, 
it is projected that in 2040 almost one quarter of all people in the UK aged at least 65 
years will be cancer survivors – the equivalent figure for 2008 was one eighth (see 
Chapter 2). This result, in particular, highlights the potential for significant increases in
the burden of cancer on health service and community care resources if current trends 
in cancer incidence and survival continue. It is vitally important, therefore, that careful
plans are laid so that resources exist to meet the needs of cancer survivors in the 
future, particularly given the likely large increases in the number of survivors over (the 
current) retirement age and the impact of cancer on a person’s fitness to work.
The precise needs of cancer survivors in the UK, and how best to meet them, is the 
subject of ongoing research (Richards et al., 2011) but still more needs to be done. The 
results presented in this chapter, and earlier in this thesis, provide some further insight.
Time since diagnosis was shown to be a key indicator of the quantity of cancer related 
acute health care utilised by the population of cancer survivors in the UK (Chapter 3). 
The first year following diagnosis and the last year of life contained the highest levels of
acute cancer related health service utilisation, but there was also a significant amount 
of usage in the period 1–5 years after diagnosis. Under projection scenario 1, the 
number of survivors in each of the time since diagnosis bands <1, 1–5 and 5 years will
increase, but the number who are long-term survivors will increase at the fastest rate – 
by 2040, 69% of all survivors will be at least five years beyond diagnosis under this 
scenario, compared with 62% in 2009. This will have an impact on the types of health 
care required by cancer survivors, with a greater focus on rehabilitation and the long-
term, post-treatment eﬀects of cancer.
It is hoped that these projections will be of use to health service commissioners and 
resource planners but, as with any long-term epidemiological projections, there are 
limitations to this work. Assumptions regarding the likely future trends in cancer 
incidence rates and survival must be made before any projections of cancer prevalence 
are possible. The approach used in this work was to provide a range of estimates based 
on two diﬀerent assumptions: a) that existing trends will persist in the future without 
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attenuation; and b) that existing trends will be arrested with incidence rates and 
survival remaining constant throughout the projected period. Scenario 1, based on the 
assumption that existing trends will persist, can be considered the ‘most likely’ of those
presented, but at the same time, by considering the results for scenarios 2–4, the 
influences of projected incidence rates and survival can be examined independently. The
most likely scenario may indeed change depending on the type of cancer, sex or age 
groups under consideration, or based on other intelligence. However, for much of this 
chapter the focus has remained on scenario 1. 
There is an inconsistency in the definition of scenario 1 which assumed static incidence 
rates for prostate cancer at the same time as allowing survival to be dynamic, since 
trends in each are inter-linked. Recorded incidence rates of prostate cancer have been 
increasing in the UK, as has survival, but both of these trends are, to a large extent, a 
consequence of the introduction of the PSA test. This test has resulted in more cancers 
being diagnosed (leading to higher recorded incidence rates) but also in generally earlier
diagnosis (leading to higher recorded survival due to a combination of earlier stage at 
diagnosis and lead time bias). Indeed, many cancers diagnosed following a PSA test 
may never have become otherwise symptomatic in the natural life of the patient (Barry,
2009; van Leeuwen et al., 2010). However, in order to provide plausible estimates of 
future prostate cancer prevalence, and by extension prevalence of all male cancers 
combined, it was necessary to exclude the projected prostate cancer incidence rates 
from scenario 1.
6.6 Summary
In this chapter, estimates of future cancer prevalence in the UK were presented in 
detail and discussed. A range of estimates were provided based on various diﬀerent 
scenarios of future cancer incidence rates, survival and population demographics, and 
some consideration was given to defining the most likely of these scenarios. The extent 
to which each of the input quantities (future incidence rates, survival and population 
demographics) was responsible for the projected trends in cancer prevalence was also 
examined. These results highlighted the potential for substantial future increases in the 
prevalence of cancer in the UK and the increased burden this would bring to the health
service.
This draws to a close the work on projections of cancer prevalence which spans 
Chapters 4–6, and also marks the end of the analysis section of this thesis. What 
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follows is the final chapter, in which the work as a whole is recapped and the main 
themes arising from it are highlighted.
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Chapter 7. General discussion
In this final chapter, a brief recap of the main results is given together with a short 
discussion of their significance and the themes arising. The main strengths and 
limitations of the work are also highlighted.
7.1 Key findings
It was estimated that, at the end of 2008, there were approximately two million cancer 
survivors in the UK. Of these, around 800,000 were male and 1.2 million were female. 
Prostate and female breast cancers were the most prevalent types, accounting for 31% 
and 46% of male and female cancer survivors, respectively. Lung cancer was, with just 
64,000 survivors, the least prevalent of the cancer types studied. Cancer prevalence 
varied greatly with attained age; less than 0.5% of people aged under 45 years were 
cancer survivors, but around 13% of those aged at least 65 were. The distribution of 
cancer survivors between time since diagnosis bands varied between cancer types and 
was largely a consequence of the survival characteristics particular to each.
To describe the population of cancer survivors in more detail, temporal phases of 
survivorship were defined based on time since diagnosis and time until death. It was 
shown that a large majority of cancer survivors (1.7 million of the 2.0 million in the 
UK) were, at the end of 2008, more than one year beyond diagnosis and more than one 
year from death. This phase of survivorship was characterised by little acute health 
service utilisation, the vast majority of which related to the first year after diagnosis or 
the last year before death. Survivors of cancer types with poorer prognoses experienced 
higher levels of acute health service utilisation soon after diagnosis but, after five years’
survival, there was little diﬀerence in the proportion of time spent admitted to hospital 
for cancer related episodes of care, regardless of the type of cancer.
A model for projecting cancer prevalence was derived and applied using cancer registry 
data to project cancer prevalence in the UK up to the year 2040. Under the assumption
that existing trends in cancer incidence rates and survival will continue, the number of 
cancer survivors was projected to increase by approximately one million per decade. By
2040, cancer prevalence was projected to be 5.3 million (6.2% of the male population 
and 8.5% of the female population). In addition to growing significantly in size, the 
population of cancer survivors was also projected to become older and, on average, 
further beyond diagnosis: 77% of cancer survivors will be at least 65 years old in 2040 
under the assumption of continuing current trends in incidence and survival, compared 
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with 63% in 2009, and 69% will be at least five years beyond diagnosis, compared with 
62% in 2009. Despite this, the number of cancer survivors less than five years beyond 
diagnosis was projected to more than double from almost 800,000 in 2009 to almost 1.7
million in 2040. Furthermore, under the same assumption, it was projected that in 2040
almost one quarter of all those aged over 65 years will be cancer survivors. Other 
results were also provided based on diﬀerent assumptions regarding future trends in 
cancer incidence and survival. It was shown that, for females, the projected increases in
cancer prevalence (all malignant neoplasms and all ages combined) were due equally to 
projected increases in incidence rates and projected increases in survival. In contrast, 
for males, projected increases in survival had a larger influence on projected prevalence 
than projected incidence rates. However, a variety of patterns was observed for diﬀerent
combinations of age group, sex and cancer type.
7.2 Strengths and limitations
The estimates of cancer prevalence presented in Chapter 2 are the most up-to-date for 
the UK and, notably, were produced from an analysis of a long time series of cancer 
registry data from all four constituent countries of the UK. The person-time analysis of 
linked cancer registry and hospital activity data from HES is, as far as the author is 
aware, the first of its type using this dataset and greatly enriched the basic prevalence 
estimates. Projections of cancer prevalence were produced in a flexible way, such that 
the eﬀects of changing incidence rates, survival and population demographics could be 
assessed independently.
A limitation of this work is that the available hospital activity data only contained 
details of in-patient and day case episodes of care and no data were available for health 
service utilisation not involving a visit to hospital. A full description of cancer 
survivorship must consider other types of health and social care, as well as that 
received in hospital. The work in Chapter 3 should therefore be considered in 
conjunction with other recently published research, for example that concerning cancer 
survivors and primary health care (Khan et al., 2008, 2010, 2011a, b).
The projections of cancer prevalence in Chapter 6 were based on the projections of 
cancer incidence and mortality contained in Chapter 5. More complex modelling of each
individual type of cancer could improve the projections of cancer prevalence by, for 
example, building in explicit assumptions regarding the impact of historical or likely 
future cancer screening programmes. However, there is a level of uncertainty in such 
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long-term projections that cannot be avoided entirely and, in this thesis, projections 
were produced for a variety of possible future scenarios.
7.3 Interpretation
Cancer survivorship is currently high on the public health agenda, and the need for a 
greater focus on the needs of cancer survivors has been championed by both statutory 
and voluntary organisations in the UK. Primary prevention of cancer remains an 
ultimate goal for society, but it is clear that many public health initiatives and 
advances in cancer treatments have resulted in higher cancer prevalence due to 
increased recorded incidence rates and survival. Accordingly, the characteristics of the 
population of cancer survivors have also changed. Many more people can expect to live 
further beyond their cancer diagnosis, and it is no longer the death sentence it was once
perceived to be.
Despite this, there has been little systematic study of cancer prevalence in the UK. 
This thesis, by describing cancer prevalence in terms of demographics, temporal 
features and acute health service utilisation, adds much to the understanding of the 
cancer survivor population and survivorship in the UK today. It has answered partly or
wholly some of the research questions (as set out by the NCSI) which have been 
identified as key to ensuring that those living with cancer in the UK experience the 
best possible health outcomes now and in the future.
Despite being a large population, the majority of cancer survivors are neither recently 
diagnosed nor in the final year of their life and experience very little cancer related 
acute health service care. Most of the cancer burden to the acute health service comes 
from initial treatment and end of life care, and as general life expectancy increases and 
prognoses for many cancer types improve, the proportion of cancer survivors who are in
the last year of their life decreases. However, the extent to which cancer survivors may 
require, or are receiving, other forms of care was not considered in this work. In the 
medium and long term, cancer survivors face day-to-day struggles – such as relationship
and financial diﬃculties, or problems returning to work – and addressing these falls to 
community and social care services.
Increasing cancer prevalence, and the changing characteristics of cancer survivorship, 
present challenges to health service providers and society in general. Despite evidence 
that only a small proportion of cancer survivors have high levels of acute health service 
utilisation, the projections of cancer prevalence contained in this thesis highlight the 
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potential for significantly elevated demands on health service resources in the future. 
The number of cancer survivors requiring initial and ongoing treatment during the first 
five years after diagnosis will increase substantially as the population of the UK grows 
and ages, and as cancer incidence rates and survival continue to increase in general. It 
is clear, therefore, that adequate planning to ensure that the best possible use is made 
of available health service resources for cancer survivors is essential. Furthermore, as 
the population of cancer survivors becomes older, cancer will increasingly need to be 
considered as one of multiple co-morbidities, and eﬃcient integration of diﬀerent clinical
specialities will be vital.
7.4 Summary
This thesis contains a detailed description of cancer prevalence and selected aspects of 
cancer survivorship in the UK. Various methods, concepts and models were developed 
and could form the basis of future research. The results presented here not only provide
valuable insights into the characteristics of the current population of cancer survivors, 
but also describe some of the most important factors that will influence future changes 
in these characteristics. Society faces many challenges related to the growing and ageing
general population of the UK – a large growth in the number of cancer survivors is not 
least among them. The coming decades are likely to bring diﬃcult financial 
circumstances which will, therefore, test the ability of statutory and voluntary 
organisations to meet the diverse needs of those diagnosed with cancer. The work 
contained in this thesis, however, provides valuable intelligence that will help society 
meet these challenges.
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BACKGROUND: Identifying and addressing the requirements of cancer survivors is currently a high priority for the NHS, yet little is
known about the population of cancer survivors in the United Kingdom.
METHODS: Data from cancer registries in England, Northern Ireland, Scotland and Wales were analysed to provide limited-duration
prevalence estimates for 2004. Log-linear regression models were used to extend these to complete prevalence estimates. Trends in
prevalence from 2000 to 2004 were used to project complete prevalence estimates forward from 2004 to 2008.
RESULTS: We estimated that in total, there were 2 million cancer survivors in the United Kingdom at the end of 2008, B3% of
the population overall and 1 in 8 of those aged 65 years and more. Prostate and female breast cancers were the most prevalent.
The number of cancer survivors is increasing by B3% each year. Estimates are also provided by time since diagnosis.
CONCLUSION: These estimates are the most up-to-date available, and as such will be useful for statutory and voluntary sector
organisations that are responsible for planning and providing treatment and support to cancer survivors in the United Kingdom.
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Cancer survivors are defined as those people living with a
diagnosis of cancer from some point in their past. Cancer
prevalence is expressed as the number or proportion of cancer
survivors in a population at a given point in time. Identifying and
addressing the requirements of cancer survivors in England is a
high priority in the Cancer Reform Strategy (Department of
Health, 2007) and, as a result, the National Cancer Survivorship
Initiative was set up in 2008. Similar initiatives are being
established in Northern Ireland, Scotland and Wales. However,
little is known about the size and demography of the population of
cancer survivors in the United Kingdom; the most recent estimate,
provided by the EUROPREVAL project (Forman et al, 2003), was
for 1992.
In this paper, we provide up-to-date estimates of cancer
prevalence in the United Kingdom at the end of 2008 using cancer
registry data. Cancer survivors may have been recently diagnosed
and in active treatment, or they may have survived long enough to
be considered cured. However, in our analysis, we do not make
such distinctions; once an individual is diagnosed with cancer, he
(or she) is considered a survivor until death. We adopt this
approach because, first, a diagnosis of cancer may affect a person’s
life in different ways (mental health, fear of recurrence, financial
hardship, relationship issues, etc.), and its effects may be felt for
many years after diagnosis. Second, this approach is practical as
the currently available cancer registration data do not readily allow
survivors to be classified as having active disease, in remission or
cured of their cancer.
MATERIALS AND METHODS
The eight cancer registries in England, together with the national
registries in Scotland, Wales and Northern Ireland, provided
anonymised records of all registered malignant neoplasms (ICD-10
C00-C97) diagnosed in the residents of those countries, excluding
non-melanoma skin cancer (ICD-10 C44) as it is not covered
systematically by all registries. Each record included demographic,
tumour, diagnosis, follow-up and death details. Data were available
for the periods 1971–2004 for England, 1971–2005 for Scotland,
1990–2006 for Wales and 1993–2006 for Northern Ireland.
All tumours apparently diagnosed in patients over the age of
99 years were excluded (B0.04% of the total), leaving 7.7 million
registration records for analysis.
The UK cancer registries receive death notifications from the
Office for National Statistics (ONS) (England and Wales) and the
General Register Offices (Scotland and Northern Ireland), which
are then matched to the cancer registration records, although a
small percentage are never so matched. The patients associated
with these ‘lost-to-follow-up’ registrations are at face value,
effectively immortal, resulting in apparent cancer survivors of
a much higher age than we know to be likely. The proportion
of registrations lost to follow-up in European registries is believed
to be o1% (Capocaccia et al, 1999), but is unknown in the
United Kingdom. Therefore, in computing prevalence, cancer
survivors were censored at the age of 105 years.
Cancer prevalence can be expressed as the number of prevalent
tumours or the number of prevalent patients. As each patient may,
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in their lifetime, be diagnosed with more than one tumour, patient
prevalence will always be lower than tumour prevalence. This
analysis focuses on patient prevalence, and only the first diagnosed
malignant neoplasm (excluding non-melanoma skin cancer) in
each patient was considered.
Although cancer registry data for Scotland, Wales and Northern
Ireland were available for the years 2005 and 2006, for England it
was available only up to 2004 at the time of analysis. For this
reason, we used the most recent index date common to all data,
that is, 31 December 2004. The number of cancer patients alive on
this date was counted and disaggregated by country of residence,
sex, age group on the index date (0–44, 45–64 and 65þ years),
number of years since diagnosis and the following broad groups of
cancer diagnoses:
(1) colon, rectum and anus (ICD-10 C18-C21),
(2) lung, bronchus and trachea (ICD-10 C33-C34),
(3) female breast (ICD-10 C50),
(4) prostate (ICD-10 C61),
(5) all other malignant neoplasms excluding non-melanoma skin
cancer (ICD-10 C00-C97 excluding C44 and (1) to (4)).
Death-Certificate-Only (DCO) registrations are those for which
the only source of patient/tumour information is the death
certificate stating the cause of death. These registrations lack
much information, particularly the actual date of diagnosis. An
unknown proportion of the DCO registrations since the index date
will pertain to patients diagnosed before, and alive on, the index
date. We have not attempted to estimate this proportion, and
therefore they are not included in our prevalence estimates.
Complete prevalence
N-year limited-duration prevalence counts include only those
survivors diagnosed in the last N years before the index date.
Complete prevalence includes all cancer survivors, regardless of
when they were diagnosed. It is not possible to directly count
complete prevalence on the basis of registry data, given that no UK
cancer registry has been collecting data for a sufficiently long
period of time. Instead, we estimated complete prevalence by
extrapolating from limited-duration prevalence.
With an index date of 31 December 2004, the available cancer
registry data provided 34-year prevalence estimates for England
and Scotland, 15-year estimates for Wales and 12-year estimates
for Northern Ireland. To extend these limited-duration estimates
to complete estimates, a negative binomial regression model with a
log-link function was constructed for each type of cancer, sex and
age group (0–44, 45–64, 65þ years). The prevalence count on the
index date was the response variable, and the predictor variables
were country of residence and number of years since diagnosis.
Given that our primary objective was to obtain a reasonable
estimate for the number of people surviving at least 12 years
(Northern Ireland) and 15 years (Wales) beyond diagnosis, data
pertaining to recent diagnoses (years since diagnosisp5) were not
used in the models. Prostate cancer was treated as a special case
and modelled in two stages; first, for years of diagnosis between
1992 and 1999 and second, for all years before 1992. We also
included an offset term in all models, defined as the log of the
number of people in a given country who could contribute to
the prevalence count, taking into account the age group being
considered and the fact that years since diagnosis cannot exceed
age on the index date. The models were run using the PROC
GENMOD procedure in SAS (SAS Institute Inc, Cary, NC, USA).
The validity of the regression models was tested by initially
excluding data for Scotland covering years of diagnosis between
1971 and 1992, and by comparing the modelled estimates with the
actual data for those years. Furthermore, we compared the
published estimated ratios of 15-year prevalence to complete
prevalence (the completeness index) in England and Scotland
(Forman et al, 2003) with those of our own (Table 1).
Trends
Through an analysis of recent trends in observed cancer
prevalence, we projected estimates of complete cancer prevalence
in the United Kingdom from 31 December 2004 forward to 2008.
We used the combined data from England and Scotland covering
diagnoses between 1971 and 2004 to estimate trends in limited-
duration prevalence during the years 2000–2004, for each site and
sex. Log-linear functions, considered appropriate for short-term
projections, were fitted to the trend data and provided estimates of
the annual growth in cancer survivor numbers that we expected
from 2004 to 2008. The following assumptions were made:
(1) the yearly rates of change of cancer prevalence in England and
Scotland combined can be applied to each country in the
United Kingdom;
(2) cancer prevalence in each age group (0–44, 45–64 and 65þ
years) is changing at the same rate as overall prevalence;
(3) complete prevalence is changing at the same rate as 30-year
prevalence.
Estimated prevalence counts were converted to proportions of
the population by using the mid-year ONS population estimates
for 2007; these were the most recently available estimates and
likely to be only slightly lower than the actual population at the
end of 2008 (ONS, 2008a).
RESULTS
Tables 2 and 3 and Figure 2 present complete prevalence – the sum
of observed prevalence from the years of diagnosis that were
available in our data and modelled prevalence from those that were
not. We have indicated by italicised text in Tables 2–4 those
estimates for which more than 20% of the total is derived from
modelling. We estimated that by the end of 2008, there were just
over 2 million cancer survivors in the United Kingdom (59%
women and 41% men), equating toB2.7% of the male and 3.8% of
the female population. Table 2 shows the variation in prevalence
by country and cancer sites. Wales had the most number of cancer
Table 1 Comparison of 15-year completeness indices, by cancer site
and sex
Maddams et ala EUROPREVALb
Males
Colon, rectum and anus 0.81 0.87c
Lung, bronchus and trachea 0.58 0.73d
Prostate 0.95 0.97
All malignant neoplasmse 0.78 0.82
Females
Breast 0.74 0.80
Colon, rectum and anus 0.74 0.80
Lung, bronchus and trachea 0.77 0.79
All malignant neoplasmse 0.70 0.72
ICD¼ International Classification of Diseases. The 15-year completeness index is
defined as 15-year prevalence divided by complete prevalence. a15-year prevalence
divided by estimated complete prevalence in the United Kingdom. Index date: 31
December 2004. bAverage 15-year completeness index for prevalence as estimated
using data from South Thames, West Midlands, Yorkshire and Scotland cancer
registries. Index date: 31 December 1992. Published by Forman et al (2003), Ann
Oncol 14: 648–654. cAverage of indices for cancers of the colon and rectum. dCancer
of the lung only. eExcluding non-melanoma skin cancer (ICD-10 C44).
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survivors per capita (3.1% men and 4.2% women), and Northern
Ireland had the fewest (2.4% men and 3.4% women).
Prostate and female breast cancers were the most prevalent, and
accounted for 31 and 46% of male and female cancer prevalence,
respectively. Of the cancers studied in this paper, lung cancer was
the least prevalent. Figure 1 shows, for each sex, the proportions
of total incident cases, cancer deaths and cancer survivors that
are accounted for by colorectal, lung, prostate and female breast
Table 2 Prevalence of cancer on 31 December 2008 in the United Kingdom, by country of residence
England Scotland Wales Northern Ireland United Kingdom
Males
Colon, rectum and anus 100 608 (401) 11 522 (464) 6921 (476) 3480 (404) 122 531 (410)
Lung, bronchus and trachea 32 034 (128) 3 760 (151) 1889 (130) 1058 (123) 38 741 (130)
Prostate 215 654 (859) 19 163 (771) 13 312 (916) 5307 (616) 253 436 (847)
All other malignant neoplasmsa 334 147 (1330) 36 853 (1483) 22 998 (1582) 10 482 (1216) 404 480 (1352)
All malignant neoplasmsa 682 443 (2717) 71 298 (2868) 45 120 (3103) 20 327 (2358) 819 188 (2738)
Females
Breast 460 041 (1771) 46 211 (1738) 29 838 (1955) 12 908 (1439) 548 998 (1768)
Colon, rectum and anus 92 439 (356) 11 419 (430) 5885 (386) 3542 (395) 113 285 (365)
Lung, bronchus and trachea 19 634 (76) 3215 (121) 1239 (81) 693 (77) 24 781 (80)
All other malignant neoplasmsa 409 284 (1576) 46 607 (1753) 26 683 (1749) 13 690 (1526) 496 264 (1598)
All malignant neoplasmsa 981 398 (3778) 107 452 (4042) 63 645 (4171) 30 833 (3437) 1 183 328 (3810)
ICD¼ International Classification of Diseases. The number of survivors (crude proportion per 100 000) is indicated; the sum of observed prevalence was available from cancer
registry data, whereas modelled prevalence was not. Italicised numbers are those that are based on estimates of prevalence in 2004 that were at least 20% modelled. aExcluding
non-melanoma skin cancer (ICD-10 C44).
Table 3 Prevalence of cancer on 31 December 2008 in the United Kingdom, by time since diagnosis
0–1 years 1–5 years 5–10 years 10–20 years 420 years Total
Males
Colon, rectum and anus 14 619 (49) 38 075 (127) 31 162 (104) 24 534 (82) 14 141 (47) 122 531 (410)
Lung, bronchus and trachea 8263 (28) 7850 (26) 3810 (13) 4769 (16) 14 049a (47)a 38 741 (130)
Prostate 37 967 (127) 125 470 (419) 61 376 (205) 22 601 (76) 6022 (20) 253 436 (847)
All other malignant neoplasmsb 40 891 (137) 97 529 (326) 87 008 (291) 98 726 (330) 80 326 (269) 404 480 (1352)
All malignant neoplasmsb 101 740 (340) 268 924 (899) 183 356 (613) 150 630 (504) 114 538 (383) 819 188 (2738)
Females
Breast 42 432 (137) 140 111 (451) 128 672 (414) 145 035 (467) 92 748 (299) 548 998 (1,768)
Colon, rectum and anus 11 309 (36) 30 341 (98) 27 128 (87) 25 532 (82) 18 975 (61) 113 285 (365)
Lung, bronchus and trachea 6905 (22) 7255 (23) 3671 (12) 2682 (9) 4268 (14) 24 781 (80)
All other malignant neoplasmsb 40 655 (131) 109 179 (352) 96 400 (310) 119 366 (384) 130 664 (421) 496 264 (1598)
All malignant neoplasmsb 101 301 (326) 286 886 (924) 255 871 (824) 292 615 (942) 246 655 (794) 1 183 328 (3810)
ICD¼ International Classification of Diseases. The number of survivors (crude proportion per 100 000) is indicated; the sum of observed prevalence was available from cancer
registry data, whereas modelled prevalence was not. Italicised numbers are those that are based on estimates of prevalence in 2004 that were at least 20% modelled. aThe
estimate of the number of long-term male lung cancer survivors (420 years from diagnosis) is likely over-estimated; see the section ‘Discussion’ for details. A more plausible
figure is 6000 (20 per 100 000). bExcluding non-melanoma skin cancer (ICD-10 C44).
Table 4 Prevalence of cancer on 31 December 2008 in the United Kingdom, by age
0–44 years 45–64 years 65+ years Total
Males
Colon, rectum and anus 2091 (11) 25 690 (343) 94 750 (2238) 122 531 (410)
Lung, bronchus and trachea 441 (2) 6643 (89) 31 657 (748) 38 741 (130)
Prostate 181 (1) 34 511 (461) 218 744 (5168) 253 436 (847)
All other malignant neoplasmsa 68 539 (377) 125 077 (1671) 210 864 (4982) 404 480 (1352)
All malignant neoplasmsa 71 252 (392) 191 921 (2563) 556 015 (13 136) 819 188 (2738)
Females
Breast 25 428 (143) 208 076 (2694) 315 494 (5688) 548 998 (1768)
Colon, rectum and anus 2134 (12) 19 723 (255) 91 428 (1648) 113 285 (365)
Lung, bronchus and trachea 530 (3) 5904 (76) 18 347 (331) 24 781 (80)
All other malignant neoplasmsa 67 530 (380) 151 756 (1965) 276 978 (4994) 496 264 (1598)
All malignant neoplasmsa 95 622 (538) 385 459 (4990) 702 247 (12 661) 1 183 328 (3810)
ICD¼ International Classification of Diseases. The number of survivors (crude proportion per 100 000) is indicated; the sum of observed prevalence was available from cancer
registry data, whereas modelled prevalence was not. Italicised numbers are those that are based on estimates of prevalence in 2004 that were at least 20% modelled. aExcluding
non-melanoma skin cancer (ICD-10 C44).
Cancer prevalence in the United Kingdom
J Maddams et al
543










Appendix C. Publication reprints
209
cancers. For both men and women, colorectal cancer accounted
for approximately 10–15% of all the three measures. In contrast,
for men, lung cancer accounted for 15% of all newly diagnosed
cancers, 25% of cancer deaths and for only 5% of cancer
prevalence. A similar pattern was seen for female lung cancer,
which accounted only for 2% of cancer prevalence in women.
Prostate and female breast cancers provided further contrasts, the
latter accounting for 31% of newly diagnosed cancers, 17% of
cancer deaths and for 46% of cancer prevalence among women.
Table 3 presents cancer prevalence in the United Kingdom, by
the number of years that had passed since diagnosis. This varied
across the sexes and cancer sites, as illustrated in Figure 2. Overall,
female cancer survivors tended to be further from their diagnosis
than males, 67% of them being diagnosed more than 5 years
earlier, compared with 55% of males.
Table 4 shows the variation of cancer prevalence with age. Less
than 1% of the UK population aged o45 years at the end of 2008
were cancer survivors, compared with 13% of those aged 65 years and
more. There were twice as many female survivors aged between 45
and 64 years as there were males, largely because of the dominance of
female breast cancer that accounted for 54% of female survivors in
this age range. The most prevalent types of cancer in those aged 65
years and more were prostate and female breast cancers; 5% of males
and 6% of females in this age group were survivors of these cancers.
Figure 3 shows the trends in 1-, 5-, 10-, 20- and 30-year limited-
duration prevalence during the period 2000–2004, projected to
2008. Only male lung cancer did not show an increasing trend, the
total number of survivors declining by 1.4% per year. By far, the
most rapidly increasing prevalence is that of prostate cancer,
the total number of survivors increasing by 9.8% per year. Overall,
the number of cancer survivors increased by 3.8% per year for men
and 2.7% for women.
DISCUSSION
For producing our prevalence estimates, we have, where available,
used incidence and follow-up data collected by cancer registries in
the United Kingdom. We have not adjusted our estimates for DCO
registrations that occurred after the index date. DCOs account for
o5% of all registrations in the UK and most often relate to patients
who have died soon after diagnosis. We have therefore assumed that
their effect on cancer prevalence is negligible. We have not
attempted to estimate the proportion lost to follow-up nor
emigrations. Nor have we been able to include UK immigrants
with a diagnosis of cancer pre-dating their move. To a certain
extent, the effects of including emigrants and excluding immigrants
will cancel each other out.
For estimating the number of survivors from a period before
cancer registration in their country, we have developed log-linear
regression models for the prevalence count as a function of time
since diagnosis. Treating prevalence in this manner as an isolated
statistic does not explicitly model the joint effect of incidence and
survival, and is based on the observation that the relationship
between the number of years since diagnosis and the number of
prevalent cases is approximately log linear (Phillips et al, 2002).
However, as this relationship is not log linear for prostate cancer,
the regression model was applied in two stages. This accounted for
the introduction of PSA testing in the early 1990s, which effectively
changed the definition of the disease with many more localised
tumours diagnosed (Evans and Moller, 2003). The number of
prostate cancer survivors is increasing at the fastest rate of cancers
studied here, by almost 10% each year. As the changes in incidence
and survival caused by the introduction of PSA testing are
relatively recent, we expect their numbers to increase at a similar
rate for some years to come, until a situation is reached in which
very few were diagnosed in the era before PSA testing.
Table 1 shows that our estimated 15-year completeness indices
for 2004 were consistently lower than those previously published
for 1992 (Forman et al, 2003). The differences in the completeness
index are consistent with the improvements in survival observed
between 1992 and 2004 for many cancers (Cancer Research UK,
2007; Rachet et al, 2008). Increases in survival rates result in a
larger proportion of long-term cancer survivors and therefore, in a
smaller completeness index. Although most differences in these
indices were small, for male lung cancer, the difference was large
(0.58 compared with the published estimate of 0.73). Despite the
two estimates relating to different index dates and the changes in
lung cancer incidence between the two dates, we would not expect
such a large discrepancy. For lung cancer, as with prostate cancer,
the number of survivors is not a log-linear function of years since
diagnosis. Owing to its poor prognosis, lung cancer prevalence is
dominated by short-term survivors (Figure 2c); hence, we believe
that our models have over-estimated the number of long-term
male survivors. If we were to use a ratio of 0.73, then we would












































Figure 1 Proportion of total incidence1, mortality2 and prevalence3 that is accounted for by selected cancers. (A) Males; (B) females. 1Incidence
in England, 2006; data from National Cancer Information Service (NCIS); 2Mortality in England, 2005; data from NCIS; 3Prevalence in the
United Kingdom, 2008.
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survivors who, at the end of 2008, have survived more than 20
years since their diagnosis. This estimate seems more plausible,
especially when compared with the report stating that, in the
Northern European countries in 1992, only 31% of male lung
cancer prevalence was accounted for by survivors who were more
than 10 years from diagnosis Moller et al (2003).
We have adopted a pragmatic approach to the modelling used in
this study. Owing to the long time series of registry data in the
United Kingdom, the majority of the estimates presented contain
only a small contribution of modelled data. This contribution is
most significant in the estimates for Northern Ireland and, to a
lesser extent, for Wales. With 34-years of data available for
England and Scotland, the modelled proportions of the complete
prevalence estimates were typically B5% for men and 8% for
women. Therefore, we believe these estimates to be robust and fit
for the purpose.
Substantial results of the analysis
There are B2 million cancer survivors in the United Kingdom
today. In those aged 65 years and more, B13% of the population






























































































































Figure 2 Prevalence of cancer in the United Kingdom on 31 December 2004, by number of years since diagnosis and age. (A) Males: colon, rectum and
anus; (B) females: colon, rectum and anus; (C) males: lung, bronchus and trachea; (D) females: lung, bronchus and trachea; (E) prostate; (F) females: breast.
Prevalence of cancer in the United Kingdom on 31 December 2004: the sum of observed prevalence was available from national cancer registry data,
whereas modelled prevalence was not.
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population will be diagnosed with cancer during their lifetime and
one in four will die from it (Cancer Research UK, 2008); we can
also state that one in eight of those aged 65 years and more are
living with or beyond cancer.
Our overall estimate of 2 million is far higher than that of 1.2
million at the end of 1992 (Forman et al, 2003). However, we have
found that in recent years the absolute number of cancer survivors




































































































































































































































































































Figure 3 Trends and projections of limited-duration cancer prevalence in the United Kingdom, 2000–2008. (A) Males: colon, rectum and anus;
(B) females: colon, rectum and anus; (C) males: lung, bronchus and trachea; (D) females: lung, bronchus and trachea; (E) prostate; (F) females: breast;
(G) All malignant neoplasms1; males. (H) All malignant neoplasms1; females; 1Excluding non-melanoma skin cancer (ICD-10 C44).
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 if a similar rate of increase is assumed to apply over the entire
period between 1992 and 2008, then the two figures are consistent.
Not only is cancer prevalence increasing overall but the relative
prevalence of different types of cancer is also changing. For
example, prostate and female breast cancers have shown some of the
largest increases in incidence and improvements in survival of all
cancers in the United Kingdom since 1992 (Cancer Research UK,
2007), resulting in the proportion of total sex-specific prevalence
accounted for by each increasing from 14 and 37% in 1992 (Forman
et al, 2003) to 31 and 46% in 2008, respectively.
The number of cancer survivors varies within the United
Kingdom, with Northern Ireland having the lowest prevalence
proportion and Wales the highest. We have not presented age-
specific proportions for each country, but the observed differences
are, at least in part, attributable to the different age structures in
each country; Northern Ireland has the youngest population (63%
aged under 45 years; UK average of 59%) and Wales has the oldest
population (18% aged 65 years and more; UK average of 16%).
Different patterns of adopting PSA testing in the early 1990s
resulted in higher detection rates of prostate cancer in Britain,
compared with those in Northern Ireland. Consequently, recorded
prostate cancer incidence between 1993 and 2003 remained lower
in Northern Ireland than in the rest of the United Kingdom
(Fitzpatrick et al, 2006).
In areas where cancer registration is less comprehensive than in
the United Kingdom, models of incidence and survival rates have
been developed to estimate cancer prevalence (Capocaccia and De
Angelis, 1997). Owing to the large amount of cancer registry data
available, little modelling was required, and for simplicity our
approach treated prevalence as an isolated statistic. Nevertheless, it
is important to appreciate that it is not an isolated measure, and
that historical incidence and survival figures combine to produce
the prevalence figures existing today. Figure 1 provides an
illustration of this interaction: a cancer such as lung cancer, with
a poor prognosis accounts for a very small proportion of prevalent
cases, despite being one of the most commonly diagnosed cancers.
Conversely, prostate and female breast cancers, with relatively good
prognoses, account for larger proportions of cancer survivors than
they do for new incident cases. Changes in incidence and survival
(brought about by changes in lifestyle, population structure and
health-service policy) will therefore have significant consequences
for the prevalence of cancer. For example, since the 1970s, the
number of smokers in the UK male population decreased from
B50% toB20% (ONS, 2008b), resulting in a decrease in male lung
cancer incidence and, in turn, a decrease in prevalence.
The previous most recent UK estimates of cancer prevalence
were related to 1992 (Forman et al, 2003), since then, as we have
shown, cancer prevalence has changed markedly. Therefore, our
estimates are highly relevant for both statutory and voluntary
sector organisations that are responsible for planning and
providing treatment and support to cancer survivors in the United
Kingdom. In the coming years, cancer prevalence will continue to
increase as a result of the growing and ageing population of the
United Kingdom, increased detection of cancer and improving
survival rates. We estimated that, overall, the annual rate of
increase in the number of cancer survivors is currentlyB3%, and
we anticipate that this rate of increase will continue in the near
future. Issues surrounding care and support for cancer survivors
should, therefore, remain high on the public health agenda, with
analysis and projections of cancer incidence, prevalence and
mortality becoming increasingly central to resource-planning
decisions. Cancer detection and treatment resources tend to focus
on the most commonly diagnosed types of cancer, or major killers,
but for cancer survivors, the most significant cancers are those
with both a high incidence rate and a relatively good prognosis
(such as prostate cancer and female breast cancer).
Knowledge of the natural progression of a particular type of
cancer, together with the analysis of prevalence by time since
diagnosis, gives some indication of different phases of survivor-
ship, but does not fully show the extent to which survivors require,
or are receiving, care and support. Many survivors will be newly
diagnosed and in active treatment, others may be in a state of
remission or recurrence with or without late effects of treatment,
others may be receiving palliative care, whereas some may
consider themselves to be completely free of cancer. Awareness
of these differences is important when assessing the health-care
burden of cancer, the financial costs of which are the highest
during initial treatment and end of life care (Brown et al, 1999).
We intend to extend the work presented in this paper in order to
provide additional details about the different phases of survivor-
ship and to analyse the factors that influence cancer prevalence
over time.
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A B S T R A C T
Background: In the United Kingdom, there are approximately two million cancer survivors
(3.2% of the entire population), composed of groups of people in different phases of survi-
vorship and with different health service needs. The aim of this study was to quantify the
level of acute health service utilisation by cancer survivors in the UK, according to tumour
type, age, sex, time since diagnosis, and time until death.
Methods: Linked national cancer registry and hospital activity data were analysed. The data
covered all cancer-related admissions to public hospitals operated by the National Health
Service in England occurring in 2006 among people diagnosed with cancer in the period
1990–2006. The intensity of cancer-related health service utilisation was categorised as
‘none’, ‘low’ (up to 10% of an individual’s time), or ‘high’ (>10% of an individual’s time),
among groups defined by time since diagnosis and time until death. Results were extrapo-
lated from the population of England in 2006 (51 million) to that of the UK in 2008 (61 mil-
lion).
Findings: Sixty one thousand of the twomillion cancer survivors (3%) were in the ‘high’ util-
isation category; 240,000 (12%) were in the ‘low’ category; 1.70 million (85%) had no cancer-
related hospital admissions. 147,000 cancer survivors (7%) were in the last year of their life,
and it was this group that had the highest levels of hospital utilisation. 1.57 million cancer
survivors (78%) were more than 1 year from both diagnosis and death, and had no cancer
related hospital admissions.
Interpretation: A considerable proportion of cancer survivors in the UK have a high level of
hospital utilisation soon after diagnosis or before death, but the large majority of them are
neither recently diagnosed nor near the end of their life, and do not utilise acute health ser-
vices for cancer-related care.
! 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Cancer prevalence, the proportion of a population that has
been diagnosed with cancer, is one measure of the cancer
burden on society. The prevalent population comprises ‘can-
cer survivors’ – those people alive following a diagnosis of
cancer from some point in their past. The broad definition
of cancer survivors includes those recently diagnosed, in ac-
tive treatment, in remission, receiving treatment for recur-
rence, in end of life care, and those who are cured.
Previous work has shown that there are approximately
two million cancer survivors in the United Kingdom and that
in recent years this number has increased by approximately
3% per annum,1 largely due to an ageing population, earlier
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 detection of cancers, and improved treatment regimes lead-
ing to increased survival. The Cancer Reform Strategy2 led
to the establishment in 2008 of a National Cancer Survivor-
ship Initiative to focus on the needs of the growing population
of survivors in England. As observed cancer survival in-
creases, so does the number of long term survivors. For many
people diagnosed with cancer, it is no longer considered the
death sentence it once was.3,4 Indeed, it has been argued that
in many cases cancer may be better described as a chronic ill-
ness, i.e. one characterised by a prolonged duration and a
recurring nature.5 It is useful therefore to go beyond a simple
enumeration of survivors, since this tells us only a limited
amount about the cancer burden in terms of (a) the personal
psychosocial and physical burden to the individual survivor;
and (b) the resource implications to the health service and
society at large.
Prevalence is often estimated directly from cancer regis-
try data, and it is easy to disaggregate the prevalence esti-
mates according to year of diagnosis or equivalently time
since diagnosis.6–13 Intuitively this appears a good way to
broadly categorise cancer survivors – certainly the first year
following diagnosis is likely to be one of the most traumatic
physically and emotionally. However, in the medium and
long term after diagnosis, survivorship is likely to vary
greatly across individuals, and it may not be sufficient to
classify the population of cancer survivors simply by time
since diagnosis.
This work presents an analysis of a linked cancer registry
and health service activity dataset for England. A set of survi-
vorship ‘states’ are defined in terms of four temporal ‘phases
of survivorship’ (using time since diagnosis and time until
death) and intensity of acute health service utilisation. Using
person-time methods, the number of survivors in each of
these states at the end of 2008 is estimated. Results are pre-
sented in a novel way using bespoke graphics.
2. Methods
2.1. Data
The analysis was based on two linked datasets. The English
national merged cancer registry dataset, which featured pa-
tient and diagnostic information relating to all cancers diag-
nosed between 1990 and 2006 and recorded by the eight
regional population-based cancer registries in England, was
linked at the patient level to the English national Hospital Epi-
sode Statistics (HES) dataset14 which contained patient, clini-
cal, and administrative details for in-patients and day case
patients treated in any hospital operated by the 166 National
Health Service (NHS) providers in England. The linkage algo-
rithm was ‘rules-based’ and used national health service
number (which is unique to each patient), date of birth, date
of death where appropriate, sex and postcode of residence.
Each HES record defines a complete episode of care under a
given consultant in a given NHS facility, and a patient’s jour-
ney from admission to discharge may comprise many such
episodes.
The national cancer registry dataset was used to define a
cohort of cancer survivors who had been diagnosed with a
malignant neoplasm (other than non-melanoma skin cancer)
in the period 1990–2006, and were alive for at least some por-
tion of 2006. Sub-cohorts were defined according to type of
cancer: colon, rectum, and anus cancers (ICD-10 C18-C21);
lung, bronchus, and trachea cancers (ICD-10 C33-C34); pros-
tate cancer (ICD-10 C61); and female breast cancer (ICD-10
C50). Details of all hospital episodes of care occurring in
2006 for these cancer survivors were extracted from the
linked dataset. Episodes were included in the analysis if they
were ‘cancer related’, in that at least one of the 14 recorded
hospital diagnosis codes was for a malignancy other than
non-melanoma skin cancer.
Fig. 1 – Survivors in temporal phases A–D on 31st December 2006. dx = diagnosis; != death; A–D = temporal phase of
survivorship as defined in Box 1.
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 2.2. Survivorship states
Four distinct temporal phases of survivorship (Box 1 and
Fig. 1) were defined according to time since diagnosis and
time until death:
Box 1: temporal phases of survivorship
Phase A Less than 1 year from death and less
than 1 year from diagnosis
Phase B Less than 1 year from death and more
than 1 year from diagnosis
Phase C More than 1 year from death and less
than 1 year from diagnosis
Phase D More than 1 year from death and more
than 1 year from diagnosis
For each survivor, the person-time for which they were pre-
valent in2006 (i.e. thatwhichwaspost-diagnosis andpre-death
andoverlapped the calendar year 2006)was split into segments
according to the timepointsatwhich theymovedbetweentem-
poral phases or broad age bands (chosen to be 0–44, 45–64, and
P65 years). Since death notifications were available for survi-
vors in the cancer registry dataset up to the end of 2008, it
was possible to identify the points in timeduring 2006 atwhich
any survivors entering the last year of their life did so. This
person-time splitting procedure was executed using the SAS
software package (SAS Institute Inc., Cary, NC, United States
ofAmerica) andaseriesofprogrammesdevelopedby JMfor this
task, similar to the programme Lexis.sas by Carstensen.15
Intensity of acute health service utilisation was defined in
each segment of person-time according to the combined dura-
tion of cancer related hospital episodes that occurred. It was
considered to be ‘‘high’’ if hospital activity accounted for more
than 10% of the person-time segment; it was considered to be
‘‘low’’ if hospital activityaccounted for some,butnotmore than
10%, of the segment; and a separate category was reserved for
those segments of person-time which contained no hospital
activity. There were, therefore, 12 possible survivorship states
defined according to temporal phase and intensity of acute
health service utilisation (Fig. 2). The total amount of person-
timespentby thepopulationof survivors ineachof thesestates
was calculated separately for each tumour group and sex.
Under certain assumptions, the proportion of total popu-
lation person-time spent in each survivorship state is equal
to the proportion of the prevalent population in that state at
a given point in time during the analysis period (see
Supplementary web extra material). Using this fact, the
summed population person-time in our analysis was used
to estimate the proportion of survivors in each state at the
end of 2006.
2.3. Extrapolation to complete prevalence in 2008
In order to use our person-time analysis for the year 2006 to
estimate the proportion of survivors in each survivorship
state at the end of 2008 (the most recent estimate of preva-
lence in the UK1), it was assumed that the distribution of sur-
vivors between states did not change between 2006 and 2008.
The cancer registry dataset contained diagnoses made in
the period 1990–2006. The person-time analysis for 2006
therefore completely described only those survivors diag-
nosed up to 16 years previously (16-year prevalence). By defi-
nition, survivors more than 16 years from diagnosis are in
either temporal phase B or D. It was assumed that the distri-
bution of survivors between these two phases was the same
for those more than 16 years from diagnosis as it was for
those between 15 and 16 years from diagnosis. It was also as-
sumed that the relative numbers of survivors with an acute
health service utilisation intensity of ‘‘high’’, ‘‘low’’, or ‘‘none’’
in each temporal phase B or D were the same for survivors
greater than 16 years from diagnosis as they were for those
in that phase no more than 16 years from diagnosis.
3. Results
Results are presented graphically in Figs. 3 and 4. Each figure
contains a set of square tiles, with each tile representing can-
cer survivors of a given cancer type, sex, and broad age group.
The density of the overlaid male or female icons is propor-
tional to the total number of survivors represented by the tile.
Four horizontal divisions mark the proportion of survivors in
each of the four temporal phases (Box 1) and, in each phase,
three vertical divisions mark the proportion of survivors in
each category of acute health service utilisation. The resulting
12 areas are coloured to indicate the different survivorship
states represented (Fig. 2).
These figures aim to present a large amount of data in a
clean and simple manner, allowing for an immediate high le-
vel analysis, as well as facilitating in-depth study and easy
comparison across cancer types, age groups, and sexes. The
design was inspired by the work of the Dutch artist Piet Mon-
drian (1872–1944) who simplified visual compositions to three
primary colours and a grid of black lines on a white back-
ground.16 The underlying counts of survivors are given in
Table 1, and the corresponding proportions in Table 2.
Fig. 2 – Survivorship states defined by time since diagnosis,
time until death and health service utilisation. Key to Figs. 3
and 4.
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 Fig. 3 – Male cancer survivors, UK, 2008; by age, type of cancer and survivorship state. In each tile, the rows from top to bottom
correspond to the 4 temporal phases of survivorship (A-D) respectively, with the vertical bands from left to right
corresponding to states of increasing acute health service utilisation (see Fig. 2 and Box 1 for definitions). Each male icon
represents approximately 1,000 cancer survivors (exact counts are in Table 1). The proportion of survivors in temporal phase
D (more than 1 year from both diagnosis and death) and with a ‘high’ level of acute health service utilisation (the rightmost
area of the bottom row) may be too small to be visible.
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Fig. 4 – Female cancer survivors, UK, 2008; by age, type of cancer and survivorship state. In each tile, the rows from top to
bottom correspond to the 4 temporal phases of survivorship (A-D) respectively, with the vertical bands from left to right
corresponding to states of increasing acute health service utilisation (see Fig. 2 and Box 1 for definitions). Each female icon
represents approximately 1,000 cancer survivors (exact counts are in Table 1). The proportion of survivors in temporal phase
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A <10 20 30 60 80 260 270 610 530 710 840 2,080
B 10 40 30 80 290 510 270 1,060 4,120 2,130 1,070 7,320
C 130 150 80 360 1,050 1,820 790 3,670 2,590 3,650 1,590 7,840
D 1,490 90 <10 1,590 18,760 1,430 160 20,350 72,400 4,700 410 77,520




A <10 30 30 70 210 660 520 1,400 830 1,420 1,260 3,500
B <10 <10 <10 20 180 260 120 550 930 770 370 2,070
C 20 40 <10 70 320 630 130 1,090 830 1,090 220 2,130
D 280 10 <10 290 3,310 270 20 3,600 22,360 1,500 90 23,950
Total 310 90 50 440 4,030 1,820 790 6,640 24,950 4,780 1,940 31,660
Prostate A <10 <10 <10 <10 80 130 70 280 1,110 890 740 2,740
B <10 <10 <10 <10 220 350 180 750 7,800 5,860 3,210 16,880
C 20 10 <10 40 5,020 3,590 140 8,740 17,190 8,370 600 26,160
D 120 10 <10 130 22,830 1,830 80 24,740 152,850 18,960 1,150 172,970
Total 140 30 10 180 28,150 5,890 470 34,510 178,960 34,080 5,700 218,740
All malignant
neoplasms
A 80 210 360 650 880 2,260 2,500 5,640 4,180 6,170 6,680 17,030
B 220 360 300 880 1,960 2,680 1,790 6,430 21,210 14,480 8,060 43,750
C 2,400 2,410 1,150 5,950 10,330 10,810 2,740 23,880 24,500 19,820 4,270 48,600
D 59,200 4,020 560 63,780 142,560 12,260 1,150 155,970 398,000 45,800 2,840 446,640




A <10 10 30 50 50 140 190 390 510 500 750 1,750
B 20 30 30 80 180 300 200 680 4,010 1,470 820 6,300
C 110 150 70 330 710 1,260 540 2,510 2,310 2,790 1,190 6,290
D 1,550 110 10 1,680 15,140 910 100 16,150 73,780 3,010 310 77,090




A <10 30 20 60 160 480 440 1,080 750 1,060 1,030 2,840
B <10 10 <10 20 150 220 120 500 760 520 290 1,570
C 30 30 <10 70 300 570 130 1,000 780 860 200 1,850
D 340 30 <10 370 3,040 260 20 3,320 11,320 740 40 12,090
Total 380 110 40 530 3,660 1,530 710 5,900 13,600 3,180 1,560 18,350
Breast A 30 60 30 120 130 250 140 520 830 480 360 1,670
B 150 370 190 710 1,260 2,110 1,020 4,390 11,200 4,390 2,400 17,990
C 1,430 3,060 210 4,700 7,610 11,430 610 19,660 8,250 7,020 500 15,770
D 17,950 1,870 80 19,890 174,890 8,240 380 183,510 268,030 11,200 840 280,070
Total 19,560 5,360 510 25,430 183,890 22,030 2,150 208,080 288,300 23,090 4,100 315,490
All malignant
neoplasms
A 100 230 360 690 670 1,650 1,970 4,290 3,570 4,100 5,010 12,680
B 310 680 510 1,490 2,690 4,230 2,550 9,470 25,610 11,570 6,890 44,070
C 4,390 5,620 1,140 11,160 13,460 18,490 2,560 34,510 17,200 17,270 3,510 37,970
D 76,500 5,240 540 82,280 318,620 17,370 1,200 337,190 573,070 32,000 2,460 607,520
Total 81,300 11,770 2,550 95,620 335,440 41,730 8,280 385,460 619,440 64,940 17,870 702,250
Numbers may not sum to group totals since all are rounded to the nearest 10. Numbers less than 10 are suppressed.
a Phase A = less than 1 year from death and less than 1 year from diagnosis; phase B = less than 1 year from death and more than 1 year from
diagnosis; phase C = more than 1 year from death and less than 1 year from diagnosis; phase D = more than 1 year from death and more than
1 year from diagnosis.
b None = no time is spent as an admitted hospital patient; low = time spent as an admitted hospital patient accounts for some, but no more
than 10% of, person time; high = time spent as an admitted hospital patient accounts for more than 10% of person time.
D (more than 1 year from both diagnosis and death) and with a ‘high’ level of acute health service utilisation (the rightmost
area of the bottom row) may be too small to be visible. Similarly, the proportion of breast cancer survivors in temporal phase
A (within one year of both diagnosis and death – the top row) may be too small to be visible.
b
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 At the end of 2008, approximately 81% of all male survi-
vors and 87% of all female survivors were more than 1 year
from diagnosis and more than 1 year from death. There was
little variation in these proportions by age, except for male
survivors aged under 45 years for whom this proportion
rose to 90%. The proportion of lung cancer survivors who
were more than 1 year from both diagnosis and death was
markedly lower (72% of male survivors and 64% of female
survivors). There was little acute health service utilisation
among survivors in this phase, regardless of age or type
of cancer. Overall, 1.57 million cancer survivors in the UK
at the end of 2008 (78%) were more than 1 year from both
diagnosis and death, and had no cancer related hospital
admissions.













A 0.4 1.2 1.5 3.1 0.3 1.0 1.1 2.4 0.6 0.8 0.9 2.2
B 0.7 1.9 1.2 3.8 1.1 2.0 1.1 4.1 4.3 2.2 1.1 7.7
C 6.2 7.3 3.8 17.3 4.1 7.1 3.1 14.3 2.7 3.9 1.7 8.3
D 71.1 4.3 0.5 75.8 73.0 5.5 0.6 79.2 76.4 5.0 0.4 81.8




A 1.7 7.6 7.0 16.3 3.2 10.0 7.9 21.1 2.6 4.5 4.0 11.1
B 0.7 1.4 1.5 3.6 2.7 3.9 1.8 8.4 2.9 2.4 1.2 6.5
C 5.0 7.9 2.1 15.0 4.9 9.5 2.0 16.4 2.6 3.4 0.7 6.7
D 62.4 2.6 0.2 65.1 49.9 4.0 0.2 54.2 70.6 4.7 0.3 75.7
Total 69.8 19.5 10.7 100.0 60.7 27.5 11.9 100.0 78.8 15.1 6.1 100.0
Prostate A 0.0 0.5 1.0 1.6 0.2 0.4 0.2 0.8 0.5 0.4 0.3 1.3
B 0.8 0.5 1.3 2.6 0.6 1.0 0.5 2.2 3.6 2.7 1.5 7.7
C 13.2 7.3 2.4 22.9 14.5 10.4 0.4 25.3 7.9 3.8 0.3 12.0
D 64.5 6.8 1.7 73.0 66.2 5.3 0.2 71.7 69.9 8.7 0.5 79.1
Total 78.5 15.2 6.4 100.0 81.6 17.1 1.4 100.0 81.8 15.6 2.6 100.0
All malignant
neoplasms
A 0.1 0.3 0.5 0.9 0.5 1.2 1.3 2.9 0.8 1.1 1.2 3.1
B 0.3 0.5 0.4 1.2 1.0 1.4 0.9 3.4 3.8 2.6 1.4 7.9
C 3.4 3.4 1.6 8.3 5.4 5.6 1.4 12.4 4.4 3.6 0.8 8.7
D 83.1 5.6 0.8 89.5 74.3 6.4 0.6 81.3 71.6 8.2 0.5 80.3




A 0.2 0.6 1.5 2.4 0.3 0.7 1.0 2.0 0.6 0.5 0.8 1.9
B 1.0 1.3 1.4 3.7 0.9 1.5 1.0 3.5 4.4 1.6 0.9 6.9
C 5.2 7.0 3.4 15.5 3.6 6.4 2.7 12.7 2.5 3.0 1.3 6.9
D 72.6 5.2 0.6 78.5 76.8 4.6 0.5 81.9 80.7 3.3 0.3 84.3
Total 79.0 14.1 6.9 100.0 81.5 13.2 5.2 100.0 88.2 8.5 3.4 100.0
Lung, bronchus
and trachea
A 1.8 6.1 4.3 12.2 2.8 8.2 7.4 18.4 4.1 5.8 5.6 15.5
B 1.1 2.7 0.7 4.5 2.6 3.7 2.1 8.4 4.1 2.9 1.6 8.6
C 5.1 6.4 1.6 13.1 5.2 9.6 2.3 17.0 4.2 4.7 1.1 10.1
D 64.7 5.2 0.3 70.2 51.4 4.4 0.3 56.2 61.7 4.0 0.2 65.9
Total 72.6 20.4 7.0 100.0 62.0 25.9 12.1 100.0 74.1 17.3 8.5 100.0
Breast A 0.1 0.2 0.1 0.5 0.1 0.1 0.1 0.2 0.3 0.2 0.1 0.5
B 0.6 1.5 0.8 2.8 0.6 1.0 0.5 2.1 3.5 1.4 0.8 5.7
C 5.6 12.0 0.8 18.5 3.7 5.5 0.3 9.4 2.6 2.2 0.2 5.0
D 70.6 7.3 0.3 78.2 84.1 4.0 0.2 88.2 85.0 3.5 0.3 88.8
Total 76.9 21.1 2.0 100.0 88.4 10.6 1.0 100.0 91.4 7.3 1.3 100.0
All malignant
neoplasms
A 0.1 0.2 0.4 0.7 0.2 0.4 0.5 1.1 0.5 0.6 0.7 1.8
B 0.3 0.7 0.5 1.6 0.7 1.1 0.7 2.5 3.6 1.6 1.0 6.3
C 4.6 5.9 1.2 11.7 3.5 4.8 0.7 9.0 2.4 2.5 0.5 5.4
D 80.0 5.5 0.6 86.0 82.7 4.5 0.3 87.5 81.6 4.6 0.3 86.5
Total 85.0 12.3 2.7 100.0 87.0 10.8 2.1 100.0 88.2 9.2 2.5 100.0
Percentages sum to 100% for each type of cancer/age group (subject to rounding errors).
a Phase A = less than 1 year from death and less than 1 year from diagnosis; phase B = less than 1 year from death and more than 1 year from
diagnosis; phase C = more than 1 year from death and less than 1 year from diagnosis; phase D = more than 1 year from death and more than
1 year from diagnosis.
b None = no time is spent as an admitted hospital patient; low = time spent as an admitted hospital patient accounts for some, but no more
than 10% of, person time; high = time spent as an admitted hospital patient accounts for more than 10% of person time.
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 240,000 of the two million cancer survivors in the UK
(14.8% of male survivors and 10.0% of female survivors) were
in the ‘low’ acute health care utilisation category. Sixty one
thousand (4.0% of male survivors and 2.4% of female survi-
vors) were in the ‘high’ category. The proportion of lung can-
cer survivors in the ‘high’ category was much larger (7.2% of
males and 9.3% of females), particularly in the age group
45–64 years where the proportion rose to around 12%. Con-
versely, only 1.2% of female breast cancer survivors had a
‘high’ level of acute health care utilisation.
147,000 cancer survivors were in the last year of their life
(9.0% of male survivors and 6.2% of female survivors). It was
these survivors who had the highest intensity of cancer re-
lated acute health service utilisation, particularly those who
were also in the first year since diagnosis. Forty one percent
of the 41,000 survivors who were less than 1 year from both
diagnosis and death had a high intensity of acute health ser-
vice utilisation, compared with 19% of the 106,000 survivors
who were in the last year of their life but more than 1 year
from diagnosis.
4. Discussion
The linked dataset allowed an analysis of all recorded epi-
sodes of hospital in-patient or day case healthcare among
registered cancer survivors in England during 2006. A per-
son-time approach allowed us to quantify the intensity of
hospitalisation, and the associated burden on cancer survi-
vors and the health service, by considering the amount of
time spent in hospital, rather than just the number of
admissions.
The hospital activity data featured details of all types of
in-patient and day case care delivered to cancer survivors,
not just that which related to cancer. Each record had up
to 14 diagnostic codes (using the ICD-10 classification) and
12 operation procedure codes, with the first of each of these
codes intended to indicate the primary diagnosis or intent
of the treatment. For simplicity, we categorised episodes
as ‘related to cancer’ or ‘not related to cancer’ according
to the diagnostic codes only. This was an intentionally
broad categorisation, designed to take account of the wide
range of health problems associated with cancer and the
side effects of its treatment. Nonetheless the specificity of
the definition is unproven and it is not possible to say ex-
actly which kinds of treatment following a cancer diagnosis
are included. However, an analysis of the complementary
‘non-cancer related’ care (not presented here) indicates that
the cancer related definition does achieve its goal by remov-
ing some of the background hospitalisation experienced by
this population. The proportion of time spent by cancer sur-
vivors in hospital for non-cancer related care was much
lower than for cancer related care, and was generally con-
stant regardless of time since diagnosis. In this analysis,
therefore, ‘cancer related’ hospitalisation may be considered
as that directly or indirectly caused by, or in some way
associated with, a cancer diagnosis.
Some survivors will be diagnosed with additional primary
cancers some time after their first diagnosis. Indeed, many
studies have shown elevated cancer incidence rates in those
previously diagnosed with cancer compared with the general
population17,18 and the prevalence of multiple malignancies
among cancer survivors has been shown to be around 7%.19
However, treatment received for subsequent cancers is indis-
tinguishable in this analysis from that received for the initial
cancer, a fact to be born in mind when considering the ‘time
since diagnosis’ dimension of this study.
A small number of survivors in the cancer registry data
will have had a diagnosis pre-1990 as well as in the period
1990–2006. However, since details of diagnoses made before
1990 were not available in the linked dataset, it was necessary
to assume that all survivors alive during 2006 had their first
cancer diagnosis in the period 1990–2006. The effect of this
assumption is a possible small re-distribution of survivors be-
tween the tumour sites studied, but is not considered to be a
significant limitation.
Survivorship states were defined according to time since
diagnosis, time until death, and proportion of time spent
admitted to hospital. The first year following diagnosis was
considered to be potentially important, since this is the time
during which cancer patients receive initial treatment, the
success of which may significantly affect their subsequent
health and well-being. The final year before death was also
considered to be potentially important since for many people
who die from cancer there is a period of health deterioration
in the months beforehand. For some survivors post-diagnosis
survival is short – a separate temporal phase was therefore
defined by the intersection of the first year following diagno-
sis and the last year of life. The period of survivorship which
is more than 1 year from both diagnosis and death also de-
fined a separate temporal phase and may be characterised
by periods of remission, relapse, disease monitoring, and/or
eventual ‘cure’.
Cancer prevalence is driven by cancer incidence and sur-
vival, and the distribution of survivors between temporal
phases of survivorship can largely be explained by incidence
and survival characteristics. For example, lung cancer has a
universally poor prognosis (age-standardised five-year rela-
tive survival rates in England and Wales are under 10%20)
and accordingly a large proportion of lung cancer survivors
were less than 1 year from both diagnosis and death. On the
other hand, one quarter of prostate cancer survivors aged
45–64 were less than 1 year from diagnosis but not less than
1 year from death, reflecting the relatively good prognosis of
this disease and the rapidly increasing incidence rates
brought about by the diagnostic use of the PSA test since
the early 1990s.21
In recent decades, the number of cancer survivors in the
UK has grown steadily each year.1 The distribution of survi-
vors between temporal phases, and the intensity of acute
health service utilisation within them, provides an insight
into what is meant by the term ‘cancer survivor’, especially
given the current national survivorship initiatives in the UK
and the movement towards understanding cancer as a
chronic illness. For example, the majority of UK cancer survi-
vors (1.69 million of the 2.00 million) are more than 1 year
from both diagnosis and death, and the degree of acute health
service utilisation in this phase is small – 1.57 million are in a
period characterised by no cancer related acute health service
utilisation and these survivors account for 78% of all UK can-
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 cer survivors. Cancer survivors can now realistically expect to
live longer, but this analysis suggests that the primary burden
of cancer on the health service still comes from survivors in
the first year following diagnosis and/or near the end of their
life. The term ‘cancer survivor’ was originally proposed by the
US National Coalition for Cancer Survivorship in 1986 at a
time when ‘‘cancer was a disease that people needed to learn
to fight’’ but has, according to some, become ‘‘so muddy
that. . .a new definition is needed’’.22 Alternative terms in-
clude people ‘living with or beyond cancer’ or ‘cancer pa-
tients’. However, this analysis has shown that survivorship
is heterogeneous, and finding a single term to usefully define
everyone who has ever been diagnosed with cancer may not
be possible.
A limitation of this work is that it only considered admitted
hospital episodes (in-patients and day cases). Visits to general
practitioner surgeries and other outpatient clinics are not
captured in this analysis, but much of the observation and
monitoring of survivors (especially those who are more than
1 year from both diagnosis and death) is carried out in
outpatient clinics.23 Neither does this analysis consider the
personal psychosocial or general health burden of cancer on
survivors – the trauma of being diagnosed with a life-threat-
ening illness such as cancer is associated with post traumatic
stress disorder, depression, and other mental disorders,24,25
and cancer survivors have been found to have poorer general
health outcomes than individuals who have not been diag-
nosed with cancer.26 Cancer survivors are also likely to face
day-to-day struggles (such as financial, emotional, relation-
ship, and employment difficulties) even if they have no need
for treatment in hospital.27,28 These issues present significant
burdens to cancer survivors and should be kept in mind when
considering the distribution of survivors between the states
defined in this analysis.
The extent to which the population of cancer survivors in
the UK is receiving care and treatment in hospital is central to
understanding the burden of cancer on society. The findings
contained here will be of interest to health service providers
keen to quantify the volume of acute health care adminis-
tered to cancer survivors, and the associated financial burden,
as well as to survivors themselves.
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 Full Paper
A person-time analysis of hospital activity among cancer
survivors in England
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BACKGROUND: There are around 2 million cancer survivors in the UK. This study describes the inpatient and day case hospital activity
among the population of cancer survivors in England. This is one measure of the burden of cancer on the individual and the health
service.
METHODS: The national cancer registry data set for England (1990–2006) is linked to the NHS Hospital Episode Statistics (HES)
database. Cohorts of survivors were defined as those people recorded in the cancer registry data with a diagnosis of breast,
colorectal, lung or prostate cancer before 2007. The person-time of prevalence in 2006 for each cohort of survivors was calculated
according to the cancer type, sex, age and time since diagnosis. The corresponding HES episodes of care in 2006 were used to
calculate the person-time of admitted hospital care for each cohort of survivors. The average proportion of time spent in hospital by
survivors in each cohort was calculated as the summed person-time of hospital activity divided by the summed person-time of
prevalence. The analysis was conducted separately for cancer-related episodes and non-cancer-related episodes.
RESULTS: Lung cancer survivors had the highest intensity of cancer-related hospital activity. For all cancers, cancer-related hospital
activity was highest in the first year following diagnosis. Breast and prostate cancer survivors had peaks of cancer-related hospital
activity in the relatively young and relatively old age groups. The proportion of time spent in hospital for non-cancer-related care was
much lower than that for cancer-related care and increased gradually with age but was generally constant regardless of time since
diagnosis.
CONCLUSION: The person-time approach used in this study is more revealing than a simple enumeration of cancer survivors
and hospital admissions. Hospital activity among cancer survivors is highest soon after diagnosis. The effect of age on the amount of
hospital activity is different for each type of cancer.
British Journal of Cancer (2011) 105, S38 – S45; doi:10.1038/bjc.2011.421 www.bjcancer.com
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Cancer survivors are defined as people who are alive following
a diagnosis of cancer from some point in their past. In UK,
there are approximately 2 million cancer survivors (approxi-
mately 1.66 million of these in England), and this number is
increasing by 3% per year (Maddams et al, 2009). The size and
demographics of the population of cancer survivors has been
described, but there is still a need for more detailed analyses of the
burden of cancer on the individual and on health-service
resources.
This work presents a person-time analysis of a linked cancer
registry and health-service activity data set. ‘Person-time of
survivorship’ refers to the total time at risk of hospitalisation
experienced by a population of survivors, and ‘person-time of
hospitalisation’ refers to the total time spent in hospital by this
population. Acute health-service utilisation among cancer survi-
vors in England is described according to age and time since
diagnosis, for both cancer- and non-cancer-related care. The work
presented here is complementary to that previously published by
the same authors (Maddams et al, 2011).
MATERIALS AND METHODS
Data
The analysis was based on two linked data sets (Maddams et al,
2011). The first was a national merged cancer registry data set
featuring patient and diagnostic information relating to all cancers
recorded by the eight regional population-based cancer registries
in England. The merging process was carried out by the staff at the
Thames Cancer Registry (TCR), on behalf of the United Kingdom
Association of Cancer Registries (UKACR). This provided 100%
coverage of geographical regions of England and included all
registered cancers diagnosed from 1990 to 2006 (inclusive).
This data set was linked to an extract from the NHS Hospital
Episode Statistics (HES). Hospital Episode Statistics is a record-
level data repository managed by the National Health Service
Information Centre on behalf of the Secretary of State for Health. It
contains patient, clinical and administrative details for admitted
patients and outpatients treated in NHS hospitals in England, and
is mainly populated by extracts from routine data flows exchanged
between health-care providers and commissioners (NHS Health
and Social Care Information Centre, 2010). Each HES record*Correspondence: Dr J Maddams; E-mail: jacob.maddams@kcl.ac.uk
British Journal of Cancer (2011) 105, S38 – S45
& 2011 Cancer Research UK All rights reserved 0007 – 0920/11
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 defines a finished consultant episode (FCE) of care under a given
consultant in a given NHS provider. A patient’s journey from
admission to discharge may be made up of several FCEs. The
English Cancer Registries’ National HES extract is a subset of the
complete HES database and contains only episodes for admitted
patients (i.e., inpatients and day patients) who have at least one
recorded episode ‘for or with’ cancer. An episode is considered to
be ‘for or with’ cancer if any of its 14 diagnostic fields contain an
ICD-10 code between C00 and C97 (malignant neoplasms),
between D01 and D48 (in situ, benign or uncertain neoplasms)
or equal to O01 (hydatidiform mole).
The linkage between these two data sets was designed and
developed jointly by the TCR and the Northern and Yorkshire
Cancer Registry and Information Service on behalf of the UKACR.
The methodology matches fields such as sex, date of birth, date of
death, NHS number and postcode across the two data sets and
provides a unique patient identifier for matched patients. Using
the patient identifier as a link, it is possible to extract all HES
episodes of care for a cohort of cancer patients, as defined in the
national cancer registry data set.
The national cancer registry data set was used to identify a cohort
of cancer survivors who had been both diagnosed with a malignant
neoplasm (ICD-10 C00–C97 excluding C44) in the period 1990–
2006, and alive for at least some portion of 2006 (Maddams et al,
2011). Subcohorts were defined according to the type of cancer
diagnosis received: colon, rectum and anus cancers (ICD-10 C18–
C21); lung, bronchus and trachea cancers (ICD-10 C33–C34);
prostate cancer (ICD-10 C61); and female breast cancer (ICD-10
C50). Survivors with multiple diagnoses entered multiple subco-
horts. The unique patient identifiers were then used to extract all the
HES episodes of care that occurred in, or overlapped, the year 2006
for the cohorts of cancer survivors. As the English Cancer Registries’
HES extract contains all inpatient and day case episodes for those
patients with at least one cancer-related episode in the entire HES
data set, the extracted cancer survivor episodes may or may not
mention cancer. Episodes not mentioning cancer may have
pertained to an entirely unrelated condition, or (less likely) may
have been incorrectly coded. Some cancer survivors had no
matching HES episode of care in 2006, because of a failure to
register episodes that did occur, a failure in the matching procedure
between the two data sets or simply because they were not admitted
to hospital in 2006. In this analysis, matched episodes of care were
considered to be ‘cancer related’ if one of the 14 diagnostic codes
was between C00 and C97 (excluding C44); otherwise, they were
considered to be ‘non-cancer related’.
Hospital activity among cancer survivors
A person-time approach was used to describe the effect of age and
time since diagnosis on the amount of hospital activity in the
population of cancer survivors. When considering the interaction
of survivors with the health service, a person-time approach has a
distinct advantage, as it allows us to estimate the proportion of
survivor time spent admitted to hospital, as well as to count the
number of admissions. The calendar year 2006 was the period of
analysis. The effect of age was analysed in 5-year age groups, and
the effect of time since diagnosis was analysed in 1-year periods
and broader periods (o1, 1–5 and 5–16 years since diagnosis).
Diagnoses were available for the period 1990–2006, and thus
there were some survivors in the 2006 cohort who had been
diagnosed more than 16 years (but less than 17 years) previously.
However, the cohort did not contain all such survivors (as no
diagnoses from 1989 were available), and therefore the maximum
time since diagnosis considered was 16 years.
For each survivor in each cohort, the person-time for which they
were prevalent in 2006 (i.e., that which was postdiagnosis and
predeath and overlapped the calendar year 2006) was split into
segments according to the time points at which the indexing
variables ‘time since diagnosis’ and ‘age’ changed (Maddams et al,
2011). The amount of time spent in hospital by cancer survivors
was counted in a similar way, according to age and time since
diagnosis, for cancer-related and non-cancer-related episodes of
care separately. This was achieved using the SAS software package
(SAS Institute Inc., Cary, NC, USA) and code developed by
JM specifically for this task, similar to the program Lexis.sas by
Carstensen (2007).
The proportion of person-time each cohort of survivors spent
admitted to hospital, according to age and time since diagnosis,
was then calculated by dividing the total population person-time
spent in HES activity by the total population person-time
of prevalence. This quantity may be interpreted as the mean
proportion of time spent in HES activity by a survivor of a given
age and time since diagnosis sampled at random. An alternative
interpretation is that the quantity provides an estimate of the
probability of that survivor being an admitted hospital patient on
any given day in the period. It may be presented either as the
number of days spent admitted to hospital per 100 person-days or
as a percentage of time. Confidence intervals (CIs) for this
proportion were calculated by using a standard binomial model,
modified to include a dependence parameter (Klotz, 1973;
Budescu, 1985), to account for the fact that days spent in hospital
for an individual survivor are likely to be clustered together in
episodes or spells of care, rather than randomly distributed in
time. The dependence was assumed to be of the first-order Markov
type, and both the dependence parameters and CIs were estimated
using the methods described in Budescu (1985).
RESULTS
Tables 1 and 2, and the corresponding Figures 1 and 2, display the
average number of days (per 100 person-days) that cancer
survivors spent admitted to hospital in England during 2006, by
5-year age group or 1-year time since diagnosis period. Data are
presented for cancer-related and non-cancer-related episodes of
care separately, but are omitted if less than 20 person-years of
survivorship contributed to the estimate.
In all age groups older than 35 years, the number of days
admitted to hospital for cancer-related episodes of care (per 100
person-days) was highest among lung cancer survivors; it was
lowest among prostate and breast cancer survivors. Among
prostate cancer survivors, the relatively young and relatively old
age groups spent a higher number of days admitted to hospital for
cancer-related episodes (per 100 person-days) than the middle-age
groups (55–75 years). A similar trend was observed among breast
cancer survivors, although the observed increase in the number of
days spent admitted to hospital above the age of 75 years was not
as significant as among prostate cancer survivors. Among male
lung and colorectal cancer survivors, the number of days spent
admitted to hospital for cancer-related episodes of care (per 100
person-days) generally decreased as age increased – this associa-
tion was reversed in male lung cancer survivors under the age of 50
years, but CIs were wide because of a relatively small number of
lung cancer survivors in these age groups. Similar age effects were
observed among female lung and colorectal cancer survivors.
The number of days spent admitted to hospital for non-cancer-
related episodes of care (per 100 person-days) generally increased
as age increased above 60 years. Colorectal and lung cancer
survivors spent a similar number of days admitted for non-cancer-
related episodes of care (per 100 person-days); however, prostate
and breast cancer survivors spent significantly fewer.
The number of days survivors spent admitted to hospital (per
100 person-days) for cancer-related episodes of care was much
higher in the first year following diagnosis than at any other time.
In the first 5 years after diagnosis, it was highest among survivors
of lung cancer.
Hospital activity among cancer survivors
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 Three periods of time after diagnosis were considered in detail:
o1 year, between 1 and 5 years and 5–16 years (as only diagnoses
from 1990–2006 were available). The first period contained the
majority of the cancer-related hospital activity for all cancer
survivors, but the period between 1 and 5 years after diagnosis also
had a significant amount of hospital activity.
Figure 3 displays the average number of days spent admitted to
hospital (per 100 person-days) by cancer survivors in England in
2006, by 5-year age group and broad post-diagnosis period. Only
cancer-related episodes of care are presented in this figure. As with
all tables and figures, data are omitted if less than 20 person-years of
survivorship contributed. Figure 3 shows that, for each age group,
the number of days spent admitted to hospital for cancer-related
episodes of care (per 100 person-days) was highest in the first year
after diagnosis. For colorectal cancer survivors, it was approxi-
mately 30 times higher than in the period45 years after diagnosis.
Similarly, for lung cancer survivors, it was approximately 35 times
higher than in the period45 years after diagnosis. The period 1–5
years after diagnosis also contained significantly more cancer-
related hospital activity than the period45 years after diagnosis: it
was approximately four times higher among colorectal cancer
survivors, and 7 times higher among lung cancer survivors,
although Figure 2 shows that much of this increase is due to the
high activity in years 2 and 3 after diagnosis. There was a smaller
difference in the cancer-related activity in the periods 1–5 and 45
years after diagnosis among prostate and female breast cancer
survivors, compared with colorectal and lung cancer survivors.
The number of days spent admitted to hospital for cancer-
related episodes of care (per 100 person-days) in the first year after
diagnosis was significantly higher among survivors over the age of
75 years, compared with younger survivors. This is most notice-
able for survivors of prostate cancer – those agedX85 years spent
around three times as many days admitted in the first year after
diagnosis, compared with those aged 70–74 years.
Table 1 Mean admitted patient hospital activity (cancer related and non-cancer related) among cancer survivors, England, 2006. Number of days in
hospital per 100 person-days,z by 5-year age group
Cancer diagnosis























20–24 3.4 (2.5–4.2) 1.0 (0.5–1.5)
25–29 3.2 (2.6–3.8) 0.9 (0.7–1.2) 2.3 (0.8–3.9) 0.4 (0.0–0.9)
30–34 2.4 (2.0–2.9) 0.3 (0.2–0.5) 2.0 (1.1–2.9) 0.1 (0.0–0.3)
35–39 2.5 (2.2–2.8) 0.5 (0.4–0.6) 3.6 (2.9–4.3) 0.4 (0.0–0.7)
40–44 2.0 (1.8–2.2) 0.5 (0.4–0.5) 3.9 (3.5–4.4) 0.3 (0.1–0.5) 1.8 (1.2–2.4) 0.2 (0.0–0.5)
45–49 2.1 (2.0–2.2) 0.6 (0.6–0.7) 4.6 (4.3–5.0) 0.4 (0.3–0.6) 1.2 (0.9–1.4) 0.2 (0.1–0.3)
50–54 2.2 (2.1–2.3) 0.5 (0.5–0.6) 4.4 (4.2–4.6) 0.6 (0.5–0.7) 0.9 (0.8–1.0) 0.2 (0.2–0.3)
55–59 2.1 (2.0–2.2) 0.5 (0.5–0.6) 4.7 (4.5–4.8) 0.6 (0.5–0.7) 0.6 (0.6–0.7) 0.2 (0.2–0.2)
60–64 1.9 (1.9–2.0) 0.7 (0.6–0.7) 4.2 (4.0–4.3) 0.7 (0.6–0.8) 0.6 (0.6–0.7) 0.3 (0.3–0.3)
65–69 2.0 (1.9–2.0) 0.7 (0.7–0.7) 4.1 (4.0–4.2) 0.6 (0.6–0.7) 0.6 (0.6–0.7) 0.3 (0.3–0.3)
70–74 1.7 (1.7–1.8) 0.8 (0.8–0.9) 4.0 (3.9–4.1) 0.7 (0.7–0.8) 0.7 (0.7–0.7) 0.4 (0.4–0.4)
75–79 1.7 (1.6–1.7) 0.9 (0.9–1.0) 4.0 (3.9–4.1) 0.8 (0.7–0.8) 0.9 (0.9–0.9) 0.5 (0.5–0.6)
80–84 1.6 (1.5–1.6) 1.2 (1.2–1.2) 3.7 (3.5–3.8) 0.9 (0.9–1.0) 1.2 (1.2–1.2) 0.8 (0.8–0.8)
X85 1.4 (1.3–1.5) 1.4 (1.3–1.4) 3.2 (3.0–3.4) 0.7 (0.6–0.8) 1.7 (1.6–1.7) 1.1 (1.1–1.1)
Females




15–19 1.4 (0.1–2.6) 0.2 (0.0–0.5)
20–24 3.3 (2.3–4.2) 0.6 (0.3–0.9) 1.7 (1.1–2.3) 0.6 (0.2–1.0)
25–29 2.8 (2.2–3.4) 0.5 (0.3–0.7) 2.0 (0.0–4.7) 0.2 (0.0–0.8) 2.1 (2.0–2.4) 0.3 (0.1–0.4)
30–34 2.1 (1.6–2.5) 0.5 (0.4–0.7) 1.5 (0.6–2.5) 0.2 (0.0–0.5) 1.6 (1.5–1.7) 0.3 (0.2–0.4)
35–39 2.5 (2.2–2.8) 0.6 (0.5–0.7) 3.1 (2.4–3.7) 0.3 (0.1–0.5) 1.3 (1.2–1.3) 0.3 (0.2–0.3)
40–44 2.3 (2.1–2.5) 0.5 (0.4–0.6) 3.3 (2.9–3.6) 0.4 (0.2–0.6) 1.0 (0.9–1.0) 0.3 (0.2–0.3)
45–49 2.2 (2.0–2.3) 0.6 (0.5–0.7) 3.9 (3.6–4.2) 0.5 (0.4–0.7) 0.8 (0.8–0.8) 0.2 (0.2–0.2)
50–54 2.0 (1.9–2.1) 0.5 (0.4–0.5) 4.2 (4.0–4.4) 0.5 (0.4–0.6) 0.6 (0.6–0.6) 0.2 (0.2–0.3)
55–59 1.8 (1.7–1.9) 0.5 (0.5–0.5) 4.3 (4.2–4.5) 0.4 (0.4–0.5) 0.5 (0.5–0.5) 0.2 (0.2–0.2)
60–64 1.7 (1.6–1.8) 0.5 (0.4–0.5) 4.2 (4.1–4.4) 0.5 (0.5–0.6) 0.5 (0.4–0.5) 0.2 (0.2–0.2)
65–69 1.6 (1.6–1.7) 0.6 (0.5–0.6) 4.0 (3.9–4.1) 0.6 (0.5–0.6) 0.5 (0.5–0.5) 0.3 (0.3–0.3)
70–74 1.6 (1.5–1.7) 0.7 (0.7–0.7) 4.1 (4.0–4.3) 0.7 (0.7–0.8) 0.5 (0.5–0.5) 0.4 (0.4–0.4)
75–79 1.5 (1.5–1.6) 0.8 (0.8–0.9) 3.9 (3.8–4.1) 0.9 (0.9–1.0) 0.6 (0.6–0.6) 0.6 (0.6–0.6)
80–84 1.5 (1.4–1.5) 1.2 (1.1–1.2) 4.3 (4.2–4.6) 1.0 (0.9–1.1) 0.7 (0.6–0.7) 0.9 (0.9–0.9)
X85 1.1 (1.1–1.2) 1.3 (1.2–1.3) 3.8 (3.5–4.1) 0.9 (0.8–1.0) 0.8 (0.8–0.8) 1.2 (1.2–1.2)
zWith 95% confidence intervals. Only observations with at least 20 survivor person-years are included.
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 DISCUSSION
This paper presents a person-time analysis of a linked cancer
registry and hospital activity data set for England. Age and time
since diagnosis were anticipated to be important factors in the
level of health-care utilisation among cancer survivors, and were
studied in detail. The linked data sets allowed an analysis of all
recorded episodes of hospital inpatient or day case health care in
England during 2006 among registered cancer survivors, with at
least one cancer-related episode recorded in the HES in the period
1990–2006. A person-time approach was used throughout, which
made it possible to quantify the intensity of hospitalisation, as well
as the associated burden on cancer survivors and the health
service, by considering the amount of time spent in hospital, rather
than just the number of admissions. Person-time of survivorship
and person-time of hospitalisation were classified according to the
variables of interest (age and time since diagnosis) – this made it
possible to describe in detail the ways in which acute health-service
utilisation among survivors was related to these factors.
It is not possible to distinguish between the cancer survivors
who had no recorded hospital activity and those for whom the
linkage process between the cancer registry and HES data failed.
It was therefore not possible to exclude patients with ‘no match’ to
HES. This results in an underestimation of the amount of hospital
activity among the cancer survivors, but this is believed to be only
a small effect.
Each record in the HES data had up to 14 diagnostic codes
(using the ICD-10 classification), and 12 operation procedure
codes (using the OPCS4 classification), with the first of each of
these codes intended to indicate the primary diagnosis/intent
of the episode (Maddams et al, 2011). For simplicity, episodes of
care were broadly categorised as ‘related to cancer’ or ‘not related
to cancer’ according to the diagnostic codes only – an episode was
considered to be cancer related if any of the diagnostic codes was
between C00 and C97 (excluding C44). This was an intentionally
broad definition, designed to negate any possible regional
variation in coding of primary diagnosis in the HES data, and to
take account of the wide range of health problems associated with
cancer and the side effects of its treatment. Defined thus, ‘cancer-
related’ hospitalisation for a given survivor may be considered as
that directly or indirectly caused by, or associated with, a cancer
diagnosis. A future area of study may be to define ‘cancer-related’
HES admissions according to the clinical procedure codes, as well
as the admission codes.
Table 2 Mean admitted patient hospital activity (cancer related and non-cancer related) among cancer survivors, England, 2006. Number of days in
hospital per 100 person-days,z by time since diagnosis
Cancer diagnosis



















o1 7.7 (7.7–7.8) 1.3 (1.3–1.4) 9.7 (9.6–9.7) 1.0 (1.0–1.1) 1.8 (1.8–1.9) 0.5 (0.5–0.5)
1–2 1.5 (1.4–1.5) 1.0 (1.0–1.1) 3.0 (2.9–3.1) 0.6 (0.5–0.7) 0.8 (0.8–0.9) 0.4 (0.4–0.5)
2–3 1.0 (1.0–1.1) 0.9 (0.9–0.9) 1.7 (1.5–1.8) 0.7 (0.7–0.8) 0.7 (0.7–0.8) 0.5 (0.5–0.5)
3–4 0.8 (0.8–0.9) 0.9 (0.8–0.9) 1.0 (0.9–1.2) 0.6 (0.5–0.7) 0.7 (0.7–0.8) 0.5 (0.5–0.6)
4–5 0.6 (0.6–0.7) 0.9 (0.8–0.9) 0.7 (0.6–0.9) 0.7 (0.6–0.8) 0.7 (0.7–0.8) 0.5 (0.5–0.6)
5–6 0.5 (0.4–0.6) 1.0 (0.9–1.0) 0.5 (0.3–0.7) 0.7 (0.6–0.8) 0.7 (0.7–0.8) 0.6 (0.6–0.7)
6–7 0.4 (0.4–0.5) 0.9 (0.9–1.0) 0.5 (0.3–0.7) 0.8 (0.6–0.9) 0.7 (0.7–0.8) 0.6 (0.6–0.7)
7–8 0.4 (0.3–0.4) 0.9 (0.9–1.0) 0.4 (0.2–0.7) 0.7 (0.5–0.8) 0.8 (0.8–0.9) 0.6 (0.6–0.7)
8–9 0.3 (0.2–0.4) 0.8 (0.7–0.9) 0.3 (0.1–0.5) 0.7 (0.6–0.8) 0.8 (0.7–0.8) 0.8 (0.7–0.8)
9–10 0.2 (0.2–0.3) 0.6 (0.6–0.7) 0.2 (0.0–0.4) 0.4 (0.3–0.5) 0.8 (0.8–0.9) 0.6 (0.6–0.7)
10–11 0.3 (0.2–0.4) 0.6 (0.5–0.6) 0.3 (0.1–0.5) 0.2 (0.1–0.3) 0.8 (0.7–0.9) 0.6 (0.6–0.7)
11–12 0.3 (0.2–0.4) 0.5 (0.5–0.6) 0.2 (0.0–0.4) 0.3 (0.2–0.5) 0.8 (0.7–0.9) 0.6 (0.5–0.7)
12–13 0.2 (0.1–0.3) 0.4 (0.3–0.5) 0.2 (0.0–0.4) 0.2 (0.1–0.4) 0.7 (0.6–0.8) 0.5 (0.5–0.6)
13–14 0.3 (0.2–0.4) 0.4 (0.3–0.5) 0.1 (0.0–0.3) 0.2 (0.0–0.4) 0.7 (0.6–0.9) 0.5 (0.4–0.6)
14–15 0.2 (0.1–0.3) 0.4 (0.3–0.5) 0.2 (0.0–0.4) 0.3 (0.1–0.5) 0.6 (0.5–0.8) 0.5 (0.4–0.7)
15–16 0.2 (0.1–0.4) 0.5 (0.4–0.6) 0.2 (0.0–0.5) 0.1 (0.0–0.3) 0.6 (0.4–0.8) 0.5 (0.4–0.6)
Females
Years since diagnosis
o1 7.8 (7.7–7.9) 1.3 (1.3–1.4) 9.7 (9.6–9.8) 1.0 (0.9–1.0) 2.6 (2.5–2.6) 0.5 (0.5–0.5)
1–2 1.3 (1.3–1.4) 1.0 (1.0–1.0) 2.7 (2.6–2.9) 0.6 (0.6–0.7) 0.6 (0.5–0.6) 0.5 (0.5–0.5)
2–3 0.9 (0.8–0.9) 1.0 (0.9–1.0) 1.7 (1.5–1.8) 0.6 (0.5–0.7) 0.5 (0.4–0.5) 0.5 (0.5–0.5)
3–4 0.7 (0.6–0.8) 0.8 (0.8–0.9) 1.1 (0.9–1.3) 0.6 (0.5–0.8) 0.4 (0.4–0.5) 0.5 (0.5–0.5)
4–5 0.5 (0.4–0.6) 0.8 (0.8–0.9) 0.7 (0.5–0.9) 0.8 (0.7–1.0) 0.4 (0.4–0.4) 0.5 (0.5–0.5)
5–6 0.4 (0.3–0.5) 0.9 (0.9–0.9) 0.8 (0.5–1.1) 0.7 (0.6–0.8) 0.3 (0.3–0.4) 0.5 (0.5–0.5)
6–7 0.3 (0.2–0.4) 0.9 (0.8–0.9) 0.3 (0.1–0.6) 0.7 (0.5–0.9) 0.3 (0.3–0.4) 0.5 (0.5–0.6)
7–8 0.2 (0.1–0.3) 0.9 (0.9–1.0) 0.3 (0.1–0.5) 1.1 (0.9–1.3) 0.3 (0.3–0.4) 0.5 (0.5–0.5)
8–9 0.3 (0.2–0.4) 1.0 (1.0–1.1) 0.3 (0.0–0.6) 0.5 (0.3–0.7) 0.3 (0.3–0.3) 0.5 (0.4–0.5)
9–10 0.2 (0.1–0.3) 0.6 (0.6–0.7) 0.2 (0.0–0.5) 0.5 (0.3–0.8) 0.3 (0.3–0.3) 0.3 (0.3–0.3)
10–11 0.2 (0.1–0.3) 0.4 (0.4–0.5) 0.2 (0.0–0.4) 0.2 (0.0–0.4) 0.3 (0.2–0.3) 0.2 (0.2–0.2)
11–12 0.2 (0.1–0.3) 0.3 (0.3–0.4) 0.3 (0.0–0.6) 0.1 (0.0–0.3) 0.3 (0.2–0.3) 0.2 (0.2–0.3)
12–13 0.2 (0.1–0.3) 0.3 (0.3–0.4) 0.3 (0.0–0.7) 0.3 (0.1–0.5) 0.3 (0.2–0.3) 0.2 (0.2–0.2)
13–14 0.2 (0.1–0.3) 0.3 (0.3–0.4) 0.2 (0.0–0.4) 0.1 (0.0–0.3) 0.3 (0.3–0.4) 0.2 (0.2–0.3)
14–15 0.1 (0.0–0.2) 0.4 (0.3–0.4) 0.2 (0.0–0.7) 0.1 (0.0–0.3) 0.2 (0.2–0.3) 0.2 (0.2–0.3)
15–16 0.1 (0.0–0.3) 0.3 (0.2–0.4) 0.2 (0.0–0.5) 0.1 (0.0–0.4) 0.3 (0.2–0.3) 0.2 (0.2–0.3)
zWith 95% confidence intervals.
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 Perhaps a more precise way of defining the health-care burden
directly attributable to cancer would be to compare hospitalisation
of any kind among cancer survivors with that observed in a
randomly selected age- and sex-matched subset of the cancer-free
population (or, more practically, the general population). This
would allow some measure of the ‘background’ hospitalisation
experienced by the cancer-free or general population to be
removed from the levels observed in cancer survivors. However,
no such data set was available to the authors at the time of analysis
– the Cancer Registries’ National HES extract only contains
episodes of care for patients with at least one episode ‘for or
with cancer’ – and thus it was only possible to make the broad
cancer/non-cancer-related distinction at a population level. It is
acknowledged, however, that at an individual level it may not be
possible to make such a clear distinction between cancer-related
and non-cancer-related health-service utilisation. Non-cancer-
related acute health-care utilisation was shown to generally
increase with age, but remained roughly constant regardless of
time since diagnosis, indicating that it may be a good minimum
measure of ‘background’ acute health-care utilisation. That said,
there is higher non-cancer-related acute health-care utilisation in
the first year following diagnosis, particularly among those with
lung and colorectal cancer. This may be explained by the fact that
some survivors may have had an emergency admission to hospital
during which they were diagnosed with cancer. In addition, some
genuine cancer-related hospital activity may not be coded as such
in the HES.
The primary motivation for using a person-time approach in
this analysis was the need to properly account for the length of
time cancer survivors spent ‘at risk’ of hospitalisation during
the period of analysis, and how this depended on both age and
time since diagnosis. The person-time methods allowed a precise
assessment of the influence of these variables on the amount of
hospitalisation among cancer survivors. The number of days
survivors spent admitted to hospital (per 100 person-days)
provides a more revealing assessment of the burden of cancer on
the health service than a count of the number of admissions.
However, the limitation of this approach is that, as person-time
is pooled for all survivors in the population, it provides only a
measure of the mean health-service utilisation in the population of
survivors and obscures the underlying distribution. For example,
on average male survivors of colorectal cancer who were no more
than 1 year from diagnosis in 2006 spent 9 days per 100 person-
days admitted to hospital (equivalent to approximately one month
per year); however, in reality, many such survivors spent no time
admitted to hospital at all, whereas others spent more than 9 days
per 100 as an admitted hospital patient. This variation in the
intensity of hospitalisation across survivors of a similar age and
post-diagnosis period is considered in Maddams et al (2011),














































































































































Figure 1 Mean admitted patient hospital activity among cancer survivors, England, 2006. Number of days admitted to hospital per 100 person-daysz, by
5-year age group. † Centre of 5-year age group. zWith 95% CIs. Only data points with at least 20 survivor person-years are plotted.
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 proportion of survivors with a low or high level of health-service
utilisation, as well as those with none. It was shown that the
underlying distribution of hospital activity is skewed towards
those with no hospital activity, particularly in the period more
than 1 year after diagnosis, and it should therefore be kept in mind
that the mean number of days spent in hospital per 100 person
days, as described in this paper, is largely influenced by the small
number of survivors who have a very high level of hospital activity.
Another limitation of this approach when used to assess
the burden of cancer on the health service is that each day of
hospitalisation is treated equally and the variation in the burden
presented by different types of admission and procedures is not
taken into account. For example, some survivors will be admitted
to hospital for routine observation and monitoring, whereas others
will be admitted for complicated operations that consume large
amounts of hospital resources and require intense periods of
rehabilitation.
The majority of cancer-related health-service utilisation
occurred during the first year following diagnosis, for all types
of cancer studied. Most cancer patients receive some form of care
or treatment as soon as possible after diagnosis, and thus it is
perhaps unsurprising that this period contains a large amount of
hospital activity. However, this study also shows that there is a
significant amount of cancer-related health-service utilisation in
the period 1–5 years after diagnosis, particularly among survivors
of lung and colorectal cancers. This is no longer the initial
treatment phase, but is indicative of the ongoing needs of cancer
survivors.
The highest levels of cancer-related acute health-service utilisa-
tion were observed in survivors of the relatively poor prognosis
cancers, but these differences largely disappeared more than
5 years after diagnosis. This indicates that the worse prognosis
cancers required more intensive treatment regimes (including end-
of-life care) in the short to medium term after diagnosis, but not in
the long term.
Prostate cancer survivors, despite having lower levels of cancer-
related acute health-service utilisation in the first year after
diagnosis than those with colorectal, lung or breast cancer, actually
had the highest levels five or more years after diagnosis (Figure 2).
This effect is the result of the relatively high levels of hospitalisa-
tion among prostate cancer survivors aged over 70 years and five
or more years from diagnosis (Figure 3). A more detailed
investigation (not included here) showed that these survivors
experienced a large amount of hospital activity recorded in the
HES data with a non-cancer primary diagnosis code, but with
prostate cancer recorded as one of the supplementary diagnoses,
and it was largely these episodes that resulted in the relatively high
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Figure 2 Mean admitted patient hospital activity among cancer survivors, England, 2006. Number of days admitted to hospital per 100 person-daysz, by
1-year since diagnosis period. zWith 95% CIs. Only data points with at least 20 survivor person-years are plotted.
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 among this group, compared with equivalent survivors of other
cancers. In the analysis, these episodes were considered to be
‘cancer related’ because cancer was recorded as one of the
supplementary diagnosis codes in the HES data. However, the
recorded primary diagnosis codes, together with the operation
procedure codes, indicate that these episodes were not generally
related directly to prostate cancer. For example, the most common
procedure codes were endoscopic examinations of the bladder and
urethral catheterisations of the bladder, and the most common







































































































































































Figure 3 Mean cancer-related admitted patient hospital activity among cancer survivors, England, 2006. Number of days admitted to hospital per 100
person-daysz, by 5-year age group and broad time since diagnosis period. zWith 95% CIs. Only data points with at least 20 survivor person-years are plotted.
† Centre of 5-year age group.
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There are several physiological changes that occur in men as they
get older and lead to alterations in lower urinary tract function,
making urinary disorders in elderly men common (Dubeau, 2006;
Griebling, 2008). Many prostate cancer survivors are likely to be
closely monitored in urology clinics for many years after initial
diagnosis – often an extended period of either ‘active surveillance’
or ‘watchful waiting’ is pursued, especially if the cancer is less
aggressive and treatment is not immediately necessary (Cancer
Research UK, 2010a). This may explain the greater hospital activity
recorded among prostate cancer survivors over the age of 70 years
many years after diagnosis, compared with male lung or colorectal
cancer survivors – it is possible that the increased observation and
monitoring of these survivors leads to a high level of urological
intervention, which is only indirectly related to their prostate
cancer diagnosis.
The patterns of cancer-related health-service utilisation by age,
as described in Figure 1, must be viewed in the context of the
findings presented in Figure 3. For example, older cancer survivors
are more likely to be more than 1 year from diagnosis, compared
with younger survivors, and this alone explains the apparent
decreasing levels of utilisation as age increases among lung and
colorectal cancer survivors. Acute health-service utilisation in the
first year after diagnosis was generally highest in survivors
aged over 70 years. Initial cancer treatment can be physically very
arduous, particularly for older patients who may be more frail and
suffering from comorbidities, resulting in more frequent and
extended admissions to hospital. Particularly striking was the
threefold increase in cancer-related acute health-service utilisation
in the first year after diagnosis among prostate cancer survivors
agedX85 years compared with those aged 65–69 years (Figure 3).
Similar, but not as significant, increases were observed among
survivors of colorectal, lung and breast cancers. Since the early
1990s, the PSA test has increasingly been available (usually to men
aged over 50 years of age) as a screening tool for prostate cancer,
although in the UK no organised PSA screening programme is in
place. This test is still controversial and considered to potentially
result in overdiagnosis and overtreatment of prostate cancers that
would otherwise never have become symptomatic (Barry, 2009;
van Leeuwen et al, 2010). Recorded incidence and survival
have, accordingly, greatly increased since the test’s introduction
(Evans and Møller, 2003; Cancer Research UK, 2010b, c), as have
the number of prostate cancer survivors (Maddams et al, 2009).
Men diagnosed with prostate cancer over the age of 70 years are
more likely to have symptomatic disease requiring intensive initial
treatment compared with those aged 50–70 years who are more
likely to have been diagnosed via the PSA test. Similarly, the
observed lower acute health-service utilisation in recently diag-
nosed breast cancer survivors aged 50–70 years (the age range
in which women are routinely invited to attend breast screening
units in England (NHS Breast Cancer Screening Programme, 2011),
compared with other age groups, reflects some of the benefits of
early detection offered by the screening programmes.
This paper highlights the significant effect that time since
diagnosis has on the average amount of hospitalisation experi-
enced by cancer survivors. The majority of cancer-related admitted
hospital episodes of care occurred in the first year following
diagnosis (when initial cancer treatment takes place); however,
there was also a significant amount of hospital activity in the
period 1–5 years after diagnosis, particularly among survivors of
colorectal and lung cancers, which is indicative of the ongoing
consequences of cancer and its treatment. Other work has shown
that the final year before death also contains significant amounts
of hospitalisation of cancer survivors (Maddams et al, 2011). These
findings help to understand the burden of cancer on the health
service, but further work is still required to identify potential areas
of unmet needs among cancer survivors.
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